| Package | Version | Identity | Name/Title | Status | Date | Auth |
|---|
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.1.11.159331  | Act Status | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.1.11.16866 | Act Priority (HL7) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.1.11.16926 | Basic Confidentiality Kind (HL7) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.1.11.18877 | Coverage Role Type Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19185 | Religious Affiliation Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19563 | Personal Relationship Role Type Value Set | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19579 | Family Member Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19601 | x_ServiceEventPerformer (HL7) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19717 | No Immunization Reason Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2 | Advance Directive Type Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.1.11.78 | Observation Interpretation (HL7) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.1.1.13.1 | Amniotic Fluid Conditions (HL7) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.1.1.13.10 | Type of Twin (HL7) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.1.1.13.11 | Twin Placenta (HL7) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.1.1.13.12 | Umbilical Cord Complication (HL7) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.1.1.13.13 | Infant Fetal Complications (HL7) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.1.1.13.14 | Placental Measurement (HL7) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.1.1.13.2 | Cord Insertion Type (HL7) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.1.1.13.3 | Hospital Care-Setting (HL7) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.1.1.13.4 | Maternal Exposures (HL7) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.1.1.13.5 | Intended Newborn Feeding Type (HL7) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.1.1.13.6 | Placenta Type (HL7) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.1.1.13.7 | Placental Conditions (HL7) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.1.1.13.9 | Type of Recreational Drug (HL7) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.91 | Birth Defects Diagnostic Confirmation (HL7) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.14.93 | Birth Defects Laterality at Diagnosis (HL7) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.10 | eICR Processing Status Reason Detail Type (eCR) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.11 | eICR Initiation | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.3 | Determination of Reportability (eCR) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.4 | External Resource Type (eCR) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.5 | Reportability Priority (eCR) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.6 | Location Relevance (eCR) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.7 | eICR Processing Status Reason (eCR) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.8 | eICR Processing Status (eCR) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.19465 | Healthcare Provider Taxonomy Code (NUCC) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.12.1 | Personal And Legal Relationship Role Type (HL7) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.18 | MoodCodeEvnInt (HL7) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.20 | Telecom Use - US Realm Header (HL7) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.21 | AgePQ_UCUM | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.22 | Procedure Act Status Code (HL7) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.23 | Planned moodCode - Act/Encounter/Procedure (HL7) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.24 | Planned moodCode - SubstanceAdministration/Supply | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.25 | Planned moodCode - Observation (HL7) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.26 | Entity Person Name Part Qualifier (HL7) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.33 | Role Class Codes (HL7) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.34 | Patient Education | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.38 | Current Smoking Status (NAACCR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.41 | Tobacco Use | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.49 | Residence and Accommodation Type | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.60 | Priority Level (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.13.19 | Healthcare Service Location (NHSN) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.13.277 | Birth Defect Diagnosis | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.2074.1.1.1 | Immunization Funding Source Excluding Nulls | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.2074.1.1.2 | Pt Immunization Registry Status Excluding Nulls | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.2074.1.1.3 | Race Category Excluding Nulls | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.2074.1.1.4 | Immunization Refusal Reason Excluding Nulls | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.5.20.1 | USDA Subject Descriptor | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.5.20.2 | USDA Subject Function | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.1 | NAACCR Laterality at Diagnosis | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.10 | NAACCR TNM Clinical Stage Descriptor | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.11 | NAACCR Cancer Status | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.12 | NAACCR Quality of Survival | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.13 | NAACCR Screening Result | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.14 | NAACCR Behavior Code | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.15 | NAACCR Grade | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.16 | NAACCR ICD-9-CM Cancer Reportability List | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.21 | TNM Pathologic Stage Descriptor (NAACCR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.22 | Laterality (NAACCR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.25 | Radiation Rx and Boost Radiation ICD10-PCS (NAACCR | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.26 | Radiation Rx and Boost Radiation SNOMEDCT (NAACCR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.27 | NAACCR TNM Pathologic Staged By (NAACCR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.29 | NAACCR SNOMEDCT Cancer Reportability List | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.3 | NAACCR Diagnostic Confirmation | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.4 | NAACCR TNM Clinical Staged By | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.520.4.5 | NAACCR TNM Edition Number | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.3.2 | Contact Type Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.4.2 | Provider Role Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.6.2 | Allergy/Adverse Event Type Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.6.8 | Problem Severity | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.7.2 | Problem Type Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.7.4 | Problem Value Set | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.11 | Medication Product Form Value Set | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.19 | Medication Type Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.7 | Medication Route FDA Value Set | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.9 | Body Site Value Set | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.16 | Medication Brand Name Value Set | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.18 | Medication Drug Class Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.21 | Medication Vehicle Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.39 | Immunization Information Source | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.46 | Document Class Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.47 | Document Type Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.60 | Social History Type Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.62 | Vital Sign Result Value Set | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.64 | Medication Fill Status Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.65 | V3 Result Status Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.66 | Patient Class Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.68 | Problem Status | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.2.11.7101 | VPD Reason for Study | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1000 | Identity Reliability Code (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1002 | Lab Test Result Name | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1003 | Observation Method | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1004 | Ordered Test | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1006 | Type of Long Term Care Facility | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1007 | Major Site of Disease (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1009 | Microorganism | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1010 | Microscopic Exam Culture Site (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1011 | Data Subtype | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1012 | Type of Data | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1013 | Missing Lab Result Reason | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1014 | Modifier or Qualifier | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1015 | Nationally Notifiable Disease Surveillance System (NNDSS) & Other Conditions of Public Health Importance | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1016 | Nationally Notifiable Infectious Disease reportable to the Nationally Notifiable Disease Surveillance System | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1017 | Nature of Abnormal Test (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1018 | Non Paint Lead Source | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1019 | Non-paint lead source - hobby related | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1021 | Number Of Lesions (VZ) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1022 | Occupation Risk Category (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1023 | Response Flag (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1024 | Extended Priority Codes (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1025 | Order Status (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1026 | Pregnancy Trimester | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1027 | Previous Vaccine History | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1028 | Processing ID (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1029 | Processing Mode (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1031 | Public Health Case Record Type | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1032 | Rash Distribution (VZ) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1033 | Rash Location First Noted (VZ) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1035 | Reason Therapy Stopped (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1036 | Referral Status (CRA) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1037 | Risk Category | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1038 | Sex (MFU) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1039 | Specimen Appropriateness (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1040 | Specimen Child Role (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1041 | Specimen Collection Method (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1042 | Specimen Condition | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1043 | Specimen Quality (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1044 | Specimen Reject Reason (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1045 | Specimen Risk | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1046 | Specimen Role | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1047 | Specimen Treatment | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1048 | Strain Type (VZ) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1049 | Substance Administered (CRA) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1050 | Batch Deactivation Reason | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1051 | Substance Treatment Refusal Reason | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1052 | Transmission Setting (NND) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1053 | Volume Units | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1054 | Volume Mass Units | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1055 | Universal ID Type (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1056 | Vaccination Location (CRA) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1057 | Vaccine Contraindications | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1058 | Vaccine Purchased With Funds | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1059 | Value Type (HL7) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1060 | Abnormal Chest X-ray Condition Status | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1061 | PHIN Questions (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1062 | PHIN Questions (Varicella) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1063 | PHIN Questions (Lead Case) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1064 | PHIN Questions (Lead Laboratory Report) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1065 | PHIN Questions (Lead Environmental) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1066 | Healthcare Provider Taxonomy (HIPAA) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1067 | Body Substance | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1068 | Event | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1069 | Material | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1071 | Drug Susceptibility Test Result Name | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1073 | Microbiology Test Result Name | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1074 | Animal | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1075 | Physical Object | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1076 | Situation with Explicit Context | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1089 | Botulism-like Syndrome (BT) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1090 | Fever Syndrome (BT) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1091 | Gastrointestinal Syndrome (BT) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1092 | Hemorrhagic Illness Syndrome (BT) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1093 | Localized Cutaneous Lesion Syndrome (BT) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1094 | Lymphadenitis Syndrome (BT) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1095 | Neurological Syndrome (BT) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1096 | Rash Syndrome (BT) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1097 | Respiratory Syndrome (BT) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1098 | Severe Illness Or Death Syndrome (BT) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1099 | Specific Infection Syndrome (BT) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1100 | Industry (NAICS) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1102 | Drug Active Ingredients | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1103 | Semantic Clinical Drug (Ingredient plus strength and dose form) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1104 | Semantic Clinical Drug Form (Ingredient plus dose form) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1105 | Drug Product (NDC) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1106 | Drug Manufacturers (NDC) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1107 | Notification Section Header | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1108 | Drug Classes (NDF-RT) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1109 | Procedure by Site (SNOMED) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3000 | PHLIP Questions (Flu) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3014 | Source of Comment (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3015 | Ethnicity Group including Unknown | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3016 | Lab Test Order (PHLIP Flu) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3017 | Lab Test Result (PHLIP Flu) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3018 | Patient Location Status at Specimen Collection | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3019 | Resulted Lab Test Name (PHLIP Flu) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3020 | Specimen Source (PHLIP) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3021 | Preferred Method of Contact (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3022 | PHIN Questions (Hepatitis) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3023 | Immunization Body Site | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3024 | Blood Contact Frequency (Hepatitis) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3025 | Case Confirmation Method | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3026 | Case Detection Method | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3027 | Case Transmission Mode | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3028 | Contact Type (Hepatitis A) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3029 | Contact Type (Hepatitis B and C) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3030 | Disease Acquired Jurisdiction | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3031 | Incarceration Type (Hepatitis) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3032 | Notifiable Condition (Hepatitis) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3033 | Number Of Sex Partners (Hepatitis) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3034 | Outbreak Type (Hepatitis) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3035 | Reason For Test (Hepatitis) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3036 | Reporting Source Type | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3037 | Tattoo Obtained From (Hepatitis) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3038 | Vaccine Dose Number (Hepatitis) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3039 | Isolate Availability EIP Testing | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3040 | Isolate Not Available EIP Test Reason | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3041 | Isolate Not Received Reason | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3042 | Isolate Not Sent To NARMS Reason | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3043 | Lab Test Result Name (Hepatitis) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3044 | Microbiology strain | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3045 | Microorganism (Hepatitis) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3046 | Specimen Reshipment Reason | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3047 | Specimen Shipped | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3048 | Lab Test Interpretation | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3049 | Lab Test Result Qualitative | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3050 | PHIN Questions (Animal Rabies) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3051 | PHIN Questions (ArboNet) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3052 | PHIN Questions (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3053 | PHIN Questions (Generic) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3054 | PHIN Questions (VPD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3055 | ECOTOX Chemicals (EPA) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3056 | STORET Chemicals (EPA) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3057 | TRI Chemicals (EPA) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3058 | Cancer Type | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3059 | Clinical Syndrome (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3060 | Immunosuppressed Condition | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3061 | Public Private Lab | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3062 | Transplant Organ | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3063 | Virus Type (Arboviral Disease) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3064 | Yes No Unknown No Answer | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3065 | Age Category (Animal) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3066 | Bat Species (Animal Rabies) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3067 | Virus Variant Type (Animal Rabies) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3068 | Animal Species (Animal Rabies) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3069 | Yes No Unknown Not Done | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3070 | Botulism Food Source Type (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3071 | Pregnancy Outcome (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3072 | Animal Type (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3073 | Botulinum Toxin Type (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3074 | Case Traced to Carrier | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3075 | Cholera Risk Factor (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3076 | Cholera Sequelae (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3077 | Cholera Signs Symptoms (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3078 | Cyclosporiasis Signs Symptoms (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3079 | Day Care Type (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3080 | Eosin Units (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3081 | Fetal Neonatal Infection Type (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3082 | Fetal Neonatal Specimen Type | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3083 | Food Cooking Method (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3084 | Food Processing Method (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3085 | Fresh Berries (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3086 | Fresh Herbs (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3087 | Fresh Produce (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3088 | Information Source | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3089 | Interview Status | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3090 | Lettuce Type (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3091 | Maternal Infection (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3092 | Meat Purchase Info (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3093 | Non Pork Type (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3094 | Other Related Cases | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3095 | Outbreak Type (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3096 | Pork Type (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3097 | Present Absent Unknown Not Examined | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3098 | Recreational Water (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3099 | Seafood Purchase Info (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3100 | Seafood Type (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3101 | Skin Exposure (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3102 | Skin Exposure Activity (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3103 | Suspected Food Consumed (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3104 | Swimming Pool Type (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3105 | Tap Water Source (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3106 | Travel Destination Type | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3107 | Travel Mode | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3108 | Travel Purpose | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3109 | Travelers Health Info Source | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3110 | Trichinellosis Signs Symptoms (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3111 | Typhoid Signs Symptoms (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3112 | Underlying Conditions | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3113 | Water Salinity (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3114 | Well Water Treatment (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3115 | Wound History | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3116 | Notifiable Condition (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3117 | Body Site (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3118 | Medication Treatment (FDD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3119 | Acute Convalescent IgG Difference (VPD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3120 | Antibiotic Received (Pertussis) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3121 | Birth Attendees (VPD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3122 | Birth Location (VPD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3123 | Birth Outcome (VPD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3124 | Body Region (Tetanus) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3125 | Case Classification Exposure Source | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3126 | Genotype (Measles) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3127 | Genotype (Rubella) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3128 | Immunization Information Source (CRS) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3129 | Injury Occurred Environment (VPD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3130 | Injury Type (VPD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3131 | Lab Result (Pertussis) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3132 | Lab Result (Rubella) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3133 | Live Birth Outcome (Rubella) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3134 | No Case Reason (CRS) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3135 | Non-Live Birth Outcome (VPD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3136 | PCR Performed Lab Location (VPD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3137 | Prenatal Care Provider (Rubella) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3138 | Relationship (VPD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3139 | Serology Performed Lab Location (Pertussis) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3140 | Specimen Source (CRS) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3141 | Specimen Source (VPD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3142 | Test Method EIA IgM | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3143 | Tetanus Type (VPD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3144 | Treatment Outcome Tetanus (VPD) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3145 | Vaccine Doses Received (Pertussis) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3146 | Vaccine Doses Received (Tetanus) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3147 | Medication Received (VZ) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3148 | PCR Specimen Source (VZ) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3149 | Lab Test Method (VZ) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3150 | IgM Test Type (VZ) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3151 | IgG Test Type (VZ) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3152 | Whole Cell ELISA Manufacturer (VZ) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3153 | gp ELISA Manufacturer (VZ) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3154 | Vaccines Administered (VZ) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3155 | Vaccine Manufacturer (VZ) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3156 | Reporting Area (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3157 | RVCT Link Reason (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3158 | Case Count Status (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3159 | Reporting Lab Type | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3160 | Microscopic Exam Type (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3161 | Primary Reason For Evaluation (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3162 | Risk Factors (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3163 | Immigration Status | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3164 | Sputum Culture Conversion Not Documented Reason | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3166 | Cause of Death Related to TB | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3167 | Therapy Extended Reason (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3168 | Education Level | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3169 | Birth Country (TB) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3200 | Birth Country | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3201 | Geographical location history | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3203 | Treatment status | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3204 | Non-Laboratory Intervention and Procedure | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3205 | Lab Test Result Name (TB) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3206 | Lab Test Result Name (Acute Hepatitis B) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3207 | Lab Test Result Name (Anthrax) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3208 | Lab Test Result Name (Tularemia) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3209 | Exposure Location | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3210 | Contact Type (Hepatitis B) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3211 | Material exposure type | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3212 | Signs and Symptoms (Anthrax) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3213 | Signs and Symptoms (Acute Hepatitis B) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3214 | Signs and Symptoms (TB) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3215 | Signs and Symptoms (Tularemia) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3216 | Medication Treatment (Anthrax) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3217 | Medication Treatment (Tularemia) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3218 | Medication Treatment (TB) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3219 | Vaccine Administered (Hepatitis B) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3220 | Disease Type (Anthrax) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3221 | Disease Type (Acute Hepatitis B) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3222 | Disease Type (TB) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3223 | Disease Type (Tularemia) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3224 | Blood or body fluid exposure event | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3225 | Blood or body fluid exposure frequency | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3226 | Blood or body fluid exposure related procedure | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3227 | Location performing blood or body fluid exposure procedure | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3228 | Sociobehavioral risk factor | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3230 | Disease Type (Hepatitis) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3231 | Disease Type (STD) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3232 | HIV Status (PHCR) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3236 | National Reporting Jurisdiction | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3237 | PHIN Questions (Mumps) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3238 | PHIN Questions (Measles) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3239 | PHIN Questions (Summary) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3240 | Flu Signs and Symptoms | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3241 | Notifiable Event Condition (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3242 | Risk Factor (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3243 | Lab Test Finding (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3244 | Medication Treatment (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3245 | Radiology Lab Test (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3246 | Specimen (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3250 | Vaccines Administered (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3251 | Lab Test Procedure (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3252 | Lab Test Interpretation (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3253 | Obesity Severity (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3254 | Employment Status (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3255 | Case Contact Signs and Symptoms (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3256 | Time Frame (Daily Weekly) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3257 | Surveillance Method (Novel Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3258 | Change Pattern | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3259 | Age Group (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3260 | Count Group Type (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3261 | Death Location (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3262 | Lab Test Procedure (Pediatric Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3263 | Lab Test Interpretation (Pediatric Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3264 | Sterile Specimen (Pediatric Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3265 | Positive Negative Unknown | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3266 | Microorganism (Pediatric Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3267 | Non-Sterile Specimen (Pediatric Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3268 | Acute Illness Complications (Pediatric Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3269 | Underlying Conditions (Pediatric Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3270 | Therapy 7 Days Prior or After Illness Onset (Pediatric Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3271 | Therapy Prior Illness Onset (Pediatric Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3272 | Therapy After Illness Onset (Pediatric Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3273 | Vaccines Administered (Pediatric Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3274 | Timing Prior To Illness Onset | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3275 | Relationship (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3276 | PHIN Questions (Flu Summary) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3277 | PHIN Questions (Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3278 | PHIN Questions (Pediatric Flu) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3279 | H1N1 Vaccine Manufacturer | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3282 | Specimen Collection Method | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3285 | Anatomical Entity (Body Site) | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3286 | Country Subdivision (ISO 3166-2) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3287 | Immunization Funding Source (IIS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3288 | Vaccination Contraindication (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3289 | Vaccination Reaction and Adverse Event (IIS) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3290 | Vaccination Special Indication (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3291 | Immunization Profile Identifier (IIS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3292 | Immunization Schedule Identifier (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3293 | Evidence Of Immunity (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3294 | PHIN Questions (CRS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3295 | PHIN Questions (Malaria) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3298 | PHIN Questions (Rubella) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3299 | PHIN Questions (Strep Pneumo) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3300 | Lab Test Procedure (Rubella) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3301 | Lab Test Interpretation (VPD) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3302 | Lab Test Procedure (Measles) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3303 | Specimen Source (Measles) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3304 | Parotitis Laterality (Mumps) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3305 | Type of Deafness (Mumps) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3306 | Lab Test Procedure (Mumps) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3307 | Specimen Source (Mumps) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3308 | Complications (Malaria) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3309 | Lab Test Procedure (Malaria) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3310 | Medication Missed (Malaria) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3311 | Medication Prophylaxis (Malaria) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3312 | Medication Treatment (Malaria) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3313 | Species (Malaria) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3314 | Specimen Type (Malaria) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3315 | Travel Reason (Malaria) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3316 | Antimicrobial Agent (IPD) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3317 | Antimicrobial Susceptibility Test Method (IPD) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3318 | Bacterial Infection Syndrome (IPD) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3319 | Oxacillin Interpretation (IPD) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3320 | Serotype Method (IPD) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3321 | Sterile Specimen (IPD) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3322 | Underlying Conditions (IPD) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3323 | Birth Outcome (Rubella) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3336 | Susceptibility Result (IPD) | draft | | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3337 | Event Type (HL7) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3338 | Coding System HL7 2x Table 0396 | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3339 | Check Digit Scheme (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3340 | Specimen Action Code (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3341 | Message Type (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3342 | Version ID (HL7) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3343 | Abnormal Flag (HL7 27) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3344 | Accept Application Acknowledgment Conditions (HL7) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3345 | Type of Referenced Data (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3346 | Organizational Name Type (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3347 | Alternate Character Sets (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3348 | Visit Indicator (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3349 | Message Structure (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3350 | Alternate Character Set Handling Scheme (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3351 | Name Assembly Order (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3352 | Name Address Representation (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3353 | TQ Conjunction ID (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3354 | Order Type (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3355 | Authorization Mode (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3356 | Risk Codes (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3357 | Observation Result Handling (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3358 | Lab Test Name (NND) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3359 | Evaluation Finding | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3362 | Event Type (IIS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3363 | Patient Class (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3364 | Message Type (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3365 | Relationship (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3366 | Financial Class (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3367 | Version ID (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3368 | Order Control Code (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3369 | Route Of Administration (IIS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3370 | Administrative Site (IIS) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3371 | Name Type (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3372 | Identifier Type (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3373 | Organizational Name Type (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3374 | Query Response Status (IIS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3375 | Action Code (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3376 | Message Structure (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3377 | Immunization Registry Status (HL7) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3378 | Immunization Registry Status (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3379 | Query Name (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3380 | Substance Refusal Reason (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3381 | Observation Identifier (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3382 | Query Priority (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3383 | Quantity Limited Request (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3384 | Publicity Code (IIS) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3392 | Value Type (IIS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3401 | Facility / Visit Type (Syndromic Surveillance) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3402 | Age Unit (Syndromic Surveillance) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3403 | Gender (Syndromic Surveillance) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3404 | Patient Class (Syndromic Surveillance) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3405 | Race Category including Unknown | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3406 | Disease Acquired Jurisdiction (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3407 | Case Class Status (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3408 | Age Unit (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3409 | Transmission Setting (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3410 | Vaccine Not Given Reasons (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3411 | Body Region Tetanus (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3412 | Injury Occurred Environment (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3413 | Injury Type (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3414 | Birth Attendees (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3415 | Vaccines Administered (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3416 | Manufacturers Of Vaccines (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3417 | Contact Type Hepatitis A (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3418 | Sexual Preference (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3419 | Lab Test Result Lyme (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3420 | Microorganism (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3421 | Bacterial Infection Syndrome (NETSS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16. | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4228 | Lab Test Name (Western equine encephalitis virus) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4229 | Lab Test Name (West Nile virus) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4230 | Lab Test Name (Yellow Fever) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4231 | Lab Test Name (Yersiniosis) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4239 | Lab Test Name (Diabetes, hemoglobin A1c) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4240 | Lab Test Name (Asbestosis) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4241 | Lab Test Name (Berylliosis) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4242 | Lab Test Name (Ricin poisoning) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4243 | Lab Test Name (Mushroom poisoning) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4244 | Lab Test Name (Carbon monoxide poisoning) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4245 | Lab Test Name (Pesticide poisoning) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4246 | Lab Test Name (Arsenic poisoning) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4247 | Lab Test Name (Cadmium poisoning) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4248 | Lab Test Name (Lead poisoning) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4249 | Lab Test Name (Mercury poisoning) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4250 | Lab Test Name (Acid fast stain) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4251 | Lab Test Name (Bacteria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4252 | Lab Test Name (Fungus) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4253 | Lab Test Name (Microorganism) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4254 | Lab Test Name (Mycobacteria) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4255 | Lab Test Name (Parasite) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4256 | Lab Test Name (Virus) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4257 | Lab Test Name (Antimicrobial susceptibility tests) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4258 | Lab Test Name (TB Antimicrobial susceptibility test) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4275 | Lab Result (Cancer Morphology) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.4276 | Lab Result (Pesticide) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5000 | Universal Identifier (HL7) (PHLIP) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5001 | Specimen Type PHLIP | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5002 | Order Control Codes (HL7) (PHLIP) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5004 | Specimen Reject Reason (SCT) (PHLIP) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5005 | Lab Test Order (PHLIP Sal) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5006 | Value Type (HL7) (PHLIP) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5007 | Specimen Related Observations (PHLIP Sal) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5013 | Suspected Agent (PHLIP Sal) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5014 | Observation Result Status (PHLIP) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5015 | Role (PHLIP) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5016 | Organization Unit (PHLIP) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5017 | Resulted Lab Test Name PHLIP Salmonella | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5020 | Acknowledgment Code (HL7) (PHLIP) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5021 | Original Specimen Source Site PHLIP (PLT212) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5022 | Original Specimen Source Site Modifier PHLIP | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5023 | Original Specimen Collection Method PHLIP | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5024 | Original Specimen Type PHLIP | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5026 | Lab Test Result PHLIP Salmonella | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5027 | Identifier Type (HL7) (PHLIP for PID3.5) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5028 | Method Detail (PHLIP) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6000 | Problem Goal Action Code (HL7) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6001 | Certifier Types (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6002 | Manner of Death (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6003 | Pregnancy Status (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6004 | Contributory Tobacco Use (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6005 | Transportation Relationships (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6006 | Legacy Reporting Jurisdiction (CDS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6013 | Lab Test Type (Hepatitis) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6014 | Lab Test Type Enzymes (Hepatitis) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6027 | Smoking Status (PI) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6036 | Occupation (Census) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6037 | Industry (Census) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6038 | Morphology of Neoplasms ICD-9-CM | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6039 | Funding Eligibility Observation Method (IIS) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6040 | VIS Vaccines (IIS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6041 | VIS Bar Codes (IIS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6046 | Specimen Type (HL7) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6047 | Message Structure (Syndromic Surveillance) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6048 | Event Type (Syndromic Surveillance) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6049 | Message Type (Syndromic Surveillance) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6050 | Universal ID Type (Syndromic Surveillance) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6053 | Lab Test Name (Reportable Conditions) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6054 | Lab Test Result (Reportable Conditions) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6055 | Lab Test Name (HEDIS) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6056 | Name Type (Syndromic Surveillance) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6057 | Value Type (Syndromic Surveillance) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6062 | Observation Result Status Interpretation Codes | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6063 | Universal ID Type (IIS) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6064 | Value Type (ELR) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6065 | Race (HL7) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6066 | Ethnic Group (HL7) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6067 | Universal ID Type (ELR) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6069 | NAACCR ICD-10-CM Cancer Reportability List | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6070 | Infections During Pregnancy - Live Birth (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6071 | Gonorrhea (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6072 | Trachoma (NCHS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7055 | Antituberculosis Drugs (TB) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7102 | VPD Lab Test Identifiers | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7103 | VPD Laboratory Coded Observation | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7104 | VPD Specimen Type | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7105 | VPD Specimen Collection Method | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7106 | VPD Specimen Source Body Site | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7107 | VPD Specimen Role | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7108 | VPD Specimen Condition | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7109 | VPD Lab Order Identifier | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7110 | VPD Specimen Reject Reason | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7111 | Birth Attendant Titles (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7112 | Fetal Death Time Points (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7113 | Fetal Presentations (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7115 | Karyotype Suspected Chromosomal Disorder (NCHS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7116 | Karyotype Down Syndrome (NCHS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7117 | Labor and Delivery Characteristics (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7118 | Delivery Routes (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7119 | Maternal Morbidities (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7121 | Newborn Abnormal Conditions (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7122 | Newborn Congenital Anomalies (NCHS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7123 | Onset Labor (NCHS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7124 | Birth or Delivery Occurred (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7126 | Pregnancy Risk Factors (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7129 | Employment Status (ODH) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7130 | Work Schedule (ODH) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7135 | Infections During Pregnancy Fetal Death (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7136 | Obstetric Procedures (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7137 | Autopsy Examination (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7138 | Histological Placental Examination (NCHS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7140 | Autopsy Planned (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7142 | Non-Vertex Presentation (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7143 | Steroids For Fetal Lung Maturation (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7144 | Assisted Ventilation Minutes After Birth (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7145 | Assisted Ventilation More Than Six Hours (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7153 | Estimated Time of Death No Labor Ongoing (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7154 | Fetal Presentation at Birth- Unknown (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7155 | Height (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7156 | Assisted Ventilation (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7157 | Binational Reporting Criteria | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7158 | State or Province of Exposure | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7159 | Mexican Health Jurisdictions (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7162 | Country (GEC) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7163 | Birth and Fetal Death Financial Class (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7164 | Birth and Fetal Death Report Event Reason (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7165 | Previous Cesarean (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7166 | Binational Reporting Criteria (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7167 | Case Transmission Mode (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7168 | Notifiable Event Disease Condition (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7169 | US Mexico States (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7170 | Specimen Site (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7171 | Salmonella Serogroup (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7172 | Shigella Serogroup (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7173 | Campylobacter Species (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7174 | Campylobacter Nonculture Test Type (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7175 | E. coli Culture Isolate Id Serotype (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7176 | STEC Nonculture Test Type (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7177 | E. coli Shiga Toxin Test Type (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7178 | E. coli Shiga Toxin (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7179 | Vibrio Culture Species (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7180 | Vibrio Serotype (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7181 | Vibrio Biotype (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7182 | Vibrio Cholera Toxin Test Type (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7183 | Listeria Culture Species (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7184 | Occupation CDC Census 2002 | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7185 | Industry CDC Census 2002 | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7186 | Occupation CDC Census 2010 | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7187 | Industry CDC Census 2010 | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7188 | Travel Reason (Hepatitis A) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7189 | Specimen Source (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7190 | Current Sex (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7191 | Syphilis Neurologic Involvement (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7192 | HIV Status (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7193 | YNRD (CDC) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7194 | Drugs Used (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7195 | Clinician Observed Lesions (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7196 | Non Treponemal Serologic Test (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7197 | Treponemal Serologic Test (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7198 | Transmission Category (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7199 | Detection Method (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7200 | Lab Results (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7201 | Lab Tests (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7202 | Country Imported From (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7203 | Quantitative Syphilis Test Result (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7204 | Race Category including Refused | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7205 | Race Category including Null Flavor | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7206 | Lab Test Result Qualitative (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7208 | Newborn Vital Signs (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7209 | Maternal Vital Signs (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7210 | Apgar Assessments (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7211 | Influenza Transmission Zones (PHLIP) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7212 | Certifier Titles (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7213 | PHIN Questions (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7216 | Place of Death (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7217 | Lab Test Reactivity (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7218 | Syphilis Clinical Stage (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7219 | Syphilis Surveillance Stage (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7220 | Pregnancy Treatment Stage (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7221 | Syphilis Treatment Mother (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7222 | Serologic Response (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7223 | Birth Status (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7224 | Darkfield DFA Result (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7225 | Signs Symptoms (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7226 | X-Ray Result (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7227 | VDRL Test Result (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7228 | CSF WBC Protein Result (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7229 | Syphilis Treatment Infant (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7231 | Result Status (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7234 | Qual Lab Result Positive (Reportable Conditions) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7235 | Qual Lab Result Negative (Reportable Conditions) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7236 | Qual Lab Result Inconc (Reportable Conditions) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7243 | Lab Test Name (Ebolavirus) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7244 | History of Disease as Evidence Of Immunity (IIS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7245 | Serological Evidence Of Immunity (IIS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7246 | Vital Signs (Syndromic Surveillance) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7247 | Symptoms (EVD Triage) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7248 | Countries Widespread Transmission (EVD) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7249 | Exposure Risk (EVD) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7250 | Observation Identifiers (EVD Triage) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7256 | Morphologic Abnormalities of Neoplasms | draft | | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7257 | Abdominal Pain (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7258 | Weakness (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7259 | Fever (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7260 | Headache (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7261 | Hemorrhage (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7262 | Muscle Pain (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7263 | Vomiting (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7264 | Diarrhea (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7265 | Duration Unit | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7267 | Death Report Observation Identifier (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7268 | Data Elements (NND Gen V2) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7269 | Reason for Missing Test (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7270 | Lab Test Result Interpretation (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7271 | Case Notification Specification Version (NND) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7272 | Case Notification MMG Version (NND) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7273 | Death Pronouncement Finding (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7274 | Death Pronouncement Procedure (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7275 | Nationally Notifiable Event Code (Hepatitis) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7276 | Nationally Notifiable Event Code (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7277 | Transport Mode to Hospital (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7278 | Lab Test Performed Modifier (CS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7279 | Non-Treponemal Test Result (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7282 | Complications (Mumps) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7283 | Signs and Symptoms (Mumps) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7284 | Signs and Symptoms (Pertussis) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7285 | Complications (Pertussis) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7328 | 1 Min Apgar Score (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7329 | Type of Testing at CDC (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7330 | Performing Laboratory Type (VPD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7331 | Vaccine Administered (MMR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7332 | Setting of Further Spread | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7333 | Timing of Maternal Treatment (NND) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7334 | Lab Test Interpretation (Pertussis) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7335 | Vaccine Administered (Pertussis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7336 | Lab Test Type (Mumps) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7337 | Lab Test Type (Pertussis) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7339 | Lab Test Name (Chikungunya virus) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7340 | Lab Test Name (Junin Hemorrhagic fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7341 | Lab Test Name (Lassa fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7342 | Lab Test Name (Marburgvirus) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7343 | Lab Result (Chikungunya virus) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7344 | Lab Result (Crimean-Congo hemorrhagic fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7345 | Lab Result (Guanarito hemorrhagic fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7346 | Lab Result (Junin hemorrhagic fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7347 | Lab Result (Lassa fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7348 | Lab Result (Lujo virus) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7349 | Lab Result (Machupo hemorrhagic fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7350 | Lab Result (Sabia virus hemorrhagic fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7351 | Lab Test Performed Modifier (NND) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7352 | No Prenatal Care Visit (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7354 | Part/line Number | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7356 | Diagnosis (ICD-10 CM) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7357 | Hysterectomy (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7358 | Hysterotomy (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7359 | Point of Origin (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7360 | Discharge Disposition IP (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7361 | Disposition OPD (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7362 | Follow-up Attempt Outcome (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7363 | Specialty Unit Type (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7364 | Type of clinic/location (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7365 | Priority (Type) of Admission or Visit (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7366 | Relationship (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7367 | Exposure Time Frame (NND) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7369 | Present on Admission (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7370 | Activity Type (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7371 | Procedure (ICD-10 PCS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7372 | Time Units (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7373 | Race (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7374 | Place of Injury (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7375 | Ethnicity Group (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7376 | Ethnicity Detail (NCHS) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7377 | Bridged Race (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7378 | Death Reporting Name Type Code (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7379 | Methods of Disposition (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7380 | Marital Status (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7382 | Death Reporting Identifier Type (HL70203) (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7383 | Death Reporting Event Reason (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7385 | Decedent Education Level (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7386 | Death Reporting Profiles (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7387 | Edit Flags (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7388 | Education Level Edit Flags (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7389 | Intentional Reject Edit Flags (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7390 | Marital Status Edit Flags (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7391 | Pregnancy Edit Flags (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7392 | Race Coding Flag (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7393 | Source Flags (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7395 | System Reject Codes (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7396 | Transax Conversion Flag (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7397 | Void Flags (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7398 | Nationally Notifiable Event Code (Syphilis) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7401 | Triage System (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7402 | Patient Residence (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7403 | Injury or Poisoning (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7404 | Major reason for visit (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7405 | Co-morbid Conditions (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7419 | Provider ED (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7421 | Body Weight (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7422 | Fetal Death Cause or Condition (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7423 | Pregnancy Resulting From Fertility Enhancing Drugs | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7426 | Estimated Time Of Fetal Death (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7430 | Histological Placental Exam Performed (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7431 | Surfactant Replacement Therapy (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7432 | Asthma (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7433 | Condition Control (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7436 | Disposition (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7437 | Disposition ED (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7438 | Application Error Code (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7439 | Episode of Care (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7440 | Hospital Discharge Status (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7441 | Neurological Manifestation (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7442 | Death Reporting Event Type (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7443 | Death Reporting Message Structure (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7444 | Death Reporting Message Type (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7446 | States Territories Provinces (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7447 | Nationally Notifiable Event Code (Generic) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7448 | Vaccine Type (NND) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7449 | Qualitative Lab Result (RCMT) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7450 | Vaccine Event Information Source (NND) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7451 | Type of Testing at CDC (VZ) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7452 | Age Unit (NND) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7453 | Body Region(s) of Rash | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7454 | Character of Lesions | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7456 | Lab Test Type (Varicella) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7457 | Zika-affected areas | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7458 | Transmission Mode (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7459 | Signs Symptoms (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7460 | Signs Symptoms (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7462 | Prenatal Diagnostic Procedures | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7463 | Specimen Type (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7464 | Insect Repellant | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7465 | Vector (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7466 | Complications (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7467 | Drug Disease Interaction (Dengue) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7468 | Length of Gestation in Weeks | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7469 | Microcephaly Causes | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7470 | Head Circumference Findings | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7472 | Lab Test Type (Arbovirus) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7473 | Diagnostic Lab Test Findings (NND) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7474 | Type of Complication (VZ) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7475 | Epidural/Spinal Anesthesia - Medication (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7476 | Positive Negative Equivocal Not Done | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7477 | Positive Negative 4 Fold Rise Not Done | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7478 | Serotype (Dengue) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7479 | Lab Result (Zika virus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7480 | Lab Test Name (Zika virus) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7481 | Signs Symptoms (Dengue) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7482 | Signs Symptoms (Chikungunya) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7483 | Signs Symptoms Dengue ICD-10 CM | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7484 | Signs Symptoms Chikungunya ICD-10 CM | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7485 | Signs Symptoms Zika ICD-10 CM | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7486 | Yes No Not Applicable (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7487 | Reason for Hospitalization (VZ) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7488 | Specimen Type (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7489 | Transmission Mode (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7490 | Clinical Syndrome - Secondary (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7491 | Pregnancy Complications (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7492 | Newborn Complications (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7493 | Performing Lab Type (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7494 | Pregnancy Outcome | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7495 | Serotype (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7496 | Death Reporting Observation Result Status (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7497 | Death Reporting Value Type (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7512 | City Places (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7513 | Message Error Condition Codes (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7515 | Data Elements (NND Hep Core) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7516 | Data Elements (NND Hep A Acute) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7517 | Data Elements (NND Hep B Acute) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7518 | Data Elements (NND Hep B Perinatal) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7519 | Data Elements (NND Hep B Chronic) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7520 | Data Elements (NND Hep C Acute) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7521 | Data Elements (NND Hep C Chronic) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7522 | Data Elements (NND Mumps) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7523 | Data Elements (NND Pertussis) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7524 | Data Elements (NND STD) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7525 | Data Elements (NND CS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7526 | Method of Delivery VaginalSpon Finding (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7527 | Method of Delivery Cesarean Finding (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7528 | Method of Delivery Vaginal Forceps Finding (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7529 | Method of Delivery Vaginal Vacuum Finding (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7530 | Scheduled Cesarean Finding (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7531 | Induction of Labor Finding (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7532 | Augmentation of Labor Finding (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7536 | Height Unit (CDC) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7537 | Duration Unit (1) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7538 | Type of Complication (Babesiosis) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7539 | Medication Treatment (Babesiosis) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7540 | Blood Product | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7541 | Clinical Manifestations (Babesiosis) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7542 | Lab Test Name (Hantavirus Infection) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7543 | Lab Result (Hantavirus Infection) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7544 | Outdoor Activities | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7545 | Lab Test Type (Babesiosis) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7546 | NAT Tests (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7547 | IgM Ab Tests (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7548 | Neutralizing Ab Tests (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7549 | Test Type (Syphilis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7550 | Lab Test Type (STD) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7551 | Test Result Coded Qualitative | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7552 | Organism Identified AST (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7553 | Specimen Type AST (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7554 | Specimen Collection Site AST (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7555 | Susceptibility Test Type (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7556 | Susceptibility Test Method (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7557 | Susceptibility Test Interpretation (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7558 | Susceptibility Test Result Units (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7559 | Susceptibility Test Result Quantitative (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.756 | Gender Identity | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7563 | Sexual Orientation | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7564 | Birth Reporting Address Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7565 | Birthdate Edit Flags (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7566 | Pregnancy Report Edit Flags (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7567 | Estimate Of Gestation Edit Flags (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7568 | Number Of Previous Cesareans Edit Flags (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7569 | Birth Reporting Associated Party Relation (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7570 | Birth Reporting Event Reason (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7571 | Birth Reporting Event Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7572 | Birth Reporting Message Structure (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7573 | Birth Reporting Message Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7574 | Birth Reporting Value Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7575 | Birth Reporting Observation Result Status (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7576 | Birth Weight Edit Flags (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7577 | Plurality Edit Flags (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7578 | Consolidated Ethinicity (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7579 | Weight Of Fetus Edit Flag (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7580 | Informant Relationship to Mother (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7581 | Birth Reporting Associated Party ID Type (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7582 | Vital Records Education Level (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7583 | Birth Reporting Observation Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7584 | CCOFDI Observation Type (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7585 | Fetal Remains Disposition Method (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7586 | JFDI Observation Type (NCHS) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7587 | JLBI Observation Type (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7588 | PSFDI Observation Type (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7589 | PSFFDI Observation Type (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7590 | PSFLBI Observation Type (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7591 | PSLBI Observation Type (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7592 | PSMFDI Observation Type (NCHS) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7593 | Consolidated Race (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7594 | PSMLBI Observation Type (NCHS) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7596 | Adverse Event Severity (Malaria) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7597 | Work Classification (ODH) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7598 | Baby Or Fetus Weight Unit Of Measure (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7599 | Birth Reporting Mother's NameType (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7600 | Birth Reporting Related Party Address Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7601 | Jurisdiction Certificate ID Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7603 | Fetal Death Reporting Associated Party Relation (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7604 | Route Method of Delivery SpontaneousProcedure (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7605 | Tobacco Use Unit Of Measure (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7606 | Live Birth Reporting Associated Party Relation (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7607 | Type of Testing at CDC | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7608 | Type Of Complication (CRS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7609 | Sexual Orientation (STD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7610 | Gender Identity (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7611 | Clinical Manifestations (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7612 | Late Clinical Manifestation (STD) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7613 | Job Supervisory Level or Pay Grade (ODH) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7614 | Case Appraisal (CRS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7615 | Pre-Pregnancy SerologicalTestInterp (CRS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7616 | Specimen From Mother Or Infant (CRS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7617 | Organism (FDD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7618 | Yes No Unknown Refused (NND) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7619 | Antibiotics (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7620 | Antacids (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7621 | Signs and Symptoms (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7622 | Positive Negative Not Done | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7623 | Test Method (FDD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7624 | Performing Lab Type (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7625 | Test Type (FDD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7626 | Test Result (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7627 | Specimen Collection Source (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7628 | Yes No Unknown Maybe (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7629 | Yes No Don't Know Maybe (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7630 | Drinking Water (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7631 | Recreational H2O Treatment (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7632 | Raw Unpasteurized Products (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7633 | Day Care Setting (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7634 | Sexual Contact (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7635 | Medication Administered (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7636 | Medical History (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7637 | Seafood Preparation (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7638 | Seafood Source (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7639 | Shellfish Distributed (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7640 | Improper Handling Storage (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7641 | Harvest Region (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7642 | Harvest Classification (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7643 | Vibrio Species (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7644 | Vibrio Cholera Serotype (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7645 | Vibrio Cholera Biotype (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7646 | Vaccine Received (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7647 | Typhoid Paratyphoid Serotype (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7648 | Yes No Not Tested (NND) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7649 | Signs and Symptoms (Rubella) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7650 | Type Of Complication (Rubella) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7651 | Previous Case Diagnosed By (Rubella) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7652 | Mailing Address Indicator (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7653 | Specimen Type (CRS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7655 | PCR Specimen Source (CRS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7656 | Specimen Source (Rubella) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7657 | Specimen Type (Rubella) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7658 | CREI Observation Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7659 | Type of Testing at CDC(Rubella) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7660 | Type of Complication (Measles) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7661 | Lab Test Type (Measles) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7662 | Signs and Symptoms (Measles) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7663 | Data Elements (NND Malaria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7664 | Data Elements (NND Babesiosis) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7665 | Data Elements (NND Varicella) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7666 | Signs and Symptoms (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7667 | Eosinophil Units | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7668 | Meat Consumed Type (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7669 | Food Processing Method (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7670 | Meat Purchase Info (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7671 | Food Cooking Method (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7672 | Performing Lab Type (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7673 | Lab Test Type (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7674 | Lab Test Interpretation (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7675 | Specimen type (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7676 | Strain Type (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7677 | Form Status (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7678 | Discharge Location (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7679 | Pregnancy Status (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7680 | Fetal Outcome (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7681 | Underlying Condition (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7682 | Smoking Status (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7683 | Substance Abuse (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7684 | Mode of Delivery (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7685 | GBS Time Period (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7686 | Microorganism (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7687 | Performing Lab Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7688 | Vaccine Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7689 | Vaccination Information Source (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7690 | GAS Risk Factor (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7691 | GAS Risk Factor Interval (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7692 | Rehab Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7693 | Antibiotic Received (RIBD) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7694 | Administration Route (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7695 | Antibiotic Reason (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7696 | Detection Method (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7697 | Birth Location (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7698 | Gestational Age Determination (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7699 | Susceptibility Data NA (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7700 | AR Agent (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7701 | AR Test Method (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7702 | ATI Method (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7703 | MIC Operator (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7704 | Susceptibility Interpretation (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7705 | ICD Codes (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7706 | Sequelae (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7707 | Blood Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7708 | Rupture Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7709 | Delivery Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7710 | Medication Pre-Treatment (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7711 | Contact Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7712 | School Year (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7713 | College Living Situation (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7714 | Legionella Diagnosis (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7715 | Legionella Exposure (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7716 | Definitely Possibly No (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7717 | Legionella Exposure Setting (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7718 | Healthcare Exposure Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7719 | Facility Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7720 | Water Source (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7721 | Cruise Line (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7722 | Titer Test Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7723 | Signs and Symptoms (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7724 | Personal Protective Equipment (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7725 | Respiratory Protective Equipment (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7726 | Glove Material (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7727 | Titer Test Method (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7728 | Bird Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7729 | Establishment Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7730 | Residence Location (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7731 | Insurance Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7732 | Infection Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7733 | Lab Test Method (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7734 | Lab Test Interpretation (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7735 | SPN/IPD Serotype (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7736 | Serotype Method (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7737 | Legionellosis Serogroup (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7738 | Isolate Not Available (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7739 | GAS Lab Test Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7740 | Colony Count Magnitude | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7741 | H Antigens (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7743 | Lab Test Type (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7744 | Lab Test Interpretation (TB) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7745 | Type of Radiology Study | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7746 | Result of Radiology Study (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7747 | Diabetes Status | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7748 | Epidemiological Risk Factors (TB) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7749 | Smoking Status | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7750 | Diagnosis Type (TB) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7751 | Type of Link (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7752 | Strength of Link (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7753 | Directionality of Link (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7754 | Treatment Administration Type (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7755 | LTBI Drug Regimen (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7756 | Reason LTBI Not Started (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7757 | Reason LTBI Treatment Stopped (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7758 | Adverse Event Severity (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7759 | Medication (TB) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7760 | Susceptibility Test Type (TB) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7761 | Susceptibility Test Interpretation (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7762 | Susceptibility Test Method (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7763 | Gene Name (TB) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7764 | Molecular Test Results (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7765 | Molecular Indel (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7766 | Molecular Test Methods (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7767 | Reason Not Treated with RIPE (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7768 | Moved Where During Therapy (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7769 | Final Treatment Outcome (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7770 | Length of Time Drug Taken (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7771 | Side Effect Time to Onset (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7772 | Side Effect of Treatment (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7773 | Serogroup Method (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7774 | Specimen Type (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7775 | Lab Test Type (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7776 | Emergency Severity Index - Acuity | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7777 | Healthcare Service Location (Syndromic) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7778 | Specimen Site (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7779 | Condition Status (FDD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7780 | Lab Test Na | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-history-current-victimization | Questionnaire CCARS History Current Victimization | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-history-of-issues | Questionnaire CCARS History Of Issues | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-history-of-mental-health-services | Questionnaire CCARS History Of Mental Health Services | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-hope-rating | Questionnaire CCARS Hope Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-interpersonal-rating | Questionnaire CCARS Interpersonal Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-legal-rating | Questionnaire CCARS Legal Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-legal-status | Questionnaire CCARS Legal Status | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-marital-status | Questionnaire CCARS Marital Status | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-medication-psychiatric-service | Questionnaire CCARS Medication Psychiatric Service | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-mental-health-services-program | Questionnaire CCARS Mental Health Services Program | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-multiple-issues-rating | Questionnaire CCARS Multiple Issues Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-overall-level-of-functioning-rating | Questionnaire CCARS Overall Level Of Functioning Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-overall-recovery-rating | Questionnaire CCARS Overall Recovery Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-overall-symptom-severity-rating | Questionnaire CCARS Overall Symptom Severity Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-physical-health-rating | Questionnaire CCARS Physical Health Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-place-of-residence | Questionnaire CCARS Place Of Residence | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-previous-concurrent-services | Questionnaire CCARS Previous Concurrent Services | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-psychosis-rating | Questionnaire CCARS Psychosis Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-race | Questionnaire CCARS Race | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-rae-aso-identification-codes | Questionnaire CCARS RAE ASO Identification Codes | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-reason-for-discharge | Questionnaire CCARS Reason For Discharge | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-role-performance-rating | Questionnaire CCARS Role Performance Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-school-development | Questionnaire CCARS School Development | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-school-problems | Questionnaire CCARS School Problems | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-security-supervision-rating | Questionnaire CCARS Security Supervision Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-self-care-basic-needs-rating | Questionnaire CCARS Self Care Basic Needs Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-sexual-orientation | Questionnaire CCARS Sexual Orientation | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-social-support-rating | Questionnaire CCARS Social Support Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-socialization-rating | Questionnaire CCARS Socialization Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-suicide-danger-to-self-rating | Questionnaire CCARS Suicide Danger To Others Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-tobacco-use | Questionnaire CCARS Tobacco Use | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-type-of-discharge | Questionnaire CCARS Type Of Discharge | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-type-of-update | Questionnaire CCARS Type Of Update | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-yes-no-na | Questionnaire CCARS Yes No NA | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-yes-no-unable-to-assess | Questionnaire CCARS Yes No Unable To Assess | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-yes-no | Questionnaire CCARS Yes No | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-admission-route-of-administration | Questionnaire DACODS Admission Route Of Administration | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-client-disability | Questionnaire DACODS Client Disability | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-clinician-diagnostic-impression | Questionnaire DACODS Clinician Diagnostic Impression | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-discharge-progress-towards-measurable-treatment-goals | Questionnaire DACODS Discharge Progress Towards Measurable Treatment Goals | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-discharge-route-of-administration | Questionnaire DACODS Discharge Route Of Administration | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-discharge-status | Questionnaire DACODS Discharge Status | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-drug-type-code | Questionnaire DACODS Drug Type Code | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-education-employment-problems | Questionnaire DACODS Education Employment Problems | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-employment-status | Questionnaire DACODS Employment Status | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-family-issues-and-problems | Questionnaire DACODS Family Issues And Problems | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-health-insurance-status | Questionnaire DACODS Health Insurance Status | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-living-situation | Questionnaire DACODS Living Situation | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-marital-status | Questionnaire DACODS Marital Status | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-medical-physical-problems | Questionnaire DACODS Medical Physical Problems | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-reason-for-discharge | Questionnaire Dacods Reason For Discharge | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-secondary-tertiary-drug-type-code | Questionnaire DACODS Secondary Tertiary Drug Type Code | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-sexual-orientation | Questionnaire DACODS Sexual Orientation | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-socialization-problems | Questionnaire DACODS Socialization Problems | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-source-of-illicit-drugs | Questionnaire DACODS Source Of Illicit Drugs | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-source-of-income | Questionnaire DACODS Source Of Income | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-source-of-payment-for-treatment | Questionnaire DACODS Source Of Payment For Treatment | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-statutory-commitment | Questionnaire DACODS Statutory Commitment | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-tobacco-use | Questionnaire DACODS Tobacco Use | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-transfer-referral-source | Questionnaire DACODS Transfer Referral Source | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-yes-no-na | Questionnaire DACODS Yes No NA | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-yes-no-unable-to-assess | Questionnaire DACODS Yes No Unable To Assess | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-yes-no-unknown | Questionnaire DACODS Yes No Unknown | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-yes-no | Questionnaire DACODS Yes No | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/reason-for-discharge | Reason For Discharge | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/us/core/CodeSystem/signal-filerepo-classification | Signal FileRepo Classification | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://signalbhn.org/fhir/us/core/CodeSystem/signal-filerepo-docreviewstatus | Signal FileRepo Doc Review DocStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/signal-region | Signal Region | active | 2023-09 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/us/core/CodeSystem/signal-state-activity-status | Signal State Activity Status | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-screening-assessment-observation-category | US Core Screening Assessment Observation Category | active | 2023-03 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/account-status | AccountStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/account-type | Account Types | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/fips-county-co | CO FIPS Counties | draft | 2023-06 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/address-type | AddressType | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/address-use | AddressUse | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/birthsex | Birth Sex | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/chargeitem-status | ChargeItemStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/composition-status | CompositionStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/condition-clinical | Condition Clinical Status Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/condition-severity | Condition/Diagnosis Severity | draft | | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/condition-ver-status | ConditionVerificationStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/contact-attempt-results | Contact Attempt Results | draft | | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/coverage-class | Coverage Class Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/coverage-copay-type | Coverage Copay Type Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/coverage-financial-exception | Example Coverage Financial Exception Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/data-absent-reason | DataAbsentReason | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/days-of-week | DaysOfWeek | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/detailed-ethnicity | Detailed ethnicity | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/detailed-race | Detailed Race | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/device-action | Procedure Device Action Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/device-kind | FHIR Device Types | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/diagnosis-role | DiagnosisRole | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/document-classcodes | Document Class Value Set | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/document-reference-status | DocumentReferenceStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/document-relationship-type | DocumentRelationshipType | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/encounter-admit-source | Admit source | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/encounter-diet | Diet | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/encounter-location-status | EncounterLocationStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/encounter-participant-type | Participant type | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/encounter-special-arrangements | Special arrangements | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/encounter-special-courtesy | Special courtesy | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/encounter-status | EncounterStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/episode-of-care-status | EpisodeOfCareStatus | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/episodeofcare-type | Episode of care type | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/event-status | EventStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/c80-facilitycodes | Facility Type Code Value Set | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/fm-status | Financial Resource Status Codes | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/formatcodes | DocumentReference Format Code Set | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.32 | Gender Identity | active | 2022-03 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/signal-healthcare-service-category | Signal Healthcare Service Category | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/healthcare-service-procedure-code-cpt | HealthCare Service Procedure Code CPT | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/signal-program | Signal Program | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/signal-healthcare-service-type | Signal Healthcare Service Type | draft | | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/identifier-use | IdentifierUse | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/invoice-priceComponentType | InvoicePriceComponentType | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/invoice-status | InvoiceStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/languages | Common Languages | draft | 2016-08 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/location-mode | LocationMode | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/location-physical-type | Location type | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/location-status | LocationStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/observation-category | Observation Category Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/observation-status | ObservationStatus | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/omb-ethnicity-category | OMB Ethnicity Categories | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/organization-role | Organization Affiliation Role | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/signal-organization-license | Signal Organization License | draft | 2023-07 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/us/core/ValueSet/signal-organization-type | Signal Organization Type | draft | 2023-07 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/performer-role | Procedure Performer Role Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/place-of-service | Place Of Service | draft | | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/procedure-category | Procedure Category Codes (SNOMED CT) | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/procedure-followup | Procedure Follow up Codes (SNOMED CT) | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/procedure-not-performed-reason | Procedure Not Performed Reason (SNOMED-CT) | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/procedure-outcome | Procedure Outcome Codes (SNOMED CT) | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/progress-made-towards-goals | Progress Made Towards Goals | draft | | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/provider-taxonomy | Provider Taxonomy Codes | draft | 2023-03 | hl7 |
| signal.core.r4 | R4 | http://terminology.hl7.org/ValueSet/v2-2.7-0360 | v2 table 0360, Version 2.7 | active | | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/questionnaire-answers-status | QuestionnaireResponseStatus | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-action-types | Questionnaire CCARS Action Types | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-activity-involvement-rating | Questionnaire CCARS Overall Activity Involvement Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-aggression-danger-to-others-rating | Questionnaire CCARS Aggression Danger To Others Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-alcohol-use-rating | Questionnaire CCARS Alcohol Use Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-cognition-rating | Questionnaire CCARS Cognition Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-considerations-for-providers | Questionnaire CCARS Considerations For Providers | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-current-issues | Questionnaire CCARS Current Issues | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-current-living-arrangement | Questionnaire CCARS Current Living Arrangement | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-current-non-prescription-substance-use | Questionnaire CCARS Current Non-Prescription Substance Use | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-current-primary-role | Questionnaire CCARS Current Primary Role | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-depressive-issues-rating | Questionnaire CCARS Depressive Issues Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-disabilities | Questionnaire CCARS Disabilities | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-drug-use-rating | Questionnaire CCARS Drug Use Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-empowerment-rating | Questionnaire CCARS Empowerment Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-enrollment-payer | Questionnaire CCARS Enrollment Payer | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-ethnicity | Questionnaire CCARS Ethnicity | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-existence-presenting-problem | Questionnaire CCARS Existence Presenting Problem | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-family-rating | Questionnaire CCARS Family Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-gender | Questionnaire CCARS Gender | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-highest-education-level | Questionnaire CCARS Highest Education Level | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-history-current-victimization | Questionnaire CCARS History Current Victimization | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-history-of-issues | Questionnaire CCARS History Of Issues | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-history-of-mental-health-services | Questionnaire CCARS History Of Mental Health Services | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-hope-rating | Questionnaire CCARS Hope Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-interpersonal-rating | Questionnaire CCARS Interpersonal Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-legal-rating | Questionnaire CCARS Legal Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-legal-status | Questionnaire CCARS Legal Status | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-marital-status | Questionnaire CCARS Marital Status | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-medication-psychiatric-service | Questionnaire CCARS Medication Psychiatric Service | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-mental-health-services-program | Questionnaire CCARS Mental Health Services Program | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-multiple-issues-rating | Questionnaire CCARS Multiple Issues Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-overall-level-of-functioning-rating | Questionnaire CCARS Overall Level Of Functioning Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-overall-recovery-rating | Questionnaire CCARS Overall Recovery Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-overall-symptom-severity-rating | Questionnaire CCARS Overall Symptom Severity Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-physical-health-rating | Questionnaire CCARS Physical Health Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-place-of-residence | Questionnaire CCARS Place Of Residence | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-previous-concurrent-services | Questionnaire CCARS Previous Concurrent Services | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-psychosis-rating | Questionnaire CCARS Psychosis Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-race | Questionnaire CCARS Race | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-rae-aso-identification-codes | Questionnaire CCARS RAE ASO Identification Codes | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-reason-for-discharge | Questionnaire CCARS Reason For Discharge | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-role-performance-rating | Questionnaire CCARS Role Performance Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-school-development | Questionnaire CCARS School Development | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-school-problems | Questionnaire CCARS School Problems | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-security-supervision-rating | Questionnaire CCARS Security Supervision Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-self-care-basic-needs-rating | Questionnaire CCARS Self Care Basic Needs Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-sexual-orientation | Questionnaire CCARS Sexual Orientation | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-social-support-rating | Questionnaire CCARS Social Support Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-socialization-rating | Questionnaire CCARS Socialization Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-suicide-danger-to-self-rating | Questionnaire CCARS Suicide Danger To Others Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-tobacco-use | Questionnaire CCARS Tobacco Use | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-type-of-discharge | Questionnaire CCARS Type Of Discharge | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-type-of-update | Questionnaire CCARS Type Of Update | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-yes-no-na | Questionnaire CCARS Yes No NA | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-yes-no-unable-to-assess | Questionnaire CCARS Yes No Unable To Assess | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-yes-no | Questionnaire CCARS Yes No | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-admission-route-of-administration | Questionnaire DACODS Admission Route Of Administration | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-client-disability | Questionnaire DACODS Client Disability | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-clinician-diagnostic-impression | Questionnaire DACODS Clinician Diagnostic Impression | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-discharge-progress-towards-measurable-treatment-goals | Questionnaire DACODS Discharge Progress Towards Measurable Treatment Goals | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-discharge-route-of-administration | Questionnaire DACODS Discharge Route Of Administration | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-discharge-status | Questionnaire DACODS Discharge Status | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-drug-type-code | Questionnaire DACODS Drug Type Code | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-education-employment-problems | Questionnaire DACODS Education Employment Problems | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-employment-status | Questionnaire DACODS Employment Status | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-family-issues-and-problems | Questionnaire DACODS Family Issues And Problems | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-health-insurance-status | Questionnaire DACODS Health Insurance Status | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-living-situation | Questionnaire DACODS Living Situation | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-marital-status | Questionnaire DACODS Marital Status | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-medical-physical-problems | Questionnaire DACODS Medical Physical Problems | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-reason-for-discharge | Questionnaire Dacods Reason For Discharge | draft | 2023-09 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-secondary-tertiary-drug-type-code | Questionnaire DACODS Secondary Tertiary Drug Type Code | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-sexual-orientation | Questionnaire DACODS Sexual Orientation | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-socialization-problems | Questionnaire DACODS Socialization Problems | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-source-of-illicit-drugs | Questionnaire DACODS Source Of Illicit Drugs | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-source-of-income | Questionnaire DACODS Source Of Income | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-source-of-payment-for-treatment | Questionnaire DACODS Source Of Payment For Treatment | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-statutory-commitment | Questionnaire DACODS Statutory Commitment | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-tobacco-use | Questionnaire DACODS Tobacco Use | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-transfer-referral-source | Questionnaire DACODS Transfer Referral Source | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-yes-no-na | Questionnaire DACODS Yes No NA | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-yes-no-unable-to-assess | Questionnaire DACODS Yes No Unable To Assess | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-yes-no-unknown | Questionnaire DACODS Yes No Unknown | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-yes-no | Questionnaire DACODS Yes No | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/reason-for-discharge | Reason For Discharge | active | 2023-06 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/referencerange-appliesto | Observation Reference Range Applies To Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/referencerange-meaning | Observation Reference Range Meaning Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/service-provision-conditions | ServiceProvisionConditions | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/service-referral-method | ReferralMethod | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/request-intent | RequestIntent | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/servicerequest-orderdetail | Service Request Order Details Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/request-priority | RequestPriority | draft | 2016-07 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/request-status | RequestStatus | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/service-type | Service type | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/us/core/ValueSet/signal-filerepo-classification | Signal FileRepo Classification | draft | 2023-09 | hl7 |
| signal.core.r4 | R4 | http://signalbhn.org/fhir/us/core/ValueSet/signal-filerepo-docreviewstatus | Signal FileRepo DocStatus | draft | 2023-09 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/signal-organization-qualification | Signal Organization Qualification | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/signal-region | Signal Region | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/us/core/ValueSet/signal-state-activity-status | Signal State Activity Status | draft | 2023-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/subscriber-relationship | SubscriberPolicyholder Relationship Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/contact-point-system | ContactPointSystem | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/contact-point-use | ContactPointUse | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-discharge-disposition | US Core Discharge Disposition | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-encounter-type | US Core Encounter Type | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-problem-or-health-concern | US Core Problem or Health Concern | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-screening-assessment-condition-category | US Core Screening Assessment Condition Category | active | 2023-04 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-servicerequest-category | US Core ServiceRequest Category Codes | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-simple-observation-category | US Core Simple Observation Category | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-usps-state | USPS Two Letter Alphabetic Codes | active | 2022-09 | hl7 |
| tiga.health.clinical | R4 | http://tigahealth.com/SearchParameter/tiga-allergyintolerance-encounter | TigaAllergyIntoleranceEncounter | active | 2022-09 | |
| tiga.health.clinical | R4 | http://tigahealth.com/SearchParameter/tiga-immunization-encounter | TigaImmunizationEncounter | active | 2022-10 | |
| tiga.health.clinical | R4 | https://www.ama-assn.org/cdt | CDT, The Code on Dental Procedures and Nomenclature, produced by American Dental Association (ADA) | active | | |
| tiga.health.clinical | R4 | http://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx | HL7 Table 0292, Vaccine Administered (CVX) is a product of the National Center of Immunization and Respiratory Diseases (NCIRD). NCIRD is part of the Centers for Disease Control and Prevention (CDC). | active | | |
| tiga.health.clinical | R4 | http://dicom.nema.org/ | DICOM defines how to format images and image quality requirements that aid the exchange of images for clinical use. | active | | |
| tiga.health.clinical | R4 | http://tigahealth.com/fhir/ConceptMap/cpt-hcpcs | | active | | |
| tiga.health.clinical | R4 | http://tigahealth.com/fhir/ConceptMap/dicom-loinc | | active | | |
| tiga.health.clinical | R4 | http://tigahealth.com/fhir/ConceptMap/hcpcs-cpt | | active | | |
| tiga.health.clinical | R4 | http://tigahealth.com/fhir/ConceptMap/loinc-dicom | | active | | |
| tiga.health.clinical | R4 | http://tigahealth.com/fhir/ConceptMap/snomed-dicom | | active | | |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/CapabilityStatement/client | Argonaut Provider Directory Client | draft | 2016-11 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/CapabilityStatement/server | Argonaut Provider Directory Server | draft | 2017-04 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/ImplementationGuide/ig | Argonaut Provider Directory Implementation Guide | draft | | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/StructureDefinition/argo-endpoint | Argonaut Provider Directory Endpoint | draft | 2016-11 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/StructureDefinition/argo-location | Argonaut Provider Directory Location | draft | 2016-11 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/StructureDefinition/argo-organization | Argonaut Provider Directory Organization | draft | 2016-11 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/StructureDefinition/argo-practitioner | Argonaut Provider Directory Practitioner | draft | 2016-11 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/StructureDefinition/argo-practitionerrole | Argonaut Provider Directory PractitionerRole | draft | 2016-11 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/ValueSet/provider-role | Argonaut Provider Directory Provider Role (NUCC) | draft | 2016-08 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/ValueSet/provider-specialty | Argonaut Provider Directory Provider Speciality (NUCC) | draft | 2016-08 | hl7 |
| hl7.fhir.us.patient-reported-outcomes | R4 | CapabilityStatement/server | Server | draft | 2017-03 | hl7 |
| hl7.fhir.us.patient-reported-outcomes | R4 | ImplementationGuide/ig | Patient Reported Outcomes | draft | | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ConceptMap/ndc-cvx | Argonaut NDC to CVX Code Mapping | active | 2016-06 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ImplementationGuide/ig | Implementation Guide Template | draft | | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/OperationDefinition/docref | Argonaut Get DocumentReferences | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/SearchParameter/ethnicity | ArgonautEthnicity | draft | 2016-12 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/SearchParameter/race | ArgonautRace | draft | 2016-12 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-allergyintolerance | Argonaut AllergyIntolerance Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-birthsex | Sex of patient assigned at birth | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-careplan | Argonaut CarePlan Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-careteam | Argonaut CareTeam Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-condition | Argonaut Condition Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-device | Argonaut Device Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-diagnosticreport | Argonaut DiagnosticReport Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-documentreference | Argonaut DocumentReference Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-ethnicity | Argonaut ethnicity Extension | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-goal | Argonaut Goal Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-immunization | Argonaut Immunization Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-medication | Argonaut Medication Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-medicationorder | Argonaut MedicationOrder Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-medicationstatement | Argonaut MedicationStatement Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-observationresults | Argonaut Observation Results Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-patient | Argonaut Patient Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-procedure | Argonaut Procedure Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-profile-link | Profile-Resource Association | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-race | Argonaut Race Extension | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-resource-documentation | Resource level Documentation | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-smokingstatus | Argonaut Smoking Status Observation Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-vitalsigns | Argonaut Vital Signs Observation Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/argo-codesystem | Argonaut Extension Codes | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/condition-category | Argonaut Condition Category Codes | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/detailed-ethnicity | US-Core Detailed ethnicity | draft | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/detailed-race | US-Core Detailed Race | draft | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/device-kind | Argonaut Device Types | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/languages | All Languages | draft | 2016-11 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/medication-codes | Medication Clinical Drug (RxNorm) | draft | 2016-05 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/narrative-status | Narrative Status | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/ndc-vaccine-codes | Vaccine National Drug Code (NDC) | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/observation-ccdasmokingstatus | Smoking Status | active | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/observation-ccdavitalsignresult | Argonaut Vital Sign Codes | active | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/observation-value-codes | Observation Value Codes (SNOMED-CT) | draft | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/omb-ethnicity | OMB Ethnicity Categories | draft | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/omb-race | OMB Race Categories | active | 2016-05 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/procedure-icd10pcs | Argonaut Procedure Type ICD-10-PCS Codes | draft | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/procedure-type | Argonaut ProcedureType | draft | 2016-05 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/provider-role | Care Team Provider Roles | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/substance-ndfrt | DAF Substance ND-FRT codes | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/substance-rxnorm | DAF Substance RxNorm Codes | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/substance-sct | DAF SNOMED CT Substances Other Than Clinical Drugs | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/substance | Argonaut Substance-Reactant for Intolerance and Negation Codes | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/ucum-vitals-common | Argonaut Vital Signs Units | draft | 2016-05 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/ucum | UCUM units | draft | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/usrealm-birthsex | USRealm Birth Sex Value Set | active | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/vacc-status | Argonaut Immunization Status | draft | 2016-10 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/CapabilityStatement/daf-datamart | Data Mart | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/CapabilityStatement/daf-datasource | Data Source | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/CapabilityStatement/daf-research-queryrequester | Research Query Requester | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/CapabilityStatement/daf-research-queryresponder | Research Query Responder | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/CodeSystem/daf-research-data-models | DAF Research Data Models | draft | 2017-04 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/CodeSystem/daf-research-query-formats | DAF Research Query Formats | draft | 2017-04 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/ImplementationGuide/ig | Implementation Guide Template | draft | | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/OperationDefinition/daf-execute-query | Execute Query | draft | 2016-07 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/OperationDefinition/daf-extract | Extract Data | draft | 2016-07 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/OperationDefinition/daf-load | Load Data | draft | 2016-07 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/StructureDefinition/daf-capabilitystatement | U.S. Data Access Framework (DAF) Capability Statement Profile | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/StructureDefinition/daf-data-model | Data Models | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/StructureDefinition/daf-operationdefinition | U.S. Data Access Framework (DAF) OperationDefinition Profile | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/StructureDefinition/daf-provenance | U.S. Data Access Framework (DAF) Provenance | draft | 2014-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/StructureDefinition/daf-query-format | Query Formats | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/StructureDefinition/daf-queryresults | U.S. Data Access Framework (DAF) Query Results | draft | 2014-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/StructureDefinition/daf-task | U.S. Data Access Framework (DAF) Task Profile | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/ValueSet/daf-research-data-models | DAF Research Data Models | active | 2016-07 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/ValueSet/daf-research-query-formats | DAF Research Query Formats | active | 2016-07 | hl7 |
| fhir.tx.support.r4 | R4 | urn:oid:2.16.840.1.113883.3.1937.98.5.8 | TemplateStatusCode LifeCycle | active | 2013-12 | hl7 |
| fhir.tx.support.r4 | R4 | https://www.humanservices.gov.au/organisations/health-professionals/enablers/air-vaccine-code-formats | Australian Immunisation Register Vaccine | active | 2021-03 | hl7 |
| fhir.tx.support.r4 | R4 | http://cap.org/eCP | College of American Pathologists Electronic Cancer Protocol (eCP) Codes | active | 2023-03 | hl7 |
| fhir.tx.support.r4 | R4 | http://terminology.hl7.org/CodeSystem/ICHContextOfUse | ICH Context of Use | active | 2025-05 | hl7 |
| fhir.tx.support.r4 | R4 | http://devices.fhir.org/CodeSystem/MDC-concept-status | MDC Concept Status | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://devices.fhir.org/CodeSystem/MDC-designation-use | MDC Designation Use | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://standardterms.edqm.eu | EDQM Standard Terms | active | 2019-03 | hl7 |
| fhir.tx.support.r4 | R4 | http://terminology.hl7.org/CodeSystem/hl7-document-format-codes | HL7 Document Format Codes | active | 2019-07 | hl7 |
| fhir.tx.support.r4 | R4 | urn:oid:2.16.840.1.113883.2.9.6.2.7 | International Standard Classification of Occupations (ISCO) | active | 2007-12 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/spdx-license | SPDXLicense | draft | 2021-01 | hl7 |
| fhir.tx.support.r4 | R4 | https://www.usps.com/ | US State Codes | active | 2013-12 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/resource-names-r2-r3 | Resource Names R2 to R3 | active | 2019-01 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/resource-names-r2-r4 | Resource Names R2 to R4 | active | 2019-01 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/resource-names-r3-r2 | Resource Names R3 to R2 | active | 2019-01 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/resource-names-r3-r4 | Resource Names R3 to R4 | active | 2019-01 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/resource-names-r4-r2 | Resource Names R4 to R2 | active | 2019-01 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/resource-names-r4-r3 | Resource Names R4 to R3 | active | 2019-01 | hl7 |
| fhir.tx.support.r4 | R4 | http://fhir.org/packages/fhir.tx.support.r4/ImplementationGuide/fhir.tx.support.r4 | FHIR Terminology Support Package | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://devices.fhir.org/ValueSet/MDC-dimension | MDC Unit of Measurement | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://devices.fhir.org/ValueSet/MDC-metric | MDC Metric nomenclature | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://devices.fhir.org/ValueSet/MDC-object | MDC Object infrastructure and Device nomenclature | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://devices.fhir.org/ValueSet/MDC-partition | MDC Partition codes | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://devices.fhir.org/ValueSet/MDC | MDC Nomenclature | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/uv/ips/ValueSet/allergy-intolerance-substance-product-gps-uv-ips | Allergy-intolerance substance-product - GPS - IPS | active | 2021-05 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/uv/ips/ValueSet/allergy-intolerance-substance-product-snomed-extended-uv-ips | Allergy intolerance substance product - SNOMED CT extended - IPS | active | 2021-05 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/ValueSet/covid-19-cond | COVID-19 related Condition codes | draft | 2020-03 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/ValueSet/covid-19-obs | COVID-19 related Observation codes | draft | 2020-03 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/ValueSet/jurisdiction-common | Common Jurisdiction Codes | active | 2020-09 | hl7 |
| fhir.tx.support.r4 | R4 | http://terminology.hl7.org/ValueSet/snomed-intl-ips | SNOMED CT® International Patient Set (IPS) | active | 2022-06 | hl7 |
| fhir.tx.support.r4 | R4 | https://www.iana.org/time-zones | IANA Timezones | draft | 2021-01 | hl7 |
| hl7.fhir.us.sdcde | R3 | CapabilityStatement/sdc-de-curator | SDC Data Element Curator | draft | 2014-07 | hl7 |
| hl7.fhir.us.sdcde | R3 | CapabilityStatement/sdc-de-registry | SDC Data Element Manager | draft | 2014-07 | hl7 |
| hl7.fhir.us.sdcde | R3 | ImplementationGuide/sdcde | Structured Data Capture - Data Element Exchange | draft | | hl7 |
| hl7.fhir.us.sdcde | R3 | StructureDefinition/sdcde-codesystem | Structured Data Capture Code System | draft | 2014-07 | hl7 |
| hl7.fhir.us.sdcde | R3 | StructureDefinition/sdcde-dataelement | Structured Data Capture Data Element Exchange | draft | 2014-04 | hl7 |
| hl7.fhir.us.sdcde | R3 | StructureDefinition/sdcde-valueset | Structured Data Capture Data Element Exchange Value Set | draft | 2014-07 | hl7 |
| hl7.fhir.us.sdcde | R3 | ValueSet/dataelement-sdccode | DataElement SDC Concept | draft | 2017-04 | hl7 |
| hl7.fhir.us.immds | R4 | CodeSystem/ForecastReason | Forecast Reason | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | CodeSystem/ForecastStatus | Forecast Status | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | CodeSystem/StatusReason | Evaluation Status Reason | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | ImplementationGuide/hl7.fhir.us.immds | Immunization Decision Support Forecast (ImmDS) Implementation Guide | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | OperationDefinition/ImmDSForecastOperation | Immunization Decision Support Forecast | draft | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | StructureDefinition/immds-immunization | ImmDS Immunization | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | StructureDefinition/immds-immunizationevaluation | ImmDS Immunization Evaluation | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | StructureDefinition/immds-immunizationrecommendation | ImmDS Immunization Recommendation | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | StructureDefinition/immds-patient | ImmDS Patient | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | ValueSet/ForecastReason | Forecast Reason | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | ValueSet/ForecastStatus | Forecast Status | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | ValueSet/StatusReason | Evaluation Status Reason | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | ValueSet/targetDisease | Vaccine Target Disease | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | ImplementationGuide/us.nlm.vsac | US VSAC Package | active | | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.1280649 | Sneezing and Itching Grouping | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.15972546 | Conditions Indicating Appropriate Sinonasal Imaging | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.16432390 | Cerumen Impaction | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.16929355 | Allergic Rhinitis Grouping | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.18316962 | Severe Asthma | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.19613338 | Immunoglobulin G Testing Grouping | active | 2022-03 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.23618223 | Hearing Aids Grouping | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.24927846 | Specific IgE testing | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.26050446 | Ear Surgery Affecting the Tympanic Membrane | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.26878039 | Specific IgE Testing | active | 2022-03 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.29996863 | Immunoglobulin G testing | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.4352590 | Benign Prostatic Hyperplasia | active | 2017-08 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.8867.26816.649902 | Office or Outpatient Encounter | active | 2017-07 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.12009.10.2.5 | LOINC Imaging Document Codes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.33895.1.3.0.45 | Comfort Measures | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.15.1.999.1 | Selected non pharmaceutical therapies for moderate to severe chronic pain | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.16.1.1.999.3 | selected first line medications for pain control | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.16.1.11.1.999.3 | selected muscle relaxants for pain control | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.16.1.12.1.999.3 | Selected topical agents for pain control | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.17.1.1.999.2 | selected non opioids for moderate to severe pain | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.17.1.11.1.999.2 | Selected opioids for moderate to severe pain | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.18.1.1.11.1.999.1 | pain medication action plan | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.15.2.1.1.999.1 | Selected urine drug screens for opioids indicating testing is complete | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.15.7.1.1.11.1.999.1 | selected follow up visit intervals for opioid monitoring | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.2 | Selected urine screening for patients receiving opioid therapy | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.3.1 | Opioids used for pain control | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.3.2 | All prescribable opioids used for pain control including Inactive Medications | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.4.1 | malignant neoplasms and cancer pain | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.4.2 | malignant neoplasms and cancer pain | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.4.7 | malignant neoplasms and cancer pain | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.4.9 | malignancy or cancer related pain | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31172.1.1.999.150 | Cerumen on Otoscopy | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31172.1.1.999.151 | Cerumen on Otoscopy | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31172.1.1.999.152 | Cerumen on Otoscopy | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.12.1.999.172 | Hearing Loss | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.12.1.999.173 | Hearing Loss | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.12.1.999.174 | Hearing Loss | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.13.1.999.175 | Tinnitus | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.13.1.999.176 | Tinnitus | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.13.1.999.177 | Tinnitus | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.14.1.999.178 | Ear Congestion | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.15.1.999.179 | Ear Pruritus | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.16.1.999.180 | Otalgia | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.16.1.999.181 | Otalgia | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.16.1.999.182 | Otalgia | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31441.1.2.999.96 | Initial Encounter with Otolaryngologist or undefined clinician | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31471.1.11.1.999.204 | Hearing Aids | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31471.1.11.1.999.205 | Hearing Aids | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31471.1.11.1.999.206 | Hearing Aids | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31212.1.1.999.81 | Cerumen Impaction | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31212.1.1.999.82 | Cerumen Impaction | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31305.1.11.1.999.188 | Radiotherapy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31305.1.11.1.999.189 | Radiotherapy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31305.1.11.1.999.190 | Radiotherapy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31305.1.11.2.999.191 | Head and Neck Anatomic Locations | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31305.1.11.2.999.192 | Conditions Associated with Head and Neck Radiotherapy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31305.1.11.2.999.193 | Conditions Associated with Head and Neck Radiotherapy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31317.1.1.999.194 | Ear Canal Stenosis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31317.1.1.999.195 | Ear Canal Stenosis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31317.1.1.999.196 | Ear Canal Stenosis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31329.1.1.999.197 | Exostoses | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31329.1.1.999.198 | Exostoses | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31329.1.1.999.199 | Exostoses | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31341.1.1.999.200 | Non intact Tympanic Membrane | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31341.1.1.999.201 | Non Intact Tympanic Membrane | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31341.1.1.999.202 | Non Intact Tympanic Membrane | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31481.1.11.1.999.246 | Hearing Aids | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31481.1.11.1.999.250 | DO NOT USE | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31481.1.12.1.999.251 | Cerumenolytics | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31481.1.12.1.999.252 | Irrigation | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31481.1.12.1.999.253 | Irrigation | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31593.1.12.1.999.288 | Otoscopy performed on exam | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31663.1.1.999.291 | Otolaryngologist as a Clinician or Service | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.8.31102.1.1.999.123 | Cerumen Impaction | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31104.1.1.999.275 | Dermatologic Diseases of the Ear | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31108.1.1.999.20 | Keratoses Obturans | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.11.1.999.221 | Tympanoplasty | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.11.1.999.222 | Tympanoplasty | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.12.1.999.223 | Myringoplasty | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.12.1.999.224 | Myringoplasty | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.13.1.999.225 | Mastoidectomy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.13.1.999.229 | Mastoidectomy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.14.1.999.227 | Ear Surgery, Other | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.14.1.999.228 | Ear Surgery, Other | active | 2018-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.12.31833.1.1.999.334 | Sleep Apnea | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.12.31833.1.1.999.335 | Sleep Apnea | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.12.31833.1.1.999.336 | Sleep Apnea | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.34853.1.1.999.237 | Allergic Rhinitis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.34853.1.1.999.238 | Allergic Rhinitis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.34853.1.1.999.239 | Allergic Rhinitis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.34951.1.11.1.999.263 | Uncontrolled or severe asthma | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.34951.1.11.1.999.264 | Uncontrolled or severe asthma | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.34951.1.11.1.999.265 | Uncontrolled or severe asthma | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.11.1.999.300 | Rhinosinusitis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.11.1.999.301 | Rhinosinusitis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.11.1.999.302 | Rhinosinusitis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.12.1.999.303 | Nasal Polyposis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.12.1.999.304 | Nasal Polyposis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.12.1.999.305 | Nasal Polyposis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.13.1.999.306 | Suspected Nasal Neoplasm | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.13.1.999.307 | Suspected Nasal Neoplasm | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.13.1.999.308 | Suspected Nasal Neoplasm | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.14.1.999.309 | Other sinus conditions potentially requiring imaging | active | 2017-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.14.1.999.310 | Other sinus conditions potentially requiring imaging | active | 2017-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35211.1.11.1.999.319 | Intranasal Antihistamines | active | 2017-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35211.1.12.1.999.320 | Mast Cell Stabilizers | active | 2017-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35211.1.13.1.999.321 | Ophthalmic Antihistamines | active | 2017-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35282.1.11.1.999.215 | Sneezing as a finding | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35282.1.11.1.999.216 | Sneezing as a Clinical Condition | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35282.1.12.1.999.217 | Pruritus Unspecified or Other Location | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35282.1.12.1.999.218 | Pruritus Unspecified or Other Location | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.34907.1.11.1.999.272 | Specific IgE Testing for Allergies | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.34907.1.12.1.999.273 | Immunoglobulin G Testing | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.34907.1.13.1.999.274 | Total IgE Testing | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.34920.1.1.999.290 | Clinicians who perform allergy testing | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35043.1.1.999.279 | Radiography of face, head or neck | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35221.1.11.1.999.315 | Intranasal Corticosteroids | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35221.1.13.1.999.316 | Eustachian Tube Dysfunction | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35221.1.13.1.999.317 | Eustachian Tube Dysfunction | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35221.1.13.1.999.318 | Eustachian Tube Dysfunction | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35292.1.1.999.287 | Oral Second Generation and Less Sedating Antihistamines | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35464.1.1.999.266 | Leukotriene antagonist | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35607.1.11.1.999.267 | Immunotherapy that is not Identified as Subcutaneous | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35607.1.14.1.999.268 | Immunotherapy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.12.37641.1.1.999.653 | Fidaxomicin | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.12.37696.1.1.999.654 | Proton Pump Inhibitors not including for H. pylori treatment | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.37752.1.1.999.655 | Clostridium difficile infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.37752.1.1.999.656 | Clostridium difficile infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.37752.1.1.999.657 | Clostridium difficile infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38167.1.1.999.594 | Complete Blood Count (with Diff) | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38256.1.1.999.662 | Metronidazole Systemic | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38266.1.1.999.663 | Vancomycin non injectable | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38343.1.1.999.665 | Creatinine | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.11.1.999.722 | Ileus due to infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.11.1.999.723 | Ileus due to infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.11.1.999.724 | Ileus due to infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.12.1.999.725 | Vomiting potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.12.1.999.726 | Vomiting potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.12.1.999.727 | Vomiting potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.13.1.999.728 | Toxic Megacolon in adults | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.13.1.999.729 | Toxic Megacolon in adults | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.13.1.999.730 | Toxic Megacolon in adults | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.14.1.999.731 | Abdominal Distension | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.14.1.999.732 | Abdominal Distension | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38493.1.1.999.688 | Septic Shock due to C. Diff | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38493.1.1.999.689 | Septic Shock due to C. Diff | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38493.1.1.999.690 | Septic Shock due to C. Diff | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.37872.1.1.999.658 | Antiperistaltic agents to avoid in C. diff | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.37872.1.1.999.734 | Systemic Antimicrobial Medications not used for CDI | active | 2019-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.37937.1.11.1.999.659 | Recurrent Clostridium difficile infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.37937.1.13.2.999.660 | History of CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.38112.1.1.999.661 | Consult Infectious Disease | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.38827.1.1.999.691 | Abdominal Xrays for CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.38839.1.1.999.692 | CT of abdomen with contrast for fulminant CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.38904.1.1.999.693 | Surgical consult for CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.39406.1.1.999.694 | Fecal microbiota transplantation | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.4.37623.1.1.999.645 | Hospitalist | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37627.1.1.999.697 | Positive result indicator | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37627.1.1.999.698 | Clostridium Difficile Test | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37631.1.11.1.999.646 | Body Temperature | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37631.1.11.1.999.647 | Body Temperature | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37631.1.12.1.999.648 | Diarrhea Potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37631.1.12.1.999.649 | Diarrhea Potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37631.1.12.1.999.650 | Diarrhea Potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37631.1.13.1.999.651 | Leukocyte count | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.9.37637.1.1.999.652 | Inpatient Setting | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1 | ONC Administrative Sex | active | 2015-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.1 | Substance Reactant for Intolerance | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.2 | Clinical Substance | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.4 | Medication Clinical Drug | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.5 | Medication Clinical Brand specific Drug | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.6 | CVX Vaccines Administered Vaccine Set | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.7 | Clinical Drug Ingredient | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.8 | Vaccine Clinical Drug | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.9 | Substance Other Than Clinical Drug | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1018.240 | SNOMED CT CORE Problem List | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1018.98 | Route of Administration | active | 2019-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.101 | Gender Identity USCDI core | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.102 | Unknown or did not answer | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.103 | Other or unknown or refused to answer | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.12 | Low Molecular Weight Heparin for VTE prophylaxis ingredient specific | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.120 | Patient Sex for Quality Measurement | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.121 | Federal Administrative Sex | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.14 | Published test VS | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.24 | Birth Sex | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.30 | AdministrationUnitDoseForm | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.33 | Sexual Orientation | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.40 | MDP Test Intensional | active | 2019-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.41 | MDP Test HL7 Intensional | active | 2019-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.46 | Device Magnetic resonance (MR) Safety | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.47 | Device Latex Safety | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.48 | Implantable Device Status | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.56 | Medical Reason Not Done SCT | active | 2019-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.119 | Phototherapy | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.120 | Phototherapy | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.121 | Phototherapy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.122 | Neonatal Jaundice | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.123 | Neonatal Jaundice | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.124 | Neonatal Jaundice | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.125 | Maternal Drug Use | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.126 | Maternal Drug Use | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.127 | Maternal Drug Use | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.128 | Fetal Conditions | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.129 | Fetal Conditions | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.130 | Fetal Conditions | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.131 | Congenital Malformations | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.132 | Congenital Malformations | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.133 | Congenital Malformations | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.134 | Social Indications | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.135 | Social Indications | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.136 | Social Indications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.137 | Neonatal Severe Birth Trauma | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.138 | Neonatal Severe Birth Trauma | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.139 | Neonatal Severe Birth Trauma | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.140 | Neonatal Severe Hypoxia or Asphyxia | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.141 | Neonatal Severe Hypoxia or Asphyxia | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.142 | Neonatal Severe Hypoxia or Asphyxia | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.143 | Neonatal Severe Shock and Resuscitation | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.144 | Neonatal Severe Shock and Resuscitation | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.145 | Neonatal Severe Shock and Resuscitation | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.146 | Neonatal Severe Respiratory Complications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.147 | Neonatal Severe Respiratory Complications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.148 | Neonatal Severe Respiratory Complications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.149 | Neonatal Severe Infection | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.150 | Neonatal Severe Infection | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.151 | Neonatal Severe Infection | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.152 | Neonatal Severe Neurological Complications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.153 | Neonatal Severe Neurological Complications | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.154 | Neonatal Severe Neurological Complications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.155 | Neonatal Severe Shock and Resuscitation Procedures | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.156 | Neonatal Severe Shock and Resuscitation Procedures | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.157 | Neonatal Severe Shock and Resuscitation Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.158 | Neonatal Severe Respiratory Procedures | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.159 | Neonatal Severe Respiratory Procedures | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.160 | Neonatal Severe Respiratory Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.161 | Neonatal Severe Neurological Procedures | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.162 | Neonatal Severe Neurological Procedures | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.163 | Neonatal Severe Neurological Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.164 | Neonatal Severe Septicemia | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.165 | Neonatal Severe Septicemia | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.166 | Neonatal Severe Septicemia | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.167 | Neonatal Moderate Birth Trauma | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.168 | Neonatal Moderate Birth Trauma | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.169 | Neonatal Moderate Birth Trauma | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.170 | Neonatal Moderate Respiratory Complications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.171 | Neonatal Moderate Respiratory Complications | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.172 | Neonatal Moderate Respiratory Complications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.173 | Neonatal Moderate Respiratory Complications Procedures | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.174 | Neonatal Moderate Respiratory Complications Procedures | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.175 | Neonatal Moderate Respiratory Complications Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.176 | Neonatal Moderate Birth Trauma with LOS | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.177 | Neonatal Moderate Birth Trauma with LOS | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.178 | Neonatal Moderate Birth Trauma with LOS | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.179 | Neonatal Moderate Respiratory Complications with LOS | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.180 | Neonatal Moderate Respiratory Complications with LOS | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.181 | Neonatal Moderate Respiratory Complications with LOS | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.182 | Moderate Neurological Complications with LOS Procedures | active | 2019-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.183 | Neonatal Moderate Neurological Complications with LOS Procedures | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.184 | Neonatal Moderate Neurological Complications with LOS Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.185 | Neonatal Moderate Respiratory complications with LOS Procedures | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.186 | Neonatal Moderate Respiratory complications with LOS Procedures | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.187 | Neonatal Moderate Respiratory complications with LOS Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.188 | Single Liveborn Newborn Vaginal | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.189 | Single Liveborn Newborn Vaginal | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.190 | Single Liveborn Newborn Vaginal | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.191 | Single Liveborn Newborn Cesarean | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.192 | Single Liveborn Newborn Cesarean | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.193 | Single Liveborn Newborn Cesarean | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.194 | Birth Weight | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.195 | Neonatal Moderate Infection with LOS | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.196 | Neonatal Moderate Infection with LOS | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.197 | Neonatal Moderate Infection with LOS | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.203 | Neonatal Intensive Care Unit | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.204 | Intensive Care Unit | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.205 | Neonatal Intensive Care Unit | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.206 | Intensive Care Unit | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.208 | Blood Transfusion Administration | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.209 | Blood Transfusion Administration | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.213 | Blood Transfusion | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.214 | Acute Respiratory Distress Syndrome | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.217 | Amniotic Fluid Embolism | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.219 | Aortic Aneurysm | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.220 | Aortic Aneurysm | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.221 | Cardiac Arrest Ventricular Fibrillation | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.223 | Disseminated Intravascular Coagulation | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.225 | Eclampsia | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.227 | Heart Failure Cardiac Arrest Related to Procedure or Surgery | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.228 | Heart Failure Cardiac Arrest Related to Procedure or Surgery | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.229 | Puerperal Cerebrovascular Disorder | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.231 | Pulmonary Edema | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.233 | Acute Heart Failure | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.235 | Severe Anesthesia Complications | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.237 | Sepsis | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.239 | Shock | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.24 | Blood Transfusion Administration | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.241 | Sickle Cell Disease with Crisis | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.243 | Air and Thrombotic Embolism | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.245 | Blood Transfusion | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.246 | Blood Transfusion | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.247 | Conversion of Cardiac Rhythm | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.248 | Conversion of Cardiac Rhythm | active | 2021-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.249 | Hysterectomy | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.250 | Hysterectomy | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.251 | Tracheostomy | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.252 | Tracheostomy | active | 2021-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.253 | Ventilation | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.254 | Ventilation | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.255 | Severe Maternal Morbidity Diagnoses | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.256 | Severe Maternal Morbidity Procedures | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.267 | Gestational Diabetes | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.269 | Gestational Diabetes | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.271 | HIV in Pregnancy Childbirth and Puerperium | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.272 | HIV in Pregnancy Childbirth and Puerperium | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.274 | Preexisting Diabetes | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.275 | Preexisting Diabetes | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.277 | Previous Cesarean | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.278 | Previous Cesarean | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.279 | Pulmonary Hypertension | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.281 | Pulmonary Hypertension | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.282 | Multiple Pregnancy | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.284 | Multiple Pregnancy | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.286 | Bleeding Disorder | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.287 | Bleeding Disorder | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.289 | Morbid or Severe Obesity | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.290 | Morbid or Severe Obesity | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.291 | Economic Housing Instability | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.292 | Economic Housing Instability | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.295 | Thyrotoxicosis | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.296 | Thyrotoxicosis | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.297 | Preterm Birth | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.299 | Preterm Birth | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.300 | Placenta Accreta | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.302 | Placenta Accreta | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.303 | Placental Abruption | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.305 | Placental Abruption | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.306 | Neuromuscular Disease | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.308 | Neuromuscular Disease | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.309 | Autoimmune Disease | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.311 | Autoimmune Disease | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.312 | Mental Health Disorder | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.314 | Mental Health Disorder | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.315 | Bariatric Surgery | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.317 | Bariatric Surgery | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.318 | Substance Abuse | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.320 | Substance Abuse | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.321 | Anemia | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.323 | Anemia | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.324 | Severe Preeclampsia | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.326 | Mild or Moderate Preeclampsia | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.327 | Severe Preeclampsia | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.329 | Mild or Moderate Preeclampsia | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.330 | Hypertension | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.332 | Hypertension | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.333 | Renal Disease | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.335 | Renal Disease | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.336 | Gastrointestinal Disease | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.338 | Gastrointestinal Disease | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.339 | Cardiac Disease | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.341 | Cardiac Disease | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.344 | Aortic Aneurysm | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.357 | Conversion of Cardiac Rhythm | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.358 | Hysterectomy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.359 | Tracheostomy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.360 | Ventilation | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.361 | Venous Thromboembolism in Pregnancy | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.363 | Venous Thromboembolism in Pregnancy | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.364 | Long Term Anticoagulant Use | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.366 | Long Term Anticoagulant Use | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.368 | Preadmission Observation Undelivered Mother | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.369 | ED Visit and OB Triage | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.370 | Present on Admission is No or Unable To Determine | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.371 | COVID 19 Confirmed | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.372 | COVID 19 Confirmed | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.373 | COVID 19 Confirmed | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.374 | Respiratory Conditions Related to COVID 19 | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.375 | Respiratory Conditions Related to COVID 19 | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.376 | Respiratory Conditions Related to COVID 19 | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.377 | Respiratory Support Procedures | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.378 | Respiratory Support Procedures | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.379 | Respiratory Support Procedures Related to COVID 19 | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.387 | Placenta Increta or Percreta | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.388 | Placenta Increta or Percreta | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.67 | Other Health Care Facility | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.10 | Non essential Hypertension SNOMEDCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.102 | Suicide Attempt | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.11 | Cirrhosis ICD9CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.12 | Cirrhosis ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.13 | Cirrhosis SNOMEDCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.14 | Cirrhosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.151 | Polycystic Ovary Syndrome | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.16 | Low Intensity Statin Therapy/Branded | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.17 | Moderate Intensity Statin Therapy/Branded | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.18 | High Intensity Statin Therapy/Branded | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.21 | ALT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.230 | Gestational Diabetes SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.231 | Gestational Diabetes ICD10CM | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.233 | All Results of High Risk HPV Test | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.234 | High Risk HPV Positive Results | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.248 | Suicide Attempt SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.26 | Nonopioid pain medications | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.263 | High Risk Positive HPV Results Without HPV16 or HPV18 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.264 | CDS Pregnancy | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.265 | CDS Pregnancy Intensional | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.266 | Rhabdomyolysis Intensional | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.267 | CDS Rhabdomyolysis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.268 | HPV Negative Results | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.27 | Non pharmacologic treatments for chronic pain ICD10PCS | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.28 | Urine drug screen for pain management | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.29 | Non pharmacologic treatments for chronic pain SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.292 | Non pharmacologic treatments for chronic pain NCI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.296 | SCT Findings 202209 | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.298 | Cervical Cytology Test | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.299 | HPV 16 Tests | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.300 | HPV 18 Tests | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.302 | Test Cervical Excision Procedures | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.303 | Statin Combinations | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.305 | Counseling for Physical Activity CPT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.306 | Counseling for Physical Activity ICD10CM | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.307 | Counseling for Physical Activity CDS | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.308 | Cardiovascular disease 10Y risk | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.309 | SCT Findings 202309 | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.311 | SCT Procedures 202209 | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.312 | SCT Procedures 202309 | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.313 | Statin Allergen Grouping | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.319 | Steward Transfer Test | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.320 | Opioids ATCPROD N02A | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.322 | Test 123 | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.34 | Opioid pain medications | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.36 | Non pharmacologic treatments for chronic pain | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.40 | Suicide attempt | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.42 | Naloxone and Nalmefene medications | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.43 | Benzodiazepine medications | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.44 | Stool softeners and laxatives | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.47 | Anxiety | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.48 | Anxiety | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.50 | Sleep disordered breathing | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.51 | Sleep disordered breathing | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.52 | Anxiety | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.53 | Sleep disordered breathing | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.54 | Adjuvant pain medications | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.55 | Risk assessments relevant to pain management | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.6 | Non essential Hypertension ICD9CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.7 | Non essential Hypertension ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.79 | Behavioral Counseling for Nutrition and Activity Referral | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.85 | Impaired Glucose Tolerance | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.87 | Fasting Plasma Glucose | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.88 | Waist Circumference | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.9 | Hypertension | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.90 | Gestational Diabetes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.92 | First Degree Family Member | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.94 | Glucose Tolerance Test Results | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.96 | Dependence on dialysis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.99 | Gestational Diabetes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.460 | Cluster Headache (ICD10CM) | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.461 | Cluster Headache (ICD9CM) | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.464 | Cluster Headache | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.467 | Medication Therapy for Cluster Headache (RXNORM) | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.555 | Patient Declines Treatment for Cluster Headache (SNOMEDCT) | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.558 | Acute Cluster Headache Medication (RXNORM) | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.559 | Long Term Preventive Medication for Cluster Headache | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.561 | Oral Steroid for Cluster Headache | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.569 | Migraine Preventive Medication | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.601 | Acute Migraine Attack Medication | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.605 | NSAID OTC Migraine Attack Medication | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.606 | NSAID Prescribable Migraine Attack Medication | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.640 | Neurologic Disorders | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.641 | Neuromodulation for migraine | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.642 | No pain with headache | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.643 | Antiplatelets | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.644 | Anticoagulants | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.645 | Statin Medications | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.646 | Anxiety Disorders (ICD10 and SNOMED) | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.648 | Depression Diagnosis (ICD10 and SNOMED) | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.649 | Psychosis (ICD10 and SNOMED) | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.650 | Cluster Headache (SNOMED) | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.651 | Galcanezumab (RxNorm) | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.652 | Lithium (RxNorm) | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.653 | Verapamil | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.654 | Long term preventive medications for cluster headache | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.655 | Short term preventive medication for cluster headache | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.656 | Zolmitriptan | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.657 | Sumatriptan | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.658 | Dihydroergotamine | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.659 | Acute cluster headache medication | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.660 | Acute cluster headache treatment | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.661 | Short term preventive treatment for cluster headache | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.662 | Long term preventive treatment for cluster headache | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.663 | Migraine diagnosis (ICD) | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.664 | Prescribable NSAIDs and Acute Migraine Attack Medication | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.103 | Abnormal Presentation | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.105 | Abnormal Presentation | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.114 | Hematocrit Lab Test | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.117 | Potassium Lab Test | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.119 | Sodium Lab Test | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.127 | Platelet Count Lab Test | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.129 | White Blood Cells Count Lab Test | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.130 | Respiratory Rate | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.134 | Glucose Lab Test | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.139 | Bicarbonate Lab Test | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.15 | Intravenous Thrombolytic tPA Therapy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.151 | Oxygen Saturation by Pulse Oximetry | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.152 | Body Temperature | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.159 | Body Weight | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.16 | Intraarterial Thrombolytic tPA Therapy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.163 | Systolic Blood Pressure | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.171 | Abnormal Presentation | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.173 | Delivery of Singleton | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.21 | Intravenous or Intraarterial Thrombolytic tPA Therapy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.26 | Estimated Gestational Age at Delivery | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.27 | Cornual Ectopic Pregnancy | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.38 | General Or Neuraxial Anesthesia | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.39 | Low Dose Unfractionated Heparin for VTE Prophylaxis | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.41 | Glycoprotein IIb IIIa Inhibitors | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.55 | Oxytocin | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.56 | Dinoprostone | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.58 | Delivery Procedures | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.59 | Delivery Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.66 | PCI | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.67 | PCI | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.68 | Endotracheal Intubation | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.69 | Endotracheal Intubation | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.98 | Delivery of Singleton | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.99 | Delivery of Singleton | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.225 | Opioid Medication Assisted Treatment (MAT) SNOMED | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.241 | Schedule II, III and IV Opioid Medications | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.242 | Opioid Use Disorder | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.243 | Opioid Use Disorder | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.265 | Inpatient, Emergency, and Observation Locations | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.269 | Medications for Opioid Use Disorder (MOUD) | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.274 | NHSN Inpatient Encounter Class Codes | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.277 | Emergency Department Location | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.278 | Emergency Department Treatment Location | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.279 | Triage | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.283 | Emergency Department Location | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.284 | Emergency Department Location | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.285 | Mental Health Diagnosis without Substance Use Disorders | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.286 | Decision to Transfer | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.35 | Healthcare Agent or Proxy Choices | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.10 | Breastfeeding | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.100 | Familial Hypercholesterolemia | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.102 | Rhabdomyolysis | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.107 | Low Intensity Statin Therapy | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.12 | Liver Disease | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.13 | Rhabdomyolysis | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.19 | Atherosclerosis and Peripheral Arterial Disease | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.20 | Atherosclerosis and Peripheral Arterial Disease | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.21 | Atherosclerosis and Peripheral Arterial Disease | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.22 | Liver Disease ICD9 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.37 | Stable and Unstable Angina | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.39 | Cerebrovascular Disease Stroke or TIA | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.41 | Ischemic Heart Disease or Related Diagnoses | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.42 | Liver Disease | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.43 | Liver Disease | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.44 | Cerebrovascular Disease Stroke or TIA | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.46 | Ischemic Heart Disease or Related Diagnoses | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.47 | Stable and Unstable Angina | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.501 | Overweight or Obese | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.502 | Overweight or Obese | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.512 | Elevated Blood Pressure Reading | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.513 | Elevated Blood Pressure Reading | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.514 | Finding of Elevated Blood Pressure or Hypertension | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.515 | Bariatric Procedures | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.517 | Age related macular degeneration intermediate dry | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.518 | Ophthalmologist visit | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.519 | Posterior vitreous detachment (PVD) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.521 | Ophthalmoscopic exam | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.523 | Opthalmoscopic exams with Scleral Depression | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.525 | Referral (ophthalmology) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.526 | Retina Ultrasound | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.527 | Retina visualization inadequate | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.528 | Refusal or Noncompliance with treatment | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.529 | Vitreous hemorrhage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.530 | Vitreous hemorrhage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.536 | Macula examination | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.539 | Fluorescein angiography | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.541 | Optical coherence tomography (OCT) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.542 | Intravitreal injection | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.543 | Bevacizumab injection | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.544 | Ranibizumab injection | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.545 | Aflibercept injection | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.552 | Uveitis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.553 | Uveitis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.554 | Post Cataract Surgery Cystoid Macular Edema AND Idiopathic Macular Edema | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.555 | Macular edema | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.556 | Corticosteroids for Injection | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.557 | Corticosteroids for Injection | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.560 | Tonometry | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.561 | Intraocular pressure | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.571 | Retinal Vein Occlusion Related Macular Edema | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.576 | Vitreous hemorrhage | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.580 | Intravitreal and Periocular Injections | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.581 | Intravitreal and Periocular Injections | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.582 | Corticosteroids for Injection | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.583 | Endophthalmitis in the Right Eye | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.584 | Endophthalmitis in the Left Eye | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.585 | Panophthalmitis in the Right Eye | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.586 | Panophthalmitis in the Left Eye | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.587 | Lost to follow up | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.588 | Uveitis | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.610 | Scleral depressed exam | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.611 | 3 Mirror Goldmann exam | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.612 | Scleral depressed exam | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.615 | Physical Disability | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.616 | Financial difficulty | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.617 | Vitreous exam findings | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.619 | Scleral depressed exam | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.629 | Post operative follow up | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.67 | Breastfeeding | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.69 | Stable and Unstable Angina | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.70 | Ischemic Heart Disease or Related Diagnoses | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.71 | Cerebrovascular Disease Stroke or TIA | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.73 | Breastfeeding | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.85 | Familial Hypercholesterolemia | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.89 | Rhabdomyolysis | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.9 | Outpatient Encounters for Preventive Care | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.91 | Familial Hypercholesterolemia | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.93 | Hypercholesterolemia ICD 9 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.97 | High Intensity Statin Therapy | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.98 | Moderate Intensity Statin Therapy | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1056.50 | HIV Lab Tests | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1056.51 | Indicators of Human Immunodeficiency Virus (HIV) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1056.52 | Indicators of Human Immunodeficiency Virus (HIV) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1056.53 | Indicators of Human Immunodeficiency Virus (HIV) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1056.71 | Human Immunodeficiency Virus (HIV) Viral Load | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.10 | ARBs (Angiotensin Receptor Blockers) | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1000 | OIA_V2_GLP1s_RxNorms | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1001 | OIA_V2_PCSK9s_RxNorms | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1002 | OIA_RFs_Secondary_Prevention_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1003 | OIA_RFs_Secondary_Prevention_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1004 | OIA_RFs_Secondary_Prevention_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1005 | OIA_RFs_Secondary_Prevention_ICD_SM_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1006 | OIA_Asthma_COPD_Combo_Meds | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1007 | OIA_Asthma_COPD_Combo_Meds_SABA_SAMA | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1008 | OIA_Asthma_COPD_Combo_Meds_LABA_LAMA_ICS | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1009 | PAE_Patient_Conditions | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1012 | PAE Conditions Short | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1016 | OIA_TEST_VS | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1017 | Triptan Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1018 | NSAID Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1019 | Statin Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1021 | Penicillin Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1022 | Macrolide Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1023 | Quinolone Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1025 | Beta blocker Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1026 | ACE inhibitor Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1027 | ARB Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1028 | Sulfonylurea Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1030 | DPP4i Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1031 | GLP1RA Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1032 | Beta blocker allergy intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1033 | SGLT2i Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1034 | MRA Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1036 | Meglitinide Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1037 | Alpha glucosidase inhibitor Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1038 | TZD Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1041 | Hemoglobin | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1042 | Hematocrit | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1043 | Anemia for Erythropoesis Simulating Agents I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1044 | Anemia for Erythropoesis Simulating Agents SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1045 | Anemia for Erythropoesis Simulating Agents | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1046 | AZT Meds | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1047 | Ferritin | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1048 | Knee pain I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1049 | Knee pain SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.105 | conditions_heartfailure | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1050 | Knee pain | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1051 | Knee decreased ROM SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1052 | Knee effusion I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1054 | Knee effusion | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1055 | Knee crepitus SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1056 | OIA_Antiemetics | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1057 | OIA_PDE5is | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1058 | OIA_Vitamins | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1059 | OIA_Plavix | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1061 | OIA_Oral_Contraceptives | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1063 | OIA_Topical_Steroids | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1064 | OIA_Cough_Cold_Meds | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1065 | Antiperspirant aluminum salts | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1066 | Antiperspirant anticholinergics | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1067 | Antieplieptic medications | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1068 | Antidepressant medications | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1069 | Urinary incontinence SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1070 | Urinary incontinence I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1071 | Urinary incontinence | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1073 | Hemifacial spasm SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1074 | Hemifacial spasm I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1075 | Hemifacial spasm | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1076 | Spasmodic dysphonia SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1077 | Physical therapy procedure SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1078 | Occupational therapy SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1079 | Hyperhidrosis SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1080 | Hyperhidrosis I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1081 | Hyperhidrosis | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1082 | Tic disorder I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1083 | Tic disorder SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1084 | Tic disorder | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1085 | Esophageal achalasia SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1086 | Esophageal achalasia I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1087 | Esophageal achalasia | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1088 | ET propanolol or primidone | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1089 | ET topiramate alprazolam or gabapentin | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.109 | CKD stage4above I10 | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1090 | Blephraospasm SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1091 | Blepharospasm I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1092 | Blepharospasm | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1093 | Strabismus SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1094 | Strabismus I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1095 | Strabismus | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1096 | Overactive bladder SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1097 | Overactive bladder I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1098 | Overactive bladder | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1099 | Movement disorders SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.110 | CKD stage4above SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1100 | Movement disorders I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1101 | Movement disorders | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1102 | Lateral epicondylitis SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1103 | Lateral epicondyltisis I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1104 | Lateral epicondylitis | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1105 | Plantar fasciitis SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1106 | Plantar fasciitis I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1107 | Plantar fasciitits | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1108 | Cardiac CT SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1109 | Cardiac CT CPT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.111 | CKD stage4above | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1111 | Cardiac CT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1112 | Cardiac MRI SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1113 | Cardiac MRI CPT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1114 | Cardiac MRI | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1115 | CT Angiography of Coronary Artery SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1116 | CT Angiography of Coronary Artery CPT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1117 | CT Angiography of Coronary Artery | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.112 | Chronic kidney disease I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.113 | Chronic kidney disease SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.116 | DigTx Cognitive Impairment I10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.117 | DigTx Cognitive Impairment SCT | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.120 | Diabetic ketoacidosis SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.121 | Diabetic ketoacidosis | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.124 | DKD | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.146 | Long Acting Muscarinic Antagonists (LAMA) | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.147 | HFrEF SCT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.148 | HFrEF I10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.15 | Kidney tansplant | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.150 | History of Hypoglycemia I10 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.151 | History of Hypoglycemia SCD | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.153 | Hyperlipidemia | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.159 | conditions_COPD I10 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.168 | medications_COPD | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.17 | Atrial fibrillation | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.173 | Asthma I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.175 | Asthma | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.184 | DigTx Virtual Reality Contraindications Visual Impairment | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.186 | Beta blockers GDMT for heart failure | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.188 | medications_heart failure | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.189 | SGLT2i | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.193 | relatedconditions_COPD I10 | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.197 | Blood (Serum and Plasma) Potassium | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.202 | Serum Creatinine | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.21 | Thoracic aorta disease | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.214 | Type 1 Diabetes Mellitus SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.224 | Systolic Heart Failure I10 | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.226 | Systolic Heart Failure | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.238 | MRA mineralocorticoid receptor antagonists | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.244 | MRA Mineralocorticoid Receptor Antagonist Allergy | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.252 | relatedconditions_Heart failure I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.260 | UACR SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.263 | Pregnancy I10 | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.281 | Statins Allergy SCT | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.282 | Statin Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.292 | Metabolic syndrome I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.3 | Delivery I10 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.314 | relatedconditions_hyperlipidemia I10 | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.322 | Angina I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.325 | Tachyarrhythmia I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.337 | Migraine I10 | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.34 | Blood pressure panel | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.35 | Systolic Blood Pressure | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.350 | Coronary artery disease I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.367 | Trandolapril | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.369 | Candesartan | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.37 | relatedconditions_hypertension SCT | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.377 | Valsartan | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.38 | relatedconditions_hypertension I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.397 | eGFR | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.409 | Hypertension I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.412 | Statin Moderate Intensity | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.415 | LDL Cholesterol | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.43 | Urinalysis | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.434 | Insulin | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.437 | TZD Thiazolidinediones | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.438 | medications_T2DM | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.439 | relatedconditions_T2DM I10 | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.440 | relatedconditions_T2DM SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.442 | Blood Glucose | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.45 | ACE inhibitor allergy RXNORM | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.455 | Metabolic acidosis I10 | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.459 | Liver cancer | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.47 | ACE inhibitor allergy SCT | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.473 | Tetanus toxoid, diphtheria (Td) Vaccine | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.474 | Allergy to Tdap Vaccine | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.475 | Allergy to Td Vaccine | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.476 | Allergy To Vaccine Component | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.478 | Allergy to HPV Vaccine | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.481 | medications_hypertension | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.492 | Inhaled Corticosteroids Allergy | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.498 | Metformin AllergyIntolerance SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.5 | Delivery - Procedure | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.508 | Abdominal aortic imaging CPT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.516 | Allergy to Herpes Zoster Vaccine SCT | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.517 | Hemoglobin A1c | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.518 | Drug hypersensitivity I10 | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.519 | Drug hypersensitivity SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.520 | Drug hypersensitivity | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.521 | Diabetic Kidney Disease I10 | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.523 | Diabetic kidney disease | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.524 | Chronic Hepatitis SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.525 | Chronic Hepatitis | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.527 | OCS_Prednisone | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.528 | High Dose Non Combo ICS Adult | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.529 | Medium Dose Non Combo Asthma ICS Adult | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.530 | Low Dose Non Combo ICS | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.531 | Anti IgE Medications | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.532 | IL5 Antagonists | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.533 | Mast cell stabilizers for asthma | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.534 | Vasospastic disease I10 | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.535 | Vasospastic disease SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.536 | Vasospastic disease | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.537 | Hemiplegic and basilar migraine I10 | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.538 | Hemiplegic and basilar migraine SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.539 | Hemiplegic and basilar migraine | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.540 | Peptic ulcer disease I10 | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.541 | Peptic ulcer disease SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.542 | Peptic ulcer disease | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.544 | Bleeding disorder I10 | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.545 | Bleeding disorder SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.548 | Electronic cigarettes or Vaping | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.549 | Bleeding disorder | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.551 | Heart Rate | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.552 | Triptans | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.553 | CGRP receptor antagonists | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.554 | Ditans | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.555 | Ergots | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.556 | Migraine specific NSAIDs | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.557 | OTC migraine analgesics | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.558 | Butalbital analgesics | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.559 | medications_migraine_acute | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.560 | relatedconditions_migraine I10 | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.561 | conditions_migraine | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.562 | relatedconditions_migraine SCT | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.563 | relatedconditions_migraine | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.564 | Triptan Allergy Intolerance SCT | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.565 | Triptan Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.566 | Ischemic bowel disease SCT | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.567 | Ischemic bowel disease I10 | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.568 | Ischemic bowel disease | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.569 | Allergen Immunotherapy | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.570 | Allergy to house dust mites SCT | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.571 | Allergy to house dust mites I10 | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.572 | Allergy to house dust mites | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.573 | conditions_hyperlipidemia I10 | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.574 | conditions_hyperlipidemia SCT | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.575 | conditions_hyperlipidemia | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.578 | PIM_Schedule V | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.580 | PIM_Acarbose | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.581 | PIM_Avandamet | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.582 | PIM_Dulaglutide | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.583 | PIM_Glimepiride | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.585 | PIM_Glucophage | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.587 | PIM_Glucovance | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.588 | Glyburide PIM | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.590 | Alpha glucosidase inhibitors | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.592 | Azotemia | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.594 | Intolerance to ARB SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.595 | ICS Low | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.596 | ICS Medium | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.597 | ICS High | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.598 | Low Dose ICS Formoterol | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.599 | PIM_Vitamin B12 Level_LOINC_CPT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.600 | PIM_Vitamin B12 Level_LOINC | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.601 | PIM_Vitamin B12 Level_CPT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.604 | PIM_Glyburide | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.605 | PIM_Pioglitazone | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.606 | PIM_Semaglutide | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.607 | PIM_Linagliptin | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.609 | Macrolide_Azithromycin | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.61 | Secondary antihypertensives | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.610 | Long Acting Beta Agonists (LABA) Non_Formoterol | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.611 | relatedconditions_Asthma I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.612 | Wolff Parkinson White SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.613 | Wolff Parkinson White I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.614 | Wolff Parkinson White | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.615 | medications_Asthma | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.617 | HighICS_LABA_NonFormoterol | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.618 | relatedconditions_Asthma SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.619 | ICS_LABA_LAMA | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.620 | Low Dose ICS_LABA_Non Formoterol | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.621 | Medium ICS_LABA Non Formoterol | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.622 | relatedconditions_Asthma | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.623 | LAMA Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.624 | LABA Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.625 | BetaBlock NonCS Secondary Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.626 | Eplerenone Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.627 | Spironolactone Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.628 | SGLT2 Inhibitors Allergy SCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.629 | PIM_Refill_Request_Antilipemics_LFTs | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.630 | Angiotensin Receptor Neprilysin Inhibitor(ARNI) Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.631 | Pneumococcal Vaccine Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.632 | Meglitinides Allergy SCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.633 | DPP4i Allergy SCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.635 | Alpha_glucosidase inhibitors allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.636 | Glucagon_Like Peptide 1 Receptor Agonist (GLP1RA) Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.637 | Insulins Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.638 | TZD Allergy SCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.639 | T2DM_Medications Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.642 | T2DM_Medications Allergy RXNORM | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.643 | T2DM_Medications Allergy SNOMED | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.646 | T2DM_Medication Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.647 | Statins Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.649 | ACE Inhibitors Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.650 | ARB Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.652 | Long Acting Muscarinic Antagonists (LAMA) Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.653 | Long Acting Beta Agonists (LABA) Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.654 | BetaBlocker NonCS Secondary Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.656 | MRA Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.657 | Eplerenone Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.658 | Spironolactone Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.659 | SGLT2i Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.660 | Angiotensin Receptor Neprilysin Inhibitor(ARNI) Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.661 | Tetanus, Diphtheria, Pertusis (Tdap) Vaccine Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.665 | Tetanus toxoid, diphtheria (Td) Vaccine Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.666 | Human Papillomavirus (HPV) vaccine Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.667 | Herpes Zoster Vaccine Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.670 | Pneumococcal Vaccine Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.671 | Inhaled Corticosteroids(ICS) Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.672 | LABA(Formoterol only) | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.674 | PIM_Tirzepatide | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.675 | GLP1RA Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.676 | PIM_Diabetes_Testing_Supplies | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.677 | PIM_H2_Antagonists | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.678 | SGLT2i DM CKD | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.679 | SGLT2i DM ASCVD | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.680 | GLP1RA DM ASCVD | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.683 | OIA_Gout_Medications | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.684 | GlumetzaSubstitution | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.685 | MetforminER500mg | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.686 | PIM_Metformin | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.687 | PIM_Glipizide | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.689 | PIM_Glipizide_Glyburide_Glimepiride | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.690 | PIM_Insulin_Meglitinides | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.691 | PIM_Glyxambi | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.692 | PIM_Farxiga | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.693 | PIM_Invokana | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.694 | PIM_Jardiance | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.695 | PIM_Invokana_Jardiance | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.696 | Reclast | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.697 | LAMA_LABA Combination 1 Inhaler | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.698 | PIM_Contraceptives | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.699 | Selected Oral Antiemetics for Migraine | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.700 | PIM_DEXA_Scan | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.701 | PIM_DEXA_Scan_CPT_LOINC | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.702 | PIM_SSRIs | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.703 | PIM_SNRIs | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.704 | PIM_NRIs | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.705 | PIM_TCAs | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.706 | PIM_Citalopram | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.707 | PIM_Hydroxyzine | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.708 | PIM_Buspirone | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.709 | PIM_Bupropion | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.710 | PIM_Mirtazapine | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.711 | PIM_Trazodone | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.712 | PIM_IHD_CHD_CAD_ICD10 | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.713 | PIM_IHD_CHD_CAD_SNOMED | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.714 | PIM_Gabapentin | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.715 | PIM_Allergy_Nasal_Sprays | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.716 | PIM_Allergy_Oral_Meds | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.717 | PIM_Allergy_Nasal_Oral | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.719 | OCS_Prednisolone | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.72 | Inhaled corticosteroids (IC) | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.720 | COPD_Ofloxacin | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.721 | COPD_Ciprofloxacin | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.722 | COPD_Doxycycline | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.723 | Macrolide Allergy SCT | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.724 | Macrolide Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.725 | Prednisone Allergy SCT | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.727 | Tetracycline Allergy SCT | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.728 | Tetracycline Allergy Intolerance | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.729 | Fluoroquinolones Allergy SCT | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.730 | Fluoroquinolone Allergy Intolerance | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.731 | Penicillin Allergy RXNORM | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.732 | Penicillin Allergy SCT | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.733 | Penicillin Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.734 | PIM_Metformin_Single_Ingredient_Only | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.735 | PIM_Metformin_Combo_Ingredient_Only | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.736 | Pneumonia I10 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.737 | Pneumonia SCT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.738 | Pneumonia | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.739 | Pulmonary Embolism I10 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.742 | Pulmonary Embolism SCT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.743 | Pulmonary Embolism | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.744 | Influenza I10 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.745 | Influenza SCT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.746 | Influenza (Tests for influenza A or B virus Antigen) | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.747 | Influenza | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.748 | COVID 19 I10 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.749 | COVID19 SCT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.750 | COVID19 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.752 | RSV I10 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.753 | RSV SCT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.754 | RSV | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.755 | Respiratory Rate SCT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.756 | Respiratory Rate LOINC | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.757 | Respiratory Rate | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.758 | Acute Respiratory Failure I10 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.759 | Acute Respiratory Failure SCT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.760 | Acute Respiratory Failure | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.761 | Dyspnea SCT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.762 | Dyspnea I10 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.763 | Dyspnea | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.764 | Confusion I10 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.765 | Confusion SCT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.766 | Confusion | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.767 | Drowsiness SCT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.768 | Drowsiness I10 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.769 | Drowsiness | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.770 | Cyanosis I10 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.771 | Cyanosis SCT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.772 | Cyanosis | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.775 | Arterial oxygen saturation LOINC | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.776 | Arterial oxygen saturation SCT | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.777 | Arterial oxygen saturation | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.779 | PIM_Potassium_Supplements | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.780 | PIM_PPIs | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.781 | PIM_Migraine_Medications_Abortive | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.782 | PIM_Migraine_Medications_Preventive | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.783 | PIM_Bisphosphonates | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.784 | PIM_BPH_Medications | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.785 | PIM_Thyroid_Replacement_Medications | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.786 | PIM_Overactive_Bladder_Medications | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.787 | PIM_Topical_Acne_Medications | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.788 | PIM_Antidepressant_Anxiolytic_Medications | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.789 | Simple Knee Pain I10 | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.790 | Simple Knee Pain SCT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.791 | Simple Knee Pain | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.792 | Simple Left Knee Pain SCT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.793 | Simple Right Knee Pain SCT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.794 | Simple Right Knee Pain I10 | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.795 | Simple Left Knee Pain I10 | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.796 | Simple Right Knee Pain | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.797 | Simple Left Knee pain | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.798 | Knee joint surgery CPT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.799 | Knee joint surgery SCT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.800 | Knee joint surgery | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.801 | Knee Osteoarthritis I10 | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.802 | Knee Osteoarthritis SCT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.803 | Knee Osteoarthritis | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.804 | Osteoarthritis of right knee SCT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.805 | Osteoarthritis of left knee SCT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.806 | Osteoarthritis of right knee I10 | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.807 | Osteoarthritis of left knee I10 | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.808 | Osteoarthritis of right knee | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.809 | Osteoarthritis of left knee | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.810 | Hip Osteoarthritis SCT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.811 | Hip Osteoarthritis I10 | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.812 | Hip Osteoarthritis | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.813 | Hip joint surgery CPT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.814 | Hip joint surgery SCT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.815 | Hip joint surgery | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.816 | Osteoarthritis of right hip I10 | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.817 | Osteoarthritis of left hip I10 | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.818 | Osteoarthritis of right hip SCT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.819 | Osteoarthritis of left hip SCT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.820 | Osteoarthritis of right hip | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.821 | Osteoarthritis of left hip | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.822 | DigTx RelieVR inclusions I10 | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.823 | Aminoglycosides | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.824 | Carbapenems | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.826 | Monobactams | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.827 | Penicillins | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.828 | Antimycobacterials | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.829 | Beta_lactamase | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.830 | Cyclic lipopeptides | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.831 | Lincosamides | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.832 | Macrolides | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.833 | Amphenicol | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.834 | Oxazolidinones | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.835 | Fluoroquinolones | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.836 | Sulfonamides | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.837 | Tetracyclines | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.838 | Phosphonics | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.839 | Pleuromutilin | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.840 | Streptogramins | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.841 | Lipoglycopeptides | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.842 | Nitroimidazoles | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.843 | PIM_Hyd_Bus_Mir_Tra | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.844 | Nitrofurans | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.845 | Rifamycins | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.846 | Glycylcycline | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.847 | Pyrimidines | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.849 | Antibiotics oral and parenteral | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.85 | PCSK9i | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.850 | Medications_hyperkalemia | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.852 | Hyperkalemia_ICD10 | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.853 | Hyperkalemia_SCT | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.854 | Hyperkalemia Conditions | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.855 | Medications_Chronic Hyperkalemia | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.858 | PIM_Alpha_Blockers_2 | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.860 | PIM_Ambulatory_Visits_CPTs | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.862 | PIM_Ambulatory_Visits_SNOMED | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.863 | PIM_Thyroid_Stimulating_Hormone_(TSH) | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.864 | PIM_Triiodothyronine_(T3) | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.865 | PIM_Thyroxine_(T4) | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.866 | PIM_Magnesium_LOINC | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.867 | PIM_BMP_CMP_LOINC | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.868 | PIM_URIC_ACID_LOINC | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.869 | PIM_Migraine_Medications | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.870 | PIM_Triptans | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.871 | ICS_SABA Reliever | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.873 | PIM_Asthma_COPD_Meds | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.874 | PIM_Lipid_Panel_CPTs | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.875 | PIM_Hepatic_Function_Panel_CPTs | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.876 | Alpha Glucosidase Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.877 | Inflammatory bowel disease I10 | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.878 | Inflammatory bowel disease SCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.879 | Inflammatory bowel disease | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.88 | DEPRECATED Diabetes | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.880 | Gastrointestinal obstruction SCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.881 | Gastrointestinal obstruction I10 | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.882 | Gastrointestinal obstruction | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.883 | DPP4i Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.884 | Multiple endocrine neoplasia type 2 (MEN II) SCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.885 | Multiple endocrine neoplasia type 2 (MEN II) I10 | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.886 | Multiple endocrine neoplasia type 2 (MEN II) | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.887 | Gastroparesis SCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.888 | Gastroparesis I10 | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.889 | Gastroparesis | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.890 | Meglitinide Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.891 | Sulfonylurea Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.892 | Peripheral edema I10 | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.893 | Peripheral edema SCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.894 | Peripheral edema | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.895 | TZD Allergy Intolerance | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.896 | PIM_Beta_Blockers | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.897 | PIM_CCB_DHPs | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.898 | PIM_Loop_Diuretics | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.899 | PIM_Inhaled_Corticosteroids_(ICS) | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.9 | ACE inhibitors | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.90 | ASCVD I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.900 | PIM_Leukotrienes | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.901 | OIA_Asthma_COPD_Meds_Inhalers | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.902 | OIA_Asthma_COPD_Meds_Nebulizers | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.903 | OIA_Asthma_COPD_Meds_Oral | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.904 | OIA_GLP1_Injectables | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.905 | OIA_Insulin_Injectables | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.906 | OIA_Oral_Hypoglycemics | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.907 | OIA_DM1_DM2_Meds | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.908 | Medium Dose ICS Formoterol | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.909 | High Dose ICS Formoterol | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.910 | CKD stage5OrESRD I10 | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.911 | CKD stage5OrESRD SCT | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.912 | CKD stage5OrESRD | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.914 | Anxiety_I10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.915 | Anxiety_SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.916 | Anxiety | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.918 | Stress_SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.919 | Stress_I10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.92 | ASCVD | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.920 | Stress | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.921 | PBH_Anxiety_SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.922 | PBH_Depression_SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.923 | PBH_Stress_SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.924 | PBH_Insomnia_SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.925 | PIM_CMP_CPTs | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.926 | Canagliflozin meds | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.927 | Empagliflozin meds | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.928 | Dapagliflozin meds | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.929 | Ertugliflozin meds | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.93 | Albuminuria I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.930 | Dulaglutide meds | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.931 | Liraglutide meds | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.932 | Semaglutide SC meds | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.933 | T2DM meds benefitting ASCVD | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.934 | T2DM meds benefitting CKD stages 2, 3, and 4 with eGFR >= 20 mL/min | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.935 | T2DM meds benefitting CKD stage 5 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.936 | T2DM meds benefitting HF with eGFR >= 20 mL/min | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.938 | Crohn disease SCT | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.939 | Crohn disease I10 | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.94 | Albuminuria SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.940 | Crohn disease | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.941 | Celiac disease SCT | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.942 | Celiac disease I10 | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.943 | Celiac disease | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.944 | OIA_Bisoprolol | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.945 | OIA_PVD_ICD10 | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.946 | Vibration Controlled Transient Elastography (VCTE) | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.947 | OIA_Antihypertensive_Medications | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.95 | Albuminuria | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.950 | OIA_CAD_ICD10 | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.951 | OIA_DM_ICD10 | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.952 | OIA_Creatinine_Levels_LOINC | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.953 | OIA_DM_SNOMEDCT | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.954 | OIA_CAD_SNOMEDCT | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.955 | OIA_PVD_SNOMEDCT | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.956 | OIA_DM_ICD10_SNOMEDCT | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.957 | OIA_CAD_ICD10_SNOMEDCT | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.958 | OIA_PVD_ICD10_SNOMEDCT | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.959 | ACEi for HFrEF | active | 2025-01 | hl7 |
| http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.26 | Healthcare Agent or Advisor Indicator | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.27 | Initial Treatment portable medical order options | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.28 | Cardiopulmonary Resuscitation Order Options | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.30 | Cardiopulmonary Resuscitation Order Procedures | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.31 | Cardiopulmonary Resuscitation Procedures Grouping | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.32 | Additional Portable Medical Order Procedures | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.33 | Initial Treatment Portable Medical Order Procedures Grouping | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.34 | Additional portable medical order Procedures Grouping | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.35 | Medically Assisted Nutrition Order Options | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.36 | Medically Assisted Nutrition Portable Medical Order Procedures Grouping | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.37 | Healthcare Agent Powers | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.38 | Personal Health Goal Options LOINC | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.39 | Personal Health Goal Options Grouping | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.40 | Portable Medical Order Document Types | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.41 | Advance Healthcare Directive Document Types Grouper | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.5 | Advance Directive Content Type SCT | active | 2022-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.6 | Personal Health Goals LOINC | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.7 | Health Goals Grouping | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.8 | Treatment Intervention Preferences at End of Life LOINC | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.9 | Treatment Intervention Preferences Grouping | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.1 | Rituximab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.100 | Pathological M Stage M1c | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.101 | Pathological N Stage N3 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.102 | N Stage pN1a | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.103 | N Stage pN1b | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.105 | Pathological N Stage pN1mi | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.106 | Pathological N Stage N2b | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.107 | Pathological N Stage N2a | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.108 | Pathological N Stage N2 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.109 | Pathological N Stage N1b | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.110 | Pathological N Stage N1a | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.112 | Pathological N Stage N0 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.114 | Pathological T Stage T4d | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.115 | Pathological T Stage T4c | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.116 | Pathological T Stage T4b | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.117 | Pathological T Stage T4a | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.118 | Pathological T Stage T4 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.120 | N Stage N2C | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.121 | T Stage T3c | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.122 | T Stage T3b | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.123 | T Stage T3a | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.124 | Pathological T Stage T3 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.125 | T Stage T2c | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.126 | T Stage T2b | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.127 | T Stage T2a | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.128 | Pathological T Stage T2 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.129 | Pathological T Stage T1c | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.132 | Pathological T Stage T1b | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.135 | Pathological T Stage T1a | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.136 | Pathological T Stage T1 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.137 | Pathological T Stage T1mic | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.139 | Pathological T Stage T0 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.142 | Cancer Stage III | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.143 | Cancer Stage IIIA | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.144 | Cancer Stage IIIB | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.145 | Cancer Stage IIIC | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.146 | Cancer Stage IV | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.147 | Cancer Stage IVA | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.148 | Cancer Stage IVB | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.149 | Cancer Stage IVC | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.151 | Cisplatin Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.153 | Vinorelbine Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.154 | Gemcitabine Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.155 | Docetaxel | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.156 | Pemetrexed Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.158 | Vinblastine Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.160 | ECOG Performance Status | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.161 | ECOG Performance Status | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.162 | ECOG Performance Status | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.164 | Karnofsky Performance Status | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.165 | Carboplatin Injectable | active | 2020-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.166 | Paclitaxel | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.168 | Doxorubicin Injectable | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.169 | Irinotecan Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.179 | Bevacizumab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.181 | Methotrexate | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.184 | Breast Cancer | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.185 | Breast Cancer | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.191 | Cancer Stage II | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.192 | Cancer Stage IIA | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.193 | Cancer Stage IIB | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.194 | Pertuzumab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.196 | Ixabepilone Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.197 | Goserelin | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.200 | Epirubicin Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.202 | Ramucirumab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.204 | Letrozole | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.206 | Exemestane | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.209 | Fluorouracil | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.210 | Capecitabine Oral | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.222 | Aprepitant Oral | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.223 | Fosaprepitant Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.255 | Colorectal Cancer | active | 2021-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.256 | Colorectal Cancer | active | 2021-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.257 | Colorectal Cancer Chemotherapy | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.280 | Cancer Stage IA | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.281 | Cancer Stage IB | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.286 | Cancer Stage IIC | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.291 | Positive Result | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.292 | Negative Result | active | 2015-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.300 | Pathological N Stage N1C | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.332 | Daunorubicin Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.336 | Palonosetron Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.341 | External Beam Radiotherapy | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.349 | Metastatic Cancer | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.365 | Hospice Care Referral or Admission | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.439 | T Category | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.440 | N Category | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.441 | M Category | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.442 | TNM Stage Group | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.449 | Opioids | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.492 | Pharmacological interventions for depression | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.535 | Ovarian Cancer | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.536 | Ovarian Cancer | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.537 | Fallopian Tube Cancer | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.539 | Fallopian Tube Cancer | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.541 | Peritoneal Cancer | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.542 | Peritoneal Cancer | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.547 | Cancer Stage 1C | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.555 | Gender Female | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.556 | Gender Male | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.557 | Pathological N Stage N3a | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.558 | Pathological N Stage N3b | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.560 | Rolapitant Oral | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.599 | Obinutuzumab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.600 | Ofatumumab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.602 | Neurokinin 1 Receptor Antagonist | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.604 | Serotonin Receptor Antagonist | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.61 | Cetuximab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.63 | Panitumumab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.81 | Palonosetron Oral | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.88 | Lung Cancer | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.89 | Lung Cancer | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.95 | M Stage M0 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.97 | Pathological M Stage M1 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.98 | Pathological M Stage M1a | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.99 | Pathological M Stage M1b | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1121.5 | Most/Moderately Effective Contraceptive Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1121.6 | Most/Moderately Effective Contraceptive SNOMED Findings | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1125.1 | Schedule IV Benzodiazepines | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1125.7 | PROMIS Depression Assessment | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.11 | Sleep Apnea | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.12 | Toxic Megacolon in adults | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.13 | Septic Shock due to C. Diff | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.15 | Body Temperature | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.16 | Diarrhea Potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.17 | Abdominal Distension | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.18 | Vomiting potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.19 | Ileus due to infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.20 | Clostridium difficile infection | active | 2019-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.3 | Radiation Therapy Indicators from CPT | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.4 | Diagnostic Radiology Surrounding Face and Sinus | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.5 | Ear Surgery Affecting the Tympanic Membrane | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.6 | Allergic Rhinitis Immunotherapy | active | 2017-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.8 | Radiology to Head and Sinus | active | 2017-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.9 | Immunotherapy For Allergic Rhinitis | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1136.63 | Aortic Dissection or Ruptured Aortic Aneurysm | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.564 | CABG or PCI Procedure | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.565 | CABG or PCI Procedure | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.566 | CABG or PCI Procedure | active | 2018-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.1 | C2S Alcohol Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.11 | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.12 | C2S Cannabis Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.13 | C2S Cannabis Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.14 | C2S Cannabis Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.15 | C2S Cannabis Use DIsorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.16 | C2S Cocaine Use Disorder | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.17 | C2S Cocaine Use Disorder | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.18 | C2S Cocaine Use Disorder | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.19 | C2S Hallucinogens | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.2 | C2S Alcohol Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.20 | C2S Hallucinogens | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.21 | C2S Hallucinogens | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.22 | C2S Hallucinogens | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.23 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.24 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.25 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.26 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.27 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.28 | C2S Inhalants | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.29 | C2S Inhalants | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.3 | C2S Alcohol Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.30 | C2S Inhalants | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.32 | C2S Mental Health Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.33 | C2S Mental Health Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.34 | C2S Mental Health Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.35 | C2S Mental Health Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.36 | C2S Mental Health Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.38 | C2S Opioids | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.39 | C2S Opioids | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.4 | C2S Alcohol Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.40 | C2S Opioids | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.42 | C2S Opioids | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.43 | C2S Other Psychoactive Substance
Use Disorder | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.44 | C2S Other Psychoactive Substance Use Disorder | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.45 | C2S Other Psychoactive Substance Use Disorder | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.46 | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.47 | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.48 | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.49 | C2S Sexuality and reproductive health information sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.5 | C2S Alcohol Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.51 | C2S Tobacco Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.52 | C2S Tobacco Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.53 | C2S Tobacco Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.54 | C2S Tobacco Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.55 | C2S Substance Use Information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.56 | C2S Substance Use Information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.58 | C2S Sensitive Categories | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.59 | C2S Opioids | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.6 | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.60 | C2S HIV/AIDS information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.65 | Test C2S Alcohol Use Disorders | active | 2019-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.67 | Test C2S HIV/AIDS Information Sensitivity | active | 2019-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.7 | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.8 | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.9 | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.10 | Diphtheria (Tests for Corynebacterium diphtheriae by Culture and Identification Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1002 | Tuberculosis (Tests for Mycobacterium species by Culture and Identification Method) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1012 | S. Typhi Infection (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1016 | S. Paratyphi Infection (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1017 | S. Typhi Infection (Tests for S. Typhi by Culture and Identification Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1021 | Dark Urine (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1022 | Acute Onset [Qualifier Value] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1024 | Acute Viral Hepatitis (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1027 | Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1029 | Listeriosis [Listeria species] (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1030 | Meningitis [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1032 | Encephalitis [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1033 | Encephalitis [Unspecified Cause] (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1035 | Indeterminate or Equivocal Lab Result Value | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1037 | Smoking Status [Current Nonsmoker] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1040 | Organisms (Tests by Unspecified Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1041 | Organisms (Tests by Culture and Identification) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1044 | Candida auris Infection (Tests for Candida auris by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1045 | Candida auris Infection (Tests for Candida auris Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1047 | Parkinson’s disease (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1048 | Parkinson’s disease (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1049 | Parkinsonism [Secondary] (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1050 | Parkinsonism [Secondary] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1053 | Carbidopa Levodopa Combination (RXNORM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1065 | Consciousness [Decreased Level] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1071 | Drug Use [IV Evidence] (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1072 | Miosis (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1076 | Opioid Overdose and Poisoning (Tests for Opioids [Quantitative]) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1077 | Poisoning or Overdose by Other Opioids (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1078 | Opioid Overdose and Poisoning (Naloxone) (RxNorm) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1083 | Rash [Pustular Vesicular] (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1084 | Salivary Gland Swelling [Unspecified Cause] (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1090 | Syphilis [Congenital] (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1091 | Cataracts [Nonspecific]/Congenital glaucoma [Unspecified Cause] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1092 | Congenital heart disease (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1093 | Hearing impairment (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1095 | Microcephaly (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1096 | Developmental delay (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1099 | Congenital heart disease (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1100 | Hearing impairment (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1104 | Developmental delay (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1106 | Listeriosis (Tests for Listeria monocytogenes Nucleic Acid in Specimen from Normally Sterile Site) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.112 | Tetanus (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1123 | COVID_19 (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1124 | COVID_19 (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1130 | Tickborne Relapsing Fever (Tests for Borrelia hermsii/miyamotoi/parkerii/turicatae Nucleic Acid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1131 | Lyme Disease (Tests for Borrelia afzelii/garinii IgG Antibody by Immunoassay | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1138 | Staphylococcus Aureus (Tests by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1139 | VISA/VRSA (Tests for Vancomycin Resistance Gene) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1142 | COVID_19 (Tests for SARS_CoV_2 Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1143 | COVID_19 (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1145 | Resistant Lab Result Value | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1148 | Tests for Vancomycin Susceptibility [Ord] | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1149 | Proteinuria (Tests for Total Protein in 24H Urine) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.115 | Mumps (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1150 | Thrombocytopenia (Tests for Platelets [#/volume] in Blood) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1156 | Staphylococcus aureus (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1158 | COVID_19 (Tests for SARS_CoV_2 Antigen) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1169 | Chikungunya Virus Disease (Tests for Chikungunya virus Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.117 | Mumps (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1180 | Chikungunya Virus Disease (Tests for Chikungunya Virus Antibody [Quantitative]) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1186 | Eastern Equine Encephalitis Virus Disease (Tests for Eastern Equine Encephalitis Virus Antibody [Qualitative]) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1188 | Western Equine Encephalitis Virus Disease (Tests for Western Equine Encephalitis Virus Antibody [Qualitative]) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1189 | California Serogroup Virus Diseases (Tests for California Serogroup Virus Antibody [Qualitative]) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1196 | Anthrax (Tests for Bacillus cereus by Culture and Identification Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1197 | Cervical Lymphadenitis (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1207 | CRE (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1210 | Enterobacter spp., E. coli, or Klebsiella spp. (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1212 | Enterobacteriaceae species [Carbapenem Resistant] (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1213 | NU_Enterobacteriaceae [Carbapenemase Producing] (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1214 | Carbapenemase resistance mechanism (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1215 | Tests for carbapenemase production | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1216 | Tests for carbapenemase resistance mechanism | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1217 | Tests for carbapenem susceptibility [Meropenem, imipenem, and doripenem] | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1218 | Tests for carbapenem susceptibility [Ertapenem] | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1219 | Tests for Enterobacter spp., E. coli, or Klebsiella spp. by Culture and Identification Method | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1220 | NU_Tests for Enterobacteriaceae species by Culture and Identification Method | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1224 | Therapeutic Response to Medication [Improved] | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1225 | Altered Mental Status (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1230 | Eschar (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1231 | Hypotension (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1233 | Localized Edema (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1234 | Localized Edema (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1237 | Tachycardia (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1238 | Tachycardia (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1239 | RCKMS Conditions (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.124 | Poliomyelitis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1240 | Maternal Condition Puerperium (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1242 | Non pestis Yersiniosis Infection (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1244 | Blastomycosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1246 | Blastomycosis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1249 | Blastomycosis (Tests for Blastomyces species by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1250 | Non pestis Yersiniosis Infection (Tests for Yersinia non pestis species Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1251 | Blastomycosis (Tests for Blastomyces species Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1252 | Blastomycosis (Tests for Blastomyces species Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1253 | Blastomycosis (Tests for Blastomyces species Antigen) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1265 | Fatigue (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1269 | Tuberculosis [Latent Infection] (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1274 | Histoplasmosis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1275 | Histoplasmosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1281 | Histoplasmosis (Tests for Histoplasma capsulatum H band or M band Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1294 | Abscess [Liver, Lung, Spleen, Prostate, or Brain] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1295 | Seizure [Unspecified Cause] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1298 | Abscess [Liver, Lung, Spleen, Prostate, or Brain] (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1299 | Seizure [Unspecified Cause] (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.130 | Influenza (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1304 | Mycobacteria_Infection_NonTB_ExPulm (Tests for Mycobacterium species in Extrapulmonary Specimen by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1305 | Mycobacteria_Infection_NonTB_ExPulm (Tests for Mycobacterium species Nucleic Acid in Extrapulmonary Specimen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1306 | Body Temperature (Vital Sign) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1307 | Respiratory Rate (Vital Sign) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1309 | RSV (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1310 | RSV (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1312 | RSV (Tests for RSV Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1314 | Wheezing (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1317 | Bronchiolitis (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1325 | Tobacco Use and Exposure (Social History) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1330 | Tobacco Smoking Status [Current] (Social History) (LOINC) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1335 | Hospitalized [Inpatient] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1336 | Creutzfeldt Jakob Disease (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1337 | Variant Creutzfeldt Jakob Disease (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1340 | Prion Disease (Tests for 14_3_3 Protein) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1341 | Prion Disease (Tests for Abnormal Prion Protein) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1349 | Cerebrospinal Fluid (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.135 | Chronic Hepatitis B Virus Infection (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1350 | Endocervical (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1351 | Tissue (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1352 | Specimen from a Normally Sterile Site (Specimen Type)(SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1353 | Urethral Swab (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1355 | Wound (Specimen Type) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1359 | Hepatitis E (Tests for hepatitis E virus IgM Antibody) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.136 | Invasive Pneumococcal Disease (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1360 | Hepatitis E (Tests for hepatitis E virus Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1363 | Epiglottitis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1364 | Organisms (Tests by Microscopic Observation by Gram Stain) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1369 | Serum (Specimen Type) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1378 | Tests for Mycobacterium species Nucleic Acid in Unspecified XXX Specimen | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1379 | Fish Poisoning (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1388 | Occupational Asthma (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1389 | Asthma (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1390 | Asthma (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1391 | Respiratory Condition, due to inhalation of chemicals, gases, fumes or vapors (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1393 | WRA (Occupational Exposure to Potential Asthma Inducing Risk Factor) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1400 | Colorado tick fever (Tests for Colorado Tick Fever Virus Antibody [Qualitative]) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1402 | Cancer [Malignant Neoplasms] (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1403 | Cancer [Benign or Borderline CNS Tumors] (Disorders) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1404 | Cancer [Unspecified Skin Cancer, Benign Carcinoid Tumor, in situ Cervical Cancer, Intraepithelial Neoplasia, History Cancer, Complication of Cancer or Treatment] (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1405 | Cancer [Unspecified Skin Cancer, Benign Carcinoid Tumor, in situ Cervical Cancer, Intraepithelial Neoplasia, History Cancer, Complication of Cancer or Treatment] (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1407 | Cancer [Malignant Neoplasms] (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1409 | COVID_19 (Tests for SARS_CoV_2 Genomic Sequence) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1418 | Alpha gal syndrome (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1420 | Alpha gal syndrome (Tests for Alpha gal IgE Antibody [Quantitative]) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1422 | Ptosis of Eyelid [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1423 | Ptosis of Eyelid [Unspecified Cause] (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1424 | Constipation [Unspecified Cause] (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1426 | Intubation [Respiratory Tract] (Procedure) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1430 | Infant Botulism (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1446 | Viral Hemorrhagic Fever [Suspected] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1447 | MRSA (Disorders (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1449 | Staphylococcus aureus infection (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.145 | Varicella (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1450 | Staphylococcus aureus infection (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1452 | MRSA (Tests by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1453 | MRSA (Tests for Methicillin Resistance Gene) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1454 | Staphylococcus aureus (Tests for Staph aureus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1458 | Tests for Cefoxitin Susceptibility [OrdQn] | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1459 | Organisms (Tests in Blood by Culture and Identification) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1460 | Bacteria (Tests in Blood by Culture and Identification Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1461 | Organisms (Tests in Specimen from Normally Sterile Site by Culture and Identification) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1462 | Staphylococcus aureus (Tests for Staph aureus Nucleic Acid in Blood) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1463 | VRE (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1464 | VRE (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1465 | VRE (Tests by Culture and Identification Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1466 | Enterococcus species (Tests by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1468 | Enterococcus gallinarum or E. casseliflavus/E. flavescens (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1469 | Enterococcus faecium or E. faecalis (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1470 | Enterococcus species (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1471 | Amebiasis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1473 | Amebiasis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1476 | Amebiasis (Tests for Entamoeba histolytica Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1482 | Norovirus (Tests for Norovirus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1485 | Norovirus (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1487 | Clostridioides difficile infection (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1491 | C. diff infection (Tests for C diff Toxin Nucleic Acid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1492 | C. diff infection (Tests for C diff Toxin Nucleic Acid in Stool) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1505 | Acanthamoeba Disease [Keratitis] (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1507 | Arsenic Exposure and Toxicity (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1509 | Arsenic Exposure and Toxicity (Tests for Arsenic [Quantitative] in Unspecified Specimen) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1513 | Urine (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1514 | Mercury Exposure and Toxicity (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1515 | Cryptococcosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1516 | Cryptococcosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1520 | Cryptococcosis (Tests for Cryptococcus species by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1523 | Cryptococcosis (Tests for Cryptococcus species Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1524 | Cryptococcosis (Tests for Cryptococcus species Antigen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1525 | Mercury Exposure and Toxicity (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1528 | Mercury Exposure and Toxicity (Tests for Mercury [Quantitative] in Unspecified Specimen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1532 | Drug Overdose and Poisoning [Non opioid] [CNS Stimulant] (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1533 | Drug Overdose and Poisoning [Non opioid] [CNS Depressant] (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1534 | Drug Overdose and Poisoning [Non opioid] [Cannabinoid] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1538 | Drug Overdose and Poisoning [Non opioid] [Other Drug] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.154 | Hepatitis C Virus Infection (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1540 | Drug Overdose and Poisoning [Non opioid] [CNS Stimulant] (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1541 | Drug Overdose and Poisoning [Non opioid] [CNS Depressant] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1542 | Drug Overdose and Poisoning [Non opioid] [Hallucinogen] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1543 | Drug Overdose and Poisoning [Non opioid] [Cannabinoid] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1544 | Drug Overdose and Poisoning [Non opioid] [Analgesic] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1545 | Drug Overdose and Poisoning [Non opioid] [Other Drug] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1546 | Drug Overdose and Poisoning [Non opioid] (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1551 | Meningitis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1552 | Bacterial Meningitis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1553 | Fungal Meningitis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1554 | Parasitic Meningitis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1555 | Bacterial Meningitis (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1559 | Photophobia (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1562 | Bacteria [Causing Meningitis] (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1563 | Fungi [Causing Meningitis and Encephalitis] (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1564 | Viruses [Causing Meningitis] (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1565 | Viruses [Causing Meningitis] (Tests for Nucleic Acid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1566 | Viruses [Causing Meningitis] (Tests for Nucleic Acid in Cerebrospinal Fluid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1567 | Bacteria [Causing Meningitis] (Tests by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1574 | Invasive Group B Streptococcus (Disorders) (ICD10CM)) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1577 | Group A Streptococcus (Tests for Group A Strep by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1578 | Group B Streptococcus (Tests for Group B Strep by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1580 | Animal Bite [Dog] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1581 | Animal Bite [Mammal, Excluding Dogs] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1582 | Animal Bite [Excluding Mammals] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1584 | Animal Bite [Unspecified Animal] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1585 | Animal Bite [Dog] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1586 | Animal Bite [Mammal, Excluding Dogs] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1587 | Animal Bite [Excluding Mammals] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1588 | Cadmium Exposure and Toxicity (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1594 | HIV Infection (ARV Nucleoside Reverse Transcriptase Inhibitors [NRTIs]) (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1595 | HIV Infection (ARV Non nucleoside Reverse Transcriptase Inhibitors [NNRTIs]) (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1597 | HIV Infection (ARV Combination Treatment for HIV) (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1598 | HIV Infection (ARV Protease Inhibitors [PIs]) (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1600 | HIV Infection (ARV Integrase Strand Transfer Inhibitors [INSTIs]) (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1604 | Vaccine Adverse Event (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1605 | Vaccine Adverse Event (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1606 | Vaccinia disease or adverse event  (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.161 | Vibriosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1612 | Blepharitis [Unspecified Cause] (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1613 | Keratitis [Unspecified Cause] (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1614 | Keratitis [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1618 | Smallpox Vaccine (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1620 | Anaphylaxis [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1626 | Thrombocytopenic Purpura [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1634 | Sofosbuvir Velpatasvir Combination (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1640 | Typhus Fever (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1641 | Typhus Fever (Tests for Rickettsia Typhus Group IgG Antibody) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1642 | Typhus Fever (Tests for Rickettsia Typhus Group IgM Antibody) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1643 | Typhus Fever (Tests for Rickettsia Typhus Fever Group IgG Antibody [Quantitative] by Immunofluorescence) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1651 | Chagas Disease (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1654 | Chagas Disease (Tests for Trypanosoma cruzi Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1661 | Cervical lymphadenopathy [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1662 | Conjunctival injection (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1663 | Drying of lips (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1667 | Edema of hands or feet (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1676 | Tests for Acinetobacter baumannii Nucleic Acid | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1677 | Tests for Pseudomonas aeruginosa by Culture and Identification Method | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1678 | Tests for Pseudomonas aeruginosa Nucleic Acid | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1679 | Pseudomonas aeruginosa (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1687 | NU_Gunshot Wound (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1688 | NU_Gunshot Wound (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.169 | Gonorrhea [Neisseria gonorrhoeae] (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.170 | Chlamydia trachomatis Infection (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1700 | Encephalitis [Viral] (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1702 | Encephalitis [Parasitic] (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1712 | Bacteria [Causing Encephalitis] (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1714 | Parasites [Causing Encephalitis] (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1715 | Viruses [Causing Encephalitis] (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1716 | Drowning and Submersion (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1717 | Drowning and Submersion (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1718 | Motor Vehicle Injury (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1719 | Motor Vehicle Injury (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1720 | Enterovirus Infection [Non polio] (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1721 | Enterovirus Infection [Non polio] (Disorders) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1722 | Enterovirus Infection [Non polio] (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1723 | Enterovirus Infection [Non polio] (Tests for Non Polio Enterovirus by Culture and Identification Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1725 | Enterovirus Infection [Non polio] (Tests for Non Polio Enterovirus Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1726 | Enterovirus Infection [Non polio] (Tests for Non Polio Enterovirus in Cerebrospinal Fluid Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1735 | Clostridium perfringens Infection (Tests for C perfringens by Culture and Identification Method) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1739 | Head Injury (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1740 | Head Injury (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1742 | Brain Injury [Traumatic] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1745 | Rotavirus Disease (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1746 | Rotavirus Disease (Tests for Rotavirus Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1748 | Chemical Pneumonitis (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1749 | Chemical Pneumonitis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1753 | Staphylococcal Enterotoxin B Poisoning (Tests for Staph aureus Enterotoxin B Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1755 | Vomitus (Specimen Type) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1758 | Asbestosis (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.176 | West Nile Virus Infection (Disorders) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1763 | Byssinosis (Disorders) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1769 | Farmers Lung (Tests for Aspergillus fumigatus, Saccharopolyspora rectivirgula, or Thermoactinomyces vulgaris Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1772 | Farmers Lung (Aspergillus fumigatus, Saccharopolyspora rectivirgula, or Thermoactinomyces vulgaris Antibody in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1773 | CLABSI (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1775 | Ophthalmia neonatorum (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1778 | Genital herpes (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1779 | Genital herpes (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1781 | Herpes (Tests for Herpes simplex virus Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1785 | Elevated liver enzyme (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1786 | Elevated liver enzyme (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1788 | Typhus Fever (Tests for Rickettsia Typhus Fever Group IgM Antibody [Quantitative] by Immunofluorescence) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1789 | Granuloma Inguinale (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1791 | Ulcer [Genital, Perineal, or Perianal Area] (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1792 | Ulcer [Genital, Perineal, or Perianal Area] (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1797 | Bronchial Wash (Specimen Type) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1800 | Nontuberculous Mycobacteria Infection, Pulmonary (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1803 | Bacteria (Tests in Sputum Specimen by Culture and Identification Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.181 | Coccidioidomycosis (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1819 | Louseborne relapsing fever (Tests for Borrelia species) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1820 | Louseborne relapsing fever (Tests for Borrelia species in Blood) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1823 | Borrelia species (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1824 | Spirochetes (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1829 | Polyarthritis [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1835 | Rheumatoid nodules (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1842 | Ventilator associated event (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1844 | Leishmaniasis (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1846 | Leishmaniasis (Tests for Leishmania species Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1847 | Leishmaniasis (Tests for Leishmania species Antibody) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1848 | Leishmania species (Tests by Microscopic Observation in Tissue) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.185 | Brucellosis (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1864 | Taeniasis (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1866 | Taeniasis (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.187 | Dengue Virus Infection (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1875 | Cysticercosis (Tests for Taenia solium Antibody) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1878 | Surgical Site Infection (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1880 | Tests for Enterobacter spp., E. coli, or Klebsiella spp. Nucleic Acid | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1881 | NU_Tests for Enterobacteriaceae species Nucleic Acid | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1882 | Carbapenemase production (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1892 | Toxoplasmosis (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1893 | Toxoplasmosis (Disorders) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1895 | Toxoplasmosis (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1897 | Toxoplasmosis (Tests by Microscopic Observation) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1898 | Toxoplasmosis (Tests for Toxoplasma gondii Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1901 | Toxoplasmosis (Tests for Toxoplasma gondii Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1902 | Orthopox (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1908 | Organisms (Tests by Electron Microscopic Observation) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1912 | Penicillin G [Aqueous Crystalline] [Injectable] (RXNORM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1913 | Penicillin G [Procaine] [Injectable] (RXNORM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1919 | Fungi [Causing Meningitis] (Tests by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1923 | Coronary artery aneurysm (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1924 | Coronary artery dilatation (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1925 | Ectatic coronary artery (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1926 | Left ventricular ejection fraction [Decreased Level] (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1927 | Coronary artery aneurysm (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1928 | Shock (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1929 | Shock (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1930 | Troponin [Elevated Level] (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1931 | Oral mucosa Inflammation (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1932 | Oral mucosa Inflammation (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1933 | C reactive protein (Tests by Any Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1934 | Lymphocytes [Concentration] (Tests by Any Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1935 | Strongyloidiasis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1936 | Strongyloidiasis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1937 | Strongyloidiasis (Tests for Strongyloides Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1938 | Strongyloidiasis (Tests for Strongyloides stercoralis IgG Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1939 | Strongyloidiasis (Tests for Strongyloides stercoralis IgG Antibody in Blood) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1940 | Organisms (Tests by Microscopic Observation in Stool) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1941 | Strongyloidiasis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1942 | Strongyloidiasis [Strongyloides stercoralis] (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1943 | Jamestown Canyon Virus Diseases (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1944 | Jamestown Canyon Virus Diseases (Tests for Jamestown Canyon Virus Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1945 | Jamestown Canyon Virus Diseases (Tests for Jamestown Canyon Virus IgM Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1946 | Jamestown Canyon Virus Diseases (Tests for Jamestown Canyon Virus Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1947 | Jamestown Canyon Virus Diseases (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1948 | Keystone Virus Diseases (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1949 | La Crosse Virus Diseases (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1950 | Snowshoe hare Virus Diseases (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1951 | Trivittatus Virus Diseases (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1952 | La Crosse Virus Diseases (Tests for La Crosse Virus Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1953 | Snowshoe hare Virus Diseases (Tests for Snowshoe hare Virus Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1954 | La Crosse Virus Diseases (Tests for La Crosse Virus IgM Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1955 | Snowshoe hare Virus Diseases (Tests for Snowshoe hare Virus IgM Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1956 | La Crosse Virus Diseases (Tests for La Crosse Virus Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1957 | Snowshoe hare Virus Diseases (Tests for Snowshoe hare Virus Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1958 | Trivittatus Virus Diseases (Tests for Trivittatus Virus Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1959 | Keystone Virus Diseases (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1960 | La Crosse Virus Diseases (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1961 | Snowshoe hare Virus Diseases (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1962 | Trivittatus Virus Diseases (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1963 | Hepatitis C Virus Infection, Perinatal (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1964 | Encephalomyelitis (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1965 | Encephalomyelitis (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1966 | Drug Overdose and Poisoning [Non opioid] [Muscle Relaxant] (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1967 | Drug Overdose and Poisoning [Non opioid] [Muscle Relaxant] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1968 | Hepatitis D Virus Infection (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1969 | Hepatitis D Virus Infection (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1970 | NU_Hepatitis D Virus Infection (Tests for hepatitis D virus total or IgG Antibody) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1971 | Hepatitis D Virus Infection (Tests for hepatitis D virus IgM Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1972 | Hepatitis D Virus Infection (Tests for hepatitis D virus Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1973 | Hepatitis D Virus Infection (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1974 | Baylisascariasis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1975 | Baylisascariasis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1976 | Baylisascariasis (Tests for Baylisascaris species Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1978 | Larva Migrans (Neural, Ocular, or Visceral) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1979 | Larva Migrans (Neural, Ocular, or Visceral) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1980 | California Serogroup Virus Disease [Unspecified] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1981 | California Serogroup Virus Disease [Unspecified] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1982 | California Serogroup Virus Disease [Unspecified] (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1983 | California Serogroup Virus Disease [Unspecified] (Tests for California Serogroup Virus Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1984 | California Serogroup Virus Disease [Unspecified] (Tests for California Serogroup Virus IgM Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1985 | California Serogroup Virus Disease [Unspecified] (Tests for California Serogroup Virus Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1986 | Pregnant (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1987 | Flank Pain (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1988 | Bone Pain (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1989 | Abscess (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1990 | Abscess (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1991 | Focal Brain Lesions (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1992 | Pathologic Fractures [Unspecified Cause] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1993 | Pathologic Fractures [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1994 | Granulomas (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1995 | Granulomas (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1996 | Skin Lesions (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1997 | Skin Lesions (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1998 | Angiostrongyliasis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1999 | Lymphocytic Choriomeningitis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2000 | Lymphocytic Choriomeningitis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2001 | Lymphocytic Choriomeningitis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2002 | Lymphocytic Choriomeningitis (Tests for LCMV Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2003 | Lymphocytic Choriomeningitis (Tests for LCMV Nucleic Acid in CSF or Blood) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2004 | Lymphocytic Choriomeningitis (Tests for LCMV Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2005 | Lymphocytic Choriomeningitis (Tests for LCMV Antibody in CSF or Serum) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2006 | Angiostrongyliasis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2007 | Eosinophilic meningitis (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2009 | Angiostrongyliasis (Tests for Angiostrongylus Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2010 | Eosinophils [Concentration] (Tests in CSF by Any Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2011 | Eosinophils [Percentage] (Tests in CSF by Any Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2012 | Mpox (Tests for mpox virus by Genomic Sequencing) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2013 | Mpox (Test Panels for mpox virus by Genomic Sequencing) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2017 | Rash [Macular, Papular, Vesicular, Pustular, or Centrifugal] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2018 | Interpretation of an Observation (High) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2019 | Interpretation of an Observation (Low) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.202 | Trichinellosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2020 | Lymphadenopathy [Acute] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2023 | Tick Paralysis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2024 | Bacillary angiomatosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2025 | Animal Bite or Scratch [Cat] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2026 | Animal Bite or Scratch [Cat] (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2027 | Bartonellosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2028 | Bartonellosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2029 | Bartonellosis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2030 | Bartonella henselae infection (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2031 | Bartonella quintana infection (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2032 | Bartonella bacilliformis infection (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2033 | Bartonella henselae infection (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2034 | Bartonella quintana infection (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2036 | Bartonella henselae (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2037 | Bartonella quintana (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2038 | Bartonella bacilliformis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2039 | Bartonella quintana infection (Tests for Bartonella quintana Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.204 | Giardiasis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2040 | Bartonella quintana infection (Tests for Bartonella quintana IgM Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2041 | Bartonella quintana infection (Tests for Bartonella quintana IgG or Total Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2042 | Bartonella henselae infection (Tests for Bartonella henselae Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2043 | Bartonella henselae infection (Tests for Bartonella henselae IgM Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2044 | Bartonella henselae infection (Tests for Bartonella henselae IgG or Total Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2045 | Bartonella bacilliformis infection (Tests for Bartonella bacilliformis IgM Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2046 | Bartonella bacilliformis infection (Tests for Bartonella bacilliformis IgG or Total Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2047 | Bartonellosis (Tests for Bartonella spp. Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2048 | Bartonellosis (Tests for Bartonella spp. IgM Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2049 | Bartonella spp. (Tests by Microscopic Observation) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2050 | Bartonellosis (Tests for Bartonella spp. by Culture and Identification Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2051 | Bartonellosis (Tests for Bartonella spp. IgG or Total Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2052 | Echinococcosis (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2053 | Echinococcosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2054 | Cystic Echinococcosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2055 | Cystic Echinococcosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2056 | Alveolar Echinococcosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2057 | Alveolar Echinococcosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2058 | Echinococcosis (Tests for Echinococcus species Antibody) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2059 | Echinococcus species (Tests by Microscopic Observation) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2060 | Echinococcosis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2061 | Genital Warts (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2062 | Pseudomembrane [Nose, pharynx, tonsils, or larynx] (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2063 | Genital Warts (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2064 | Diphyllobothriasis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2065 | Diphyllobothriasis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2066 | Diphyllobothriasis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2067 | Nontuberculous Mycobacteria Infection, Pulmonary (Tests for Mycobacterium species Nucleic Acid in a Pulmonary Specimen) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2068 | Angiostrongyliasis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2069 | Pelvic Inflammatory Disease (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2070 | Pelvic Inflammatory Disease [nonGC and nonCT] (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2071 | Pelvic Inflammatory Disease [Unspecified] (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2072 | Pelvic Inflammatory Disease (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2073 | Pelvic Inflammatory Disease [nonGC and nonCT] (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2074 | Pelvic Inflammatory Disease [Unspecified] (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2075 | Lower Abdominal Tenderness (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2076 | Lower Abdominal Tenderness (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2077 | Tenderness with motion of the cervix (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2078 | Adnexal Tenderness (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2079 | Uterine Tenderness (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2080 | Leukocytosis (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2081 | Leukocytosis (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2082 | Purulent material in the peritoneal cavity (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2083 | Pelvic Abscess (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2084 | Pelvic Abscess (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2085 | Leukocytes [Concentration] (Tests in Blood by Any Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2087 | Nongonococcal Urethritis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2088 | Nongonococcal Urethritis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2089 | Urethritis (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2090 | Urethritis (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2091 | Urethral discharge (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2092 | Urethral discharge (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2093 | Dysuria (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2094 | Dysuria (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2095 | Gonorrhea (Tests for Neisseria gonorrhoeae Antigen) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2096 | Cyanobacteria and Cyanotoxin Poisoning (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2098 | Rhinitis (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2100 | Rhinitis (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2101 | Pleuritis (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2102 | Pleuritis (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2103 | Gamma Glutamyl Transferase in Serum (Tests for Gamma Glutamyl Transferase in Serum) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2105 | Methemoglobinemia (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2106 | Methemoglobinemia [Non Congenital] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2107 | Methemoglobinemia (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2108 | Methemoglobinemia [Non Congenital] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2109 | Methemoglobinemia (Tests for Methemoglobin in Blood [Quantitative]) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2110 | Anencephaly (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2111 | Anencephaly (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2112 | Fetal Anencephaly (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2113 | Fetal Anencephaly (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2114 | Cleft Lip Alone (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2115 | Cleft Lip Alone (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2116 | Fetal Cleft Lip (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2117 | Cleft Palate Alone (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2118 | Cleft Palate Alone (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2119 | Cleft Lip with Cleft Palate (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2120 | Cleft Lip with Cleft Palate (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2121 | Fetal Spina Bifida (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2122 | Spina Bifida (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2123 | Spina Bifida (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2124 | Down Syndrome (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2125 | Down Syndrome (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2126 | Fetal Down Syndrome (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2127 | Fetal Down Syndrome (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2128 | Down Syndrome (Tests for Trisomy 21 Chromosomal Anomaly) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2129 | Bacteremia (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2130 | Bacteremia (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2131 | Gastroschisis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2132 | Gastroschisis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2133 | Fatal Familial Insomnia (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2134 | Fatal Familial Insomnia (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2135 | Gerstmann Straussler Scheinker Syndrome (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2136 | Gerstmann Straussler Scheinker Syndrome (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2137 | Prion Disease (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2138 | Prion Disease (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2139 | Prion Disease (Tests for Abnormal PRNP Gene Variant) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2140 | Phenylketonuria (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2141 | Phenylketonuria (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2142 | Linezolid (RXNORM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2143 | Tuberculosis (Pretomanid) (RXNORM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2144 | Tuberculosis (Bedaquiline) (RXNORM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2145 | Tuberculosis [Suspected] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2146 | Congenital Rubella Syndrome [Suspected] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2147 | Limb Reduction (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2148 | Limb Reduction (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2149 | NU_Influenza (Test Panels for Novel influenza A virus Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2150 | Congenital Hearing Loss (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2151 | Congenital Hearing Loss (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2152 | Naegleria fowleri PAM (Test Panels for Naegleria fowleri Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2153 | Primary Congenital Hypothyroidism (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2154 | Congenital Hypothyroidism [Unspecified] (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2155 | Congenital Hypothyroidism [Unspecified] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2156 | Thyroid_stimulating hormone (TSH) [Quantitative] (Tests in serum or plasma by any method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2157 | Mpox (Combination Tests that include mpox virus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2158 | Orthopox (Combination Tests that include Orthopoxvirus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2159 | Mpox (Test Panels for mpox virus Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.216 | Pertussis (Tests for Bordetella pertussis Antibody [Excluding Pertussis Toxin Antibody]) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2160 | Orthopox (Test Panels for orthopoxvirus Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2161 | COVID_19 (Combination Tests that include SARS_CoV_2 Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2163 | Dengue Virus Infection [Suspected] (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2164 | Mumps [Suspected] (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2165 | Pertussis [Suspected] (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2166 | Hantavirus Infection (Test Panels for Hantavirus IgM IgG Total Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2167 | Organisms (Tests in Cerebrospinal Fluid by Culture and Identification Method) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2168 | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis in Unspecified Specimen by Culture and Identification) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2169 | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis in Cerebrospinal Fluid by Culture and Identification) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2170 | Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis in Unspecified Specimen by Culture and Identification) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2171 | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis in Unspecified Specimen by Culture and Identification) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2172 | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Nucleic Acid in Unspecified Specimen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2173 | Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis Nucleic Acid in Unspecified Specimen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2174 | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Nucleic Acid in Unspecified Specimen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2175 | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis Nucleic Acid in Unspecified Specimen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2176 | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Antigen in Unspecified Specimen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2177 | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Antigen in Unspecified Specimen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2178 | Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis Antigen in Unspecified Specimen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2179 | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis Antigen in Unspecified Specimen) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.218 | Listeriosis (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2180 | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis in Unspecified Specimen by Microscopic Observation) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2181 | Organisms (Tests by Microscopic Observation in Cerebrospinal Fluid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2183 | Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2187 | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2188 | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Antigen in Cerebrospinal Fluid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2189 | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis in Cerebrospinal Fluid by Microscopic Observation) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2190 | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2192 | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2193 | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Antigen in Cerebrospinal Fluid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2194 | Organisms (Combination Tests by Culture and Identification) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2195 | Organisms (Combination Tests for Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2196 | Lung Tissue (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2197 | Granuloma [Unspecified] (Finding by Microscopic Observation in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2198 | Anaplasmosis (Disorders) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2199 | NU_Organisms (Tests in Specimen from Wound by Culture and Identification Method | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2200 | Organisms (Tests by Animal Inoculation Method) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2201 | Agricultural Chemical Poisoning [Unspecified Chemical] (Disorders) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2202 | Abnormal Lung Sounds (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2203 | Abnormal Lung Sounds (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2204 | Anemia [Unspecified Cause] (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2205 | Anemia [Unspecified Cause] (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2206 | Creatinine (Tests in Serum by Any Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2207 | Microangiopathic Changes (Schistocytes, Burr cells, or Helmet cells) (Tests by Microscopic Observation in Unspecified Specimen) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2208 | Microangiopathic Changes (Schistocytes, Burr cells, or Helmet cells) (Tests by Microscopic Observation in Blood) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2209 | Microangiopathic Changes (Schistocytes, Burr cells, or Helmet cells) (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2210 | Histopathology or Cytopathology Tests by Microscopic Observation | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2211 | Ehrlichiosis (Tests for Ehrlichia species IgG Antibody) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2212 | Invasive Cronobacter Infection (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2213 | Invasive Cronobacter Infection (Tests for Cronobacter species by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2214 | Necrotizing Enterocolitis (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2215 | Necrotizing Enterocolitis (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2216 | Abscess [Brain] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2217 | Abscess [Brain] (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2218 | Urinary Tract Infection (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2219 | Urinary Tract Infection (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2220 | Amniotic Fluid (Specimen Type) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2221 | Congenital Cytomegalovirus (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2222 | Organisms (Tests in Amniotic Fluid by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2223 | Congenital Cytomegalovirus (Tests for CMV Antigen by Immunohistochemical Stain) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2224 | Congenital Cytomegalovirus (Tests for CMV Antigen in Tissue by Immunohistochemical Stain) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2225 | Congenital Cytomegalovirus (Tests for CMV in Amniotic Fluid by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2226 | Congenital Cytomegalovirus (Tests for CMV Nucleic Acid in Amniotic Fluid by NAAT) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2227 | Congenital Cytomegalovirus (Tests for CMV Antigen in Whole Blood) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2228 | Congenital Cytomegalovirus (Tests for CMV Antigen) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2229 | Congenital Cytomegalovirus (Tests for CMV by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2230 | Congenital Cytomegalovirus (Tests for CMV Nucleic Acid by NAAT) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2231 | Congenital Cytomegalovirus Infection (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2232 | Congenital Cytomegalovirus Infection (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2233 | Cytomegalovirus Disease (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2234 | Cytomegalovirus Disease (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2235 | Toxoplasmosis (Tests for Toxoplasma gondii Antigen by Immunohistochemical Stain) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2236 | Toxoplasmosis (Tests for Toxoplasma gondii Antigen in Tissue by Immunohistochemical Stain) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2237 | Toxoplasmosis (Tests for Toxoplasma gondii IgG IgM IgA or IgE Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2238 | Toxoplasmosis (Tests for Toxoplasma gondii IgG IgM IgA or IgE Antibody in Blood) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2239 | Toxoplasmosis (Tests for Toxoplasma gondii IgG or IgM Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2240 | Toxoplasmosis (Tests for Toxoplasma gondii IgG or IgM Antibody in Cerebrospinal Fluid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2241 | Stillbirth (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2242 | Stillbirth (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2243 | Zika Virus Disease (Tests for Zika virus IgM Antibody in Blood or CSF) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2244 | Candida species (Tests by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2245 | Organisms (Tests in Extrapulmonary Specimen by Culture and Identification) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2246 | Organisms (Tests for Nucleic Acid in Extrapulmonary Specimen) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2247 | Extrapulmonary [NTM] (Specimen Type) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2248 | Plasmodium species (Tests by Microscopic Observation) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2249 | Baylisascariasis (Tests for Baylisascaris species Antibody in Serum or CSF) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2250 | Lower Respiratory [Excluding Sputum] (Specimen Type) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2251 | Organisms (Tests in Sputum Specimen by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2252 | Organisms (Tests in Lower Respiratory Specimen [Excluding Sputum] by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2253 | Organisms (Tests for Nucleic Acid in Lower Respiratory Specimen [Including Sputum]Â ) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2254 | Nontuberculous Mycobacteria Infection, Pulmonary (Tests for Mycobacterium species in Lower Respiratory Specimen [Excluding Sputum] by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2255 | Carbapenem Resistant Bacterial Infection [Carbapenemase Producing] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2256 | CP_CRE (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2257 | Organisms (Tests in Stool by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2258 | Loss of Consciousness (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2259 | Neonatal Abstinence Syndrome (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.226 | Lyme Disease (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2260 | Neonatal Abstinence Syndrome (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2261 | High Pitched Cry (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2262 | Inability to Console (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2263 | Inability to Console (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2264 | Hypertonia (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2265 | Hypertonia (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2266 | Tremors (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2267 | Tremors (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2268 | Myoclonus (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2269 | Myoclonus (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.227 | Lyme Disease (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2270 | Poor Sleep (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2271 | Poor Sleep (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2272 | Alterations in Feeding (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2273 | Alterations in Feeding (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2274 | Excoriation (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2275 | Excoriation (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2276 | Sneezing (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2277 http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.62 | Calcium Channel Blocker Dihydropyridine for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.63 | Calcium Channel Blocker Non Dihydropyridine for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.64 | Central Acting for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.65 | Direct Renin Inhibitor for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.762 | Angioedema | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.763 | Angioedema | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.764 | Angioedema | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.768 | Nonalcoholic Fatty Liver Disease | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.769 | Nonalcoholic Fatty Liver Disease | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.77 | Chronic Pain ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.770 | Nonalcoholic Fatty Liver Disease | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.771 | Thalassemia | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.772 | Thalassemia | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.773 | Thalassemia | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.78 | Chronic Pain SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.79 | Arthritis Disorders SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.790 | Urine Protein to Creatinine Ratio (UPCR) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.791 | 24 Hour Urine Volume | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.792 | 24 Hour Urine Protein Excretion | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.793 | Total Carbon Dioxide or Bicarbonate in blood, serum or plasma | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.794 | Calcium (Not Corrected for Serum Albumin) in Blood, Plasms, or Serum | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.795 | B Type Natriuretic Peptide [Bnp] in Blood, Serum or Plasma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.797 | N Terminal Pro_B_Type Natriuretic Peptide [Nt_Probnp] in blood, serum or plasma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.799 | Temporomandibular Disorder Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.80 | Arthritis Disorders ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.800 | Temporomandibular Disorder Diagnosis | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.801 | High Sensitivity Troponin | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.804 | Aspartate Transaminase or Alanine Aminotransferase Ratio | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.805 | Alkaline Phosphatase (Alp) in Blood, Serum or Plasma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.806 | Gamma Glutamyl Transpeptidase (Ggt) in blood, serum or plasma | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.807 | Triiodothyronine in serum or plasma | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.808 | Fasting Blood Glucose | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.809 | Random Blood Glucose Test | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.81 | Arthritis Disorders | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.810 | Uric Acid (Urate) in blood, serum or plasma | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.811 | Aldosterone/Renin Ratio | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.812 | Serum Rheumatoid Factor | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.813 | Blood Ethanol Level | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.814 | Drugs of Abuse Screen in Hair | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.815 | Drugs of Abuse Screen in Urine | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.816 | Drugs of Abuse Screen in Blood | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.817 | Drugs of Abuse Screen in Tissue | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.818 | Drugs of Abuse Screen in Body Fluid | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.819 | Urea Reduction Ratio | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.82 | Preeclampsia Disorders SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.822 | Bowel Sounds | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.823 | Uroflowmetry | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.826 | Gait Quality | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.828 | Balance Assessments | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.83 | Preeclampsia Disorders ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.836 | Sit to Stand Ability | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.84 | Preeclampsia Disorders | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.840 | Spinal Cord Compression | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.841 | Spinal Cord Compression | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.842 | Alcohol Use (Revised 2021) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.843 | Alcohol Use (Revised 2021) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.844 | Alcohol Use (Revised 2021) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.845 | Alcohol Use | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.85 | Hyperuricemia Conditions | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.86 | Hyperuricemia Conditions ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.864 | Kidney Biopsy Report | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.867 | Skin Biopsy Report | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.868 | Muscle Biopsy Report | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.869 | Gastric Tissue Biopsy Report | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.87 | Hyperuricemia Conditions SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.870 | Bone Biopsy Report | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.873 | Echocardiogram | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.88 | Vitamin D Deficiency Conditions SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.880 | Spinal or Back CT | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.881 | Chest CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.882 | Abdominal or Pelvic CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.883 | Limb CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.884 | Heart Calcium Score | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.885 | Coronary CT Angiogram | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.886 | Limb CT Angiogram | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.888 | Chest CT Angiogram | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.889 | Head and Neck CT Angiogram | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.89 | Vitamin D Deficiency Conditions ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.891 | Gastrointestinal Tract X Ray | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.892 | Gallbladder X Ray | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.893 | Kidney X Ray | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.894 | Abdomen X Ray | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.895 | Pelvis X Ray | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.896 | Hand X Ray | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.897 | Wrist X Ray | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.898 | Forearm X Ray | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.899 | Elbow X Ray | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.90 | Vitamin D Deficiency Conditions | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.900 | Upper Arm X Ray | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.901 | Shoulder X Ray | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.902 | Upper Extremity X Ray | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.903 | Foot X Ray | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.904 | Ankle X Ray | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.905 | Shin X Ray | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.906 | Knee X Ray | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.907 | Thigh X Ray | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.908 | Hip X Ray | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.909 | Lower Extremity X Ray | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.91 | Alkaline Phosphatase Deficiency Conditions SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.910 | Abdominal MRI | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.911 | Adrenal Gland MRI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.912 | Kidney MRI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.913 | Pancreas MRI | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.915 | Kidney MRA | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.916 | Chest Region MRI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.917 | Pulmonary MRI | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.918 | Cardiac MRI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.92 | Alkaline Phosphatase Deficiency Conditions ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.920 | Spine MRI | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.921 | Head and Neck MRI | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.922 | Brain MRI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.923 | Pelvic Region MRI | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.924 | Knee MRI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.925 | Foot MRI | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.927 | Shoulder MRI | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.928 | Lower Extremity MRA | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.93 | Alkaline Phosphatase Deficiency Conditions | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.930 | Spine X Ray | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.933 | Hip MRI | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.934 | Thigh or Femur MRI | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.935 | Ankle MRI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.936 | Lower Extremity MRI | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.937 | Forearm MRI | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.938 | Elbow MRI | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.939 | Wrist MRI | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.94 | Uremic Pruritus Conditions ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.940 | Hand MRI | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.942 | Upper Extremity MRI | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.943 | Abdominal MRA | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.944 | Chest MRA | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.945 | Upper Extremity MRA | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.947 | Head and Neck MRA | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.948 | Pelvic Region MRA | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.949 | Functional MRI | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.95 | Uremic Pruritus Conditions SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.951 | Optical Coherence Tomography | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.954 | Bathing or grooming/hygiene (ADL/IADL) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.955 | Dressing (ADL or IADL) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.956 | Toileting (ADL or IADL) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.957 | Transferring (ADL or IADL) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.958 | Walking or ambulation/locomotion (ADL/IADL) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.96 | Uremic Pruritus Conditions | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.960 | Domestic Duties or Household Tasks (ADL/IADL) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.961 | Telephone Use (ADL or IADL) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.962 | Bed Mobility (ADL or IADL) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.963 | Stair Use (ADL or IADL) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.964 | Medication Management (ADL or IADL) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.967 | Electromyography | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.968 | Electroencephalogram | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.969 | Exercise Stress Test | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.97 | Insomnia Disorders | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.976 | Sleep Duration, Device | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.977 | Steps Per Time, Device | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.978 | Physical Activity Level, Device | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.979 | Cognitive Function Clinician Interpretation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.98 | Insomnia Disorders ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.987 | Psychosis | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.99 | Insomnia Disorders SCT | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.991 | Suicidal Ideation and Behaviors | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.994 | Sleep Duration | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.996 | Pain Intensity or Severity | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.997 | Pain Quality | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1225.4 | Glaucoma ICD10 | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1225.5 | Glaucoma SNOMED | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.1 | Scleritis | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.2 | Scleritis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.3 | Scleritis | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.1 | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.2 | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography Non Diagnostic or Non CT | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.3 | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography Nuclear Medicine With CT | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.4 | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography CT Without Specified Body Region | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.6 | Outpatient Encounter Locations | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.7 | Outpatient Activity Codes | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.6 | Anaphylaxis, ICD10CM codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.60 | Guillain Barre Syndrome, diagnosis codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.61 | Febrile seizure, diagnosis codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.62 | Encephalomyelitis and encephalitis, diagnosis codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.63 | Disseminated Intravascular Coagulation, diagnosis codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.64 | Deep Vein Thrombosis, diagnosis codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.65 | Bells Palsy, diagnosis codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.66 | Appendicitis, diagnosis codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.67 | Anaphylaxis, diagnosis codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.68 | Acute Myocardial Infarction, diagnosis codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.69 | Multisystem Inflammatory Syndrome, SNOMED codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.7 | Anaphylaxis, SNOMED codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.70 | Multisystem Inflammatory Syndrome, diagnosis codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.71 | Transfusion CPT codes for exposure identification | active | 2021-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.72 | Transfusion ICD9 codes for exposure identification | active | 2021-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.73 | Transfusion ICD10PCS codes for exposure identification | active | 2021-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.74 | Transfusion CPT, ICD9, ICD10PCS codes for exposure identification | active | 2021-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.75 | COVID19 vaccine ICD10PCS codes for exposure identification | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.8 | Appendicitis, SNOMED codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.9 | Appendicitis, ICD10CM codes for AE reporting | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.1 | Test Diabetes codes | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.100 | Cardiomyopathy Hypertrophic Condition | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.12 | Metabolic Syndrome LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.15 | MetabolicSyndromeCondition | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.16 | Annual Physical ICD9 CN5 | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.164 | Diabetic Retinal Screening HD CPT for Tax Pair | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.165 | Optometrist and Ophthalmologist Taxonomy HD Taxonomy | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.167 | End Stage Renal Disease (ESRD)_HD_SNOMED | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.168 | End Stage Renal Disease (ESRD)_HD_ICD9 | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.169 | End Stage Renal Disease (ESRD)_HD_ICD10 | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.17 | Annual Physical ICD10 CN5 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.170 | End Stage Renal Disease (ESRD)_HD_HCPCS | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.171 | End Stage Renal Disease (ESRD)_HD_LOINC | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.172 | End Stage Renal Disease (ESRD)_HD_Clinical Condition Grouping | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.173 | Systolic Blood Pressure_HD_SNOMED | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.174 | Systolic Blood Pressure_HD_CPT | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.175 | Systolic Blood Pressure_HD_LOINC | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.176 | Systolic Blood Pressure_HD | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.177 | Diastolic Blood Pressure_HD_SNOMED | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.178 | Diastolic Blood Pressure_HD_CPT | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.179 | Diastolic Blood Pressure_HD_LOINC | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.18 | Annual Physical SNOMED CN5 | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.180 | Diastolic Blood Pressure_HD | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.181 | Remote Blood Pressure_HD_SNOMED | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.182 | Remote Blood Pressure_HD | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.183 | Remote Blood Pressure_HD_CPT | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.184 | Acute Inpatient_CN_HD_SNOMED | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.185 | Acute Inpatient_CN_HD_CPT | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.186 | Acute Inpatient_HD_Grouping | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.187 | ED Visit_CN_HD_CPT | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.188 | ED Visit_CN_HD_SNOMED | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.19 | Annual Physical Taxonomy CN5 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.190 | Pregnancy_HD_Grouping | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.191 | Pregnancy_CN_HD_SNOMED | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.192 | Pregnancy_CN_HD_ICD10 | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.193 | ED Visit_HD_Grouping | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.194 | Lipid Panel_Event_SNOMED | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.195 | Lipid Panel_Event_HCPCS | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.196 | Lipid Panel_Event_LOINC | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.197 | Lipid Panel_Event_CPT | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.198 | Lipid Panel_Event_Grouping | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.199 | Unknown Glucose_Event_ICD9 | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.20 | Annual Physical CN5 | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.200 | Unknown Glucose_Event_ICD10 | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.201 | Unknown Glucose_Event_LOINC | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.202 | Unknown Glucose_Event_CPT | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.203 | Unknown Glucose_Event_SNOMED | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.204 | Unknown Glucose_Lab_Grouping | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.205 | Bone Marrow Transplant CN_HD_SNOMED | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.206 | Bone Marrow Transplant CN_HD_ICD10 | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.207 | Bone Marrow Transplant_HD_CN_Grouping | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.208 | Immunocompromising Conditions CN_HD_ICD9 | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.209 | Immunocompromising Conditions CN_HD_ICD10PCS | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.21 | Annual Physical CPT CN5 | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.210 | Immunocompromising Conditions CN_HD_ICD10CM | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.211 | Immunocompromising Conditions_HD_CN_Grouping | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.212 | Immunocompromising Conditions CN_HD_SNOMED | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.213 | Cerebrospinal Fluid Leak CN_HD_SNOMED | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.214 | Cerebrospinal Fluid Leak CN_HD_ICD10 | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.215 | Cerebrospinal Fluid Leak_HD_CN_Grouping | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.216 | Anatomic or Functional Asplenia CN_HD_SNOMED | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.217 | Anatomic or Functional Asplenia CN_HD_ICD9 | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.218 | Anatomic or Functional Asplenia CN_HD_ICD10 | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.219 | Anatomic or Functional Asplenia_HD_CN_Grouping | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.22 | Annual Physical HCPCS CN5 | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.220 | Sickle cell Anemia and HB S Disease CN_HD_SNOMED | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.221 | Sickle cell Anemia and HB S Disease CN_HD_ICD10 | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.222 | Sickle cell Anemia and HB S Disease_HD_CN_Grouping | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.223 | Pneumococcal Vaccine CN_HD_SNOMED | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.224 | Pneumococcal Vaccine CN_HD_HCPCS | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.225 | Pneumococcal Vaccine CN_HD_CVX | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.226 | Pneumococcal Vaccine CN_HD_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.227 | Pneumococcal Vaccine_HD_CN_Grouping | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.228 | Influenza Vaccine CN_HD_SNOMED | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.229 | Influenza Vaccine CN_HD_HCPCS | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.23 | Annual Physical CPT for Tax Pair CN5 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.230 | Influenza Vaccine CN_HD_CVX | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.231 | Influenza Vaccine CN_HD_CPT | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.232 | Influenza Vaccine_HD_CN_Grouping | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.233 | Cochlear Implant CN_HD_SNOMED | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.234 | Cochlear Implant CN_HD_ICD10 | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.235 | Cochlear Implant CN_HD_HCPCS | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.236 | Cochlear Implant CN_HD_CPT | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.237 | Cochlear Implant_HD_CN_Grouping | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.238 | Chemotherapy CN_HD_SNOMED | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.239 | Chemotherapy CN_HD_ICD10 | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.24 | Annual Physical ICD9 for Tax Pair CN5 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.240 | Chemotherapy CN_HD_CPT | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.241 | Chemotherapy_HD_CN_Grouping | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.244 | Fasting Blood Glucose_Lab_Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.245 | Chronic Heart Failure (CHF)_ICD9 | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.246 | Chronic Heart Failure (CHF)_ICD10 | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.251 | Asthma_LOINC | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.253 | Asthma_Clinical Condition Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.254 | Pregnancy Loss_HD_SNOMED | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.255 | Pregnancy Loss_HD_ICD10 | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.257 | Pregnancy Loss_HD_Clinical Condition Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.258 | Heart Failure (CHF)_ICD9 | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.259 | Heart Failure (CHF)_ICD10 | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.260 | Heart Failure (CHF)_SNOMED | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.261 | Heart Failure (CHF)_HCPCS | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.262 | Heart Failure (CHF)_LOINC | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.263 | Heart Failure (CHF)_CPT | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.264 | Heart Failure (CHF)_RxNorm | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.265 | Heart Failure (CHF)_Clinical Condition Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.270 | Triglyceride_Lab_Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.274 | Total Cholesterol_CPT | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.275 | Total Cholesterol_Lab_Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.276 | LDL_SNOMED | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.280 | LDL_Lab_Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.284 | HDL_LOINC | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.285 | HDL_Lab_Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.286 | Colectomy_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.288 | Colectomy_ICD9 | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.29 | Hospice Exclusions Grouping | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.290 | Colectomy_Event_Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.291 | CT Colonography_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.292 | CT Colonography_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.294 | CT Colonography_Event_Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.295 | FIT DNA_LOINC | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.296 | FIT DNA_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.297 | FIT DNA_HCPCS | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.298 | FIT DNA_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.299 | FIT DNA Test_Lab_Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.30 | Annual Physical Codes for Tax Pair CN5 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.300 | Sigmoidoscopy_CPT | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.302 | Sigmoidoscopy_ICD9 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.303 | Sigmoidoscopy_SNOMED | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.304 | Sigmoidoscopy_Event_Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.305 | Colonoscopy_CPT | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.306 | Colonoscopy_HCPCS | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.307 | Colonoscopy_ICD9 | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.308 | Colonoscopy_SNOMED | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.309 | Colonoscopy_Event_Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.310 | FOBT Lab_CPT | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.311 | FOBT Lab_HCPCS | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.312 | FOBT Lab_LOINC | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.313 | FOBT Lab_SNOMED | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.314 | FOBT Lab Test_Lab_Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.315 | Colorectal Cancer_HD_ICD10 | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.316 | Colorectal Cancer_HD_ICD9 | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.317 | Colorectal Cancer_HD_SNOMED | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.318 | Colorectal Cancer_HD_Grouping | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.319 | Absence of Cervix Diagnosis_HD_ICD10 | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.320 | Absence of Cervix Diagnosis_HD_ICD9 | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.321 | Absence of Cervix Diagnosis_HD_SNOMED | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.322 | Absence of Cervix Diagnosis_HD_Grouping | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.323 | Hysterectomy With No Residual Cervix_HD_CPT | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.324 | Hysterectomy With No Residual Cervix_HD_ICD10 | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.325 | Hysterectomy With No Residual Cervix_HD_ICD9 | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.326 | Hysterectomy With No Residual Cervix_HD_SNOMED | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.327 | Hysterectomy With No Residual Cervix_HD_Grouping | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.328 | High Risk HPV Test_HD_CPT | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.329 | High Risk HPV Test_HD_HCPCS | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.330 | High Risk HPV Test_HD_LOINC | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.331 | High Risk HPV Test_HD_SNOMED | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.332 | High Risk HPV Test_HD_Grouping | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.333 | Cervical Cytology_HD_CPT | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.334 | Cervical Cytology_HD_HCPCS | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.335 | Cervical Cytology_HD_LOINC | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.336 | Cervical Cytology_HD_SNOMED | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.337 | Cervical Cytology_HD_Grouping | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.338 | AFib (Atrial Fibrillation)_ICD9 | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.339 | AFib (Atrial Fibrillation)_ICD10 | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.340 | AFib (Atrial Fibrillation)_SNOMED | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.341 | AFib (Atrial Fibrillation)_LOINC | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.342 | AFib (Atrial Fibrillation)_RxNORM | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.343 | AFib (Atrial Fibrillation)_CPT | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.344 | AFib (Atrial Fibrillation)_Clinical Condition Grouping | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.345 | COVID19 Vaccine_CPT | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.346 | COVID19 Vaccine_HCPCS | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.348 | COVID19 Vaccine_RxNorm | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.349 | COVID19 Vaccine_CVX | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.350 | COVID19 Vaccine_Event Clinical Grouping | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.351 | Coronary Artery Disease (CAD)_ICD9 | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.352 | Coronary Artery Disease (CAD)_ICD10PCS | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.353 | Coronary Artery Disease (CAD)_ICD10CM | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.354 | Coronary Artery Disease (CAD)_CPT | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.355 | Coronary Artery Disease (CAD)_HCPCS | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.356 | Coronary Artery Disease (CAD)_LOINC | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.357 | Coronary Artery Disease (CAD)_SNOMED | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.358 | Coronary Artery Disease (CAD)_CUI_UMLS | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.359 | Coronary Artery Disease (CAD)_Clinical Condition Grouping | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.360 | Allergy List_SNOMED | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.361 | Allergy List_ICD10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.362 | Allergy List_Clinical Grouping Event | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.363 | Statin Use_RxNorm | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.364 | Other Revascularization_SNOMED | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.365 | Other Revascularization_CPT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.366 | Other Revascularization_Grouping | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.367 | Ischemic Vascular Disease (IVD)_SNOMED | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.368 | Ischemic Vascular Disease (IVD)_ICD10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.369 | Ischemic Vascular Disease (IVD)_Grouping | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.370 | Muscular Pain and Disease_SNOMED | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.371 | Muscular Pain and Disease_ICD10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.372 | Muscular Pain and Disease_Grouping | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.373 | Cirrhosis_SNOMED | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.374 | Cirrhosis_ICD10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.375 | Cirrhosis_Grouping | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.376 | IVF_SNOMED | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.377 | IVF_HCPCS | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.378 | IVF_Grouping | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.379 | Estrogen Agonists Medications_RXNORM | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.382 | Pre_Hypertension (Pre_HTN)_Clinical Condition Grouping | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.384 | Family History Hypertension (HTN)_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.385 | Family History Hypertension (HTN)_Clinical Condition Grouping | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.386 | Obesity_Condition_UMLS | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.387 | Podiatry_Taxonomy | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.388 | Cardiology _Taxonomy | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.393 | BMI >=40_Event_Clinical Condition Grouping | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.400 | Smoker Status_Event_Clinical Condition Grouping | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.401 | First Trimester_ICD10 | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.402 | First Trimester_SNOMED | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.403 | First Trimester_LOINC | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.404 | First Trimester_CPT | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.405 | First Trimester_UMLS CUI | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.406 | First Trimester_Clinical Grouping Event | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.408 | Birth Event_ICD10 | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.409 | Birth Event_SNOMED | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.413 | Birth Event_Clinical Grouping Event | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.414 | Obesity_Condition_SNOMED | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.415 | Obesity_Condition_ICD10 | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.416 | Obesity_Condition_ICD9 | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.417 | Obesity_Clinical Grouping Condition | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.418 | Pre_Hypertension (Pre_HTN)_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.419 | Pre_Hypertension (Pre_HTN)_ICD9 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.420 | Pre_Hypertension (Pre_HTN)_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.424 | BMI >=30_Event_Clinical Condition Grouping | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.427 | Obesity_Condition_LOINC | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.428 | Vitals Body Height LOINC | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.429 | Vitals Body Height SnoMed | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.430 | Vitals Body Height | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.431 | bwell_Vital_Blood Glucose_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.432 | Anxiety_Clinical Grouping Condition_ICD9 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.433 | Anxiety_Clinical Grouping Condition_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.434 | Anxiety_Clinical Grouping Condition_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.435 | Anxiety_Clinical Grouping Condition_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.436 | Anxiety_Clinical Grouping Condition | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.437 | bwell_Vital_Blood Oxygen_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.438 | bwell_Vital_Systolic Blood Pressure_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.439 | bwell_Vital_Diastolic Blood Pressure_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.440 | bwell_Vital_Heart Rate_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.441 | bwell_Vital_BMI_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.442 | bwell_Vital_Body Fat_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.443 | bwell_Vital_Body Temperature_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.444 | bwell_Vital_Body Height_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.445 | bwell_Vital_Body Weight_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.446 | bwell_Vital_Respiratory Rate_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.447 | bwell_Vital_Waist Circumference_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.448 | bwell_Vital_Blood Glucose_Clinical Grouping Lab | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.449 | bwell_Vital_Blood Oxygen_Clinical Grouping Event | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.450 | bwell_Vital_Systolic Blood Pressure_Clinical Grouping Event | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.451 | bwell_Vital_Diastolic Blood Pressure_Clinical Grouping Event | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.452 | bwell_Vital_Heart Rate_Clinical Grouping Event | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.453 | bwell_Vital_BMI_Clinical Grouping Event | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.454 | bwell_Vital_Body Fat_Clinical Grouping Event | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.455 | bwell_Vital_Body Temperature_Clinical Grouping Event | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.456 | bwell_Vital_Body Height_Clinical Grouping Event | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.457 | bwell_Vital_Body Weight_Clinical Grouping Event | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.458 | bwell_Vital_Respiratory Rate_Clinical Grouping Event | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.459 | bwell_Vital_Waist Circumference_Clinical Grouping Event | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.460 | Pregnancy_CN_HD_LOINC | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.461 | Pregnancy_CN_HD_CPT | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.462 | Pregnancy_CN_HD_UMLS | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.463 | Second Trimester_ICD10 | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.464 | Second Trimester_SNOMED | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.465 | Second Trimester_Clinical Grouping Event | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.466 | Third Trimester_SNOMED | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.467 | Third Trimester_ICD10 | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.468 | Third Trimester_Clinical Grouping Event | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.469 | Pregnancy Due Date_LOINC | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.470 | Second Trimester_LOINC | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.472 | OGTT_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.473 | OGTT_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.475 | OGTT_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.476 | OGTT_Grouping | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.477 | Second Trimester_CPT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.479 | Prostate Cancer Screening_HD_ICD9 | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.482 | Prostate Cancer Screening_HD_Grouping | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.484 | Prostate Dysplasia_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.486 | Prostate Dysplasia_Grouping | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.487 | Prostectomy_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.488 | Prostectomy_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.490 | Prostectomy_Grouping | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.494 | PSA Testing _LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.495 | PSA Testing_Grouping | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.496 | Active Pregnancy_CPT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.497 | Active Pregnancy_ICD10 | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.498 | Active Pregnancy_LOINC | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.499 | Active Pregnancy_SNOMED | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.5 | ADD/ADHD Condition | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.500 | Active Pregnancy_Clinical Grouping Event | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.501 | Abnormal PSA Testing _SNOMED | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.502 | Prediabetes_Clinical Grouping Condition_ICD10 | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.503 | Prediabetes_Clinical Grouping Condition_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.504 | Prediabetes_Clinical Grouping Condition | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.505 | Third Trimester_CPT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.506 | Third Trimester_LOINC | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.508 | bwell_Vital_Waist Circumference_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.509 | bwell_Vital_Blood Oxygen_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.510 | bwell_Vital_Body Temperature_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.511 | bwell_Vital_Diastolic Blood Pressure_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.512 | bwell_Vital_Systolic Blood Pressure_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.513 | bwell_Vital_Systolic_and_Diastolic Blood Pressure_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.514 | bwell_Vital_Systolic_and_Diastolic Blood Pressure_Clinical Grouping Event | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.515 | bwell_Vital_Heart Rate_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.516 | bwell_Vital_Respiratory Rate_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.517 | Lupus_Clinical_Condition_ICD10 | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.519 | Lupus_Clinical_Condition_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.520 | Lupus_Clinical Condition Grouping | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.523 | UTI_Clinical_Condition_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.524 | UTI_Clinical Condition Grouping | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.525 | Postpartum_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.526 | Postpartum_HCPCS | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.527 | Postpartum_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.528 | Postpartum_ICD9CM | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.529 | Postpartum_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.530 | Postpartum_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.531 | Postpartum_Clinical Grouping Event | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.532 | bwell_Vital_Head Circumference_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.533 | bwell_Vital_Head Circumference_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.534 | bwell_Vital_Head Circumference_Clinical Grouping Event | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.535 | bwell_Vital_Body Surface Area_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.536 | bwell_Vital_Body Surface Area_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.537 | bwell_Vital_Body Surface Area_Clinical Grouping Event | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.538 | bwell_Vital_Vital Signs Panel_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.539 | bwell_Vital_Vital Signs Panel_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.540 | bwell_Vital_Vital Signs Panel_Clinical Grouping Event | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.541 | bwell_Vital_Blood Pressure Panel_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.542 | bwell_Vital_Blood Pressure Panel_Clinical Grouping Event | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.543 | Depression_Clinical Grouping Condition_CPT | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.544 | Depression_Clinical Grouping Condition_HCPCS | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.545 | Depression_Clinical Grouping Condition_ICD10 | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.546 | Depression_Clinical Grouping Condition_ICD9 | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.547 | Depression_Clinical Grouping Condition_LOINC | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.548 | Depression_Clinical Grouping Condition_SNOMED | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.549 | Depression_Clinical Grouping Condition | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.550 | MI (Myocardial Infarction)_Clinical Grouping Condition_ICD9 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.551 | MI (Myocardial Infarction)_Clinical Grouping Condition_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.552 | MI (Myocardial Infarction)_Clinical Grouping Condition_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.553 | MI (Myocardial Infarction)_Clinical Grouping Condition | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.554 | CABG_Clinical Grouping Condition_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.555 | CABG_Clinical Grouping Condition_HCPCS | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.556 | CABG_Clinical Grouping Condition_ICD10PCS | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.557 | CABG_Clinical Grouping Condition_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.558 | CABG_Clinical Grouping Condition | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.559 | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.56 | Diabetic Retinal Screening HD CPT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.560 | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_HCPCS | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.561 | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_ICD10PCS | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.562 | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_ICD9PCS | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.563 | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.564 | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.565 | Essential HTN_HD_Clinical Grouping Condition_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.566 | Essential HTN_HD_Clinical Grouping Condition_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.567 | Essential HTN_HD_Clinical Grouping Condition | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.568 | Total and Partial Neph_HD_Clinical Grouping Condition_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.569 | Total and Partial Neph_HD_Clinical Grouping Condition_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.570 | Total and Partial Neph_HD_Clinical Grouping Condition_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.571 | Total and Partial Neph_HD_Clinical Grouping Condition | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.572 | Kid Trans and Hx_HD_Clinical Grouping Condition_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.573 | Kid Trans and Hx_HD_Clinical Grouping Condition_HCPCS | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.574 | Kid Trans and Hx_HD_Clinical Grouping Condition_ICD10CM | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.575 | Kid Trans and Hx_HD_Clinical Grouping Condition_ICD10PCS | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.576 | Kid Trans and Hx_HD_Clinical Grouping Condition_ICD9 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.577 | Kid Trans and Hx_HD_Clinical Grouping Condition_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.578 | Kid Trans and Hx_HD_Clinical Grouping Condition | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.579 | HbA1c Level Less Than 8.0_HD_Clinical Grouping Condition_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.580 | HbA1c Level Less Than 8.0_HD_Clinical Grouping Condition | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.581 | Systolic Less than 140_HD_Clinical Grouping Event_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.582 | Diastolic Less than 90_HD_Clinical Grouping Event_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.583 | Systolic Less than 140_HD_Clinical Grouping Event | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.584 | Diastolic Less than 90_HD_Clinical Grouping Event | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.585 | COPD_Clinical_Grouping_Condition_ICD9 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.586 | COPD_Clinical_Grouping_Condition_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.587 | COPD_Clinical_Grouping_Condition_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.588 | COPD_Clinical Condition Grouping | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.589 | Polypharmacy_Clinical_Grouping_Condition_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.590 | Polypharmacy_Clinical_Grouping_Condition_ICD9 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.591 | Polypharmacy_Clinical_Grouping_Condition_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.592 | Polypharmacy_Clinical_Grouping_Condition_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.593 | Polypharmacy_Clinical Condition Grouping | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.595 | Thyroid Cancer_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.596 | Thyroid Cancer_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.597 | Thyroid Cancer_Grouping | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.598 | Allergy Iodine_SNOMED | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.599 | Allergy to contrast_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.600 | Allergy to contrast_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.601 | Allergy to contrast_Grouping | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.602 | Contrast induced nephropathy_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.603 | Contrast induced nephropathy_ICD10 | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.604 | Contrast induced nephropathy_Grouping | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.605 | Systolic Blood Pressure_Compliant | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.606 | Diastolic Blood Pressure_Compliant | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.607 | Diastolic Blood Pressure_Compliant_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.608 | Systolic Blood Pressure_Compliant_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.609 | bwell Systolic Blood Pressure Vitals_UI_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.610 | bwell Systolic Blood Pressure Vitals_UI_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.611 | bwell Diastolic Blood Pressure Vitals_UI_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.612 | bwell Diastolic Blood Pressure Vitals_UI_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.613 | bwell Combo Blood Pressure Vitals_UI_LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.614 | bwell Combo Blood Pressure Vitals_UI_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.615 | bwell Systolic Blood Pressure_UI | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.616 | bwell Diastolic Blood Pressure_UI | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.617 | bwell Combo Blood Pressure_UI | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.618 | b.well Herpes Zoster Vaccine CN_HD | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.619 | b.well Herpes Zoster Vaccine CN_HD_SNOMED | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.620 | b.well Herpes Zoster Vaccine CN_HD_CVX | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.621 | b.well Herpes Zoster Vaccine CN_HD_CPT | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.622 | b.well Herpes Zoster Vaccine CN_HD_2dose | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.623 | b.well Herpes Zoster Vaccine CN_HD_2dose_CPT | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.624 | b.well Herpes Zoster Vaccine CN_HD_2dose_CVX | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.625 | b.well Herpes Zoster Vaccine CN_HD_2dose_SNOMED | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.626 | b.well Herpes Zoster Vaccine CN_HD_Exclusions | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.627 | b.well Herpes Zoster Vaccine CN_HD_Exclusions_SNOMED | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.628 | b.well Adult RSV Vaccine CN_CVX | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.629 | b.well Adult RSV Vaccine CN_CPT | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.630 | b.well Adult RSV Vaccine CN_HCPCS | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.631 | b.well Adult RSV Vaccine CN_SNOMED | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.633 | Lp(a) Test_SNOMED | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.634 | Lp(a) Test_LOINC | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.635 | LP(a) Test_ICD | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.636 | Lp(a) Test_CPT | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.637 | LP(a) Test | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.638 | b.well Adult Tetanus Vaccine CN | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.639 | BWellAdultTetanusVaccineCN_SNOMED | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.640 | b.well Adult Tetanus Vaccine CN_CPT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.641 | b.well Adult Tetanus Vaccine CN_CVX | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.642 | b.well Adult Tetanus Vaccine CN_Exclusions_SNOMED | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.643 | b.well Adult Tetanus Vaccine CN_Exclusions | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.644 | BWellAdultTetanusVaccineCN_RxNorm | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.645 | Pneumococcal Vaccine HD_CN_ Allergy | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.646 | bwell COVID Vaccine CN_Allergy | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.647 | bwell Covid Vaccine CN_Allergy_SNOMED | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.648 | bwell COVID Vaccine CN_Met | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.9 | Metabolic Syndrome ICD10 | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.91 | Cardiomyopathy Dilated ICD9 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.92 | Cardiomyopathy Dilated ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.93 | Cardiomyopathy Dilated SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.94 | Cardiomyopathy Dilated Condition | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.95 | Cardiomyopathy Dilated LOINC | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.96 | Cardiomyopathy Hypertrophic ICD9 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.97 | Cardiomyopathy Hypertrophic ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.98 | Cardiomyopathy Hypertrophic SNOMED | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.99 | Cardiomyopathy Hypertrophic LOINC | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.12 | SNOMEDFindingValuesQualifierValue | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.13 | SNOMED Organism from LOINC Answer List | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.18 | Medication Prescribable Brand Name | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.2 | SNOMED Organisms | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.22 | Medicinal Ingredients RXNORM | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.1 | Mental Status Observation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.10 | Other Unknown Nulls | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.11 | Sexual Orientation Including nulls and Data Absent Reason | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.12 | Pregnancy Status Observation | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.2 | No Healthcare Agent Included Reason | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.3 | Sex | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.4 | Asked Declined Data Absent Reason | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.5 | Act Encounter Codes | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.6 | Completed or Nullified Act Status | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.7 | Data Absent Reason Types of Unknown | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.8 | Medication Adherence | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1242.2 | Sickle Cell Disease | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1242.4 | Depression | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.1 | Food Insecurity Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.100 | Intimate Partner Violence Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.101 | Less Than High School Education Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.102 | Less Than High School Education Diagnoses ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.103 | Less Than High School Education Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.106 | Transportation Insecurity Interventions SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.107 | Financial Insecurity Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.108 | Financial Insecurity Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.109 | Financial Insecurity Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.11 | Food Insecurity Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.110 | Medical Cost Burden Goals SNOMED CT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.111 | Health Insurance Coverage Status Goals SNOMED CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.112 | Health Literacy Diagnoses SNOMED CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.113 | Health Literacy Diagnoses ICD10CM | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.114 | Health Literacy Goals SNOMED CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.115 | Health Literacy Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.116 | Health Literacy Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.117 | Health Literacy Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.118 | Health Literacy Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.119 | Health Literacy Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.120 | Medical Cost Burden Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.121 | Health Insurance Coverage Status Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.122 | Medical Cost Burden Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.123 | Medical Cost Burden Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.124 | Health Insurance Coverage Status Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.125 | Health Insurance Coverage Status Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.126 | Social Determinants of Health Screening Assessments | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.127 | Food Insecurity Screening Assessments | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.128 | Transportation Insecurity Screening Assessments | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.129 | Homelessness Screening Assessments | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.13 | Homelessness Diagnoses ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.130 | Housing Instability Screening Assessments | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.131 | Inadequate Housing Screening Assessments | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.132 | Less Than High School Education Screening Assessments | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.133 | Unemployment Screening Assessments | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.134 | Veteran Status Screening Assessments | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.135 | Social Connection Screening Assessments | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.136 | Stress Screening Assessments | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.137 | Cognitive disorder Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.138 | Financial Insecurity Screening Assessments | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.139 | Material Hardship Screening Assessments | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.14 | Homelessness Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.140 | Intimate Partner Violence Screening Assessments | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.141 | Health Literacy Screening Assessments | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.142 | Medical Cost Burden Screening Assessments | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.143 | Health Insurance Coverage Status Screening Assessments | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.144 | Elder Abuse Screening Assessments | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.145 | Less Than High School Education Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.146 | Financial Insecurity Diagnoses ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.147 | Health Insurance Coverage Status Diagnoses ICD10CM | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.148 | Health Insurance Coverage Status Diagnoses | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.149 | Health Insurance Coverage Status Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.15 | Food Insecurity Interventions CPT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.150 | Material Hardship Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.151 | Medical Cost Burden Diagnoses ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.152 | Medical Cost Burden Diagnoses SNOMED CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.153 | Medical Cost Burden Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.154 | Medical Cost Burden Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.157 | Transportation Insecurity Diagnoses ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.158 | Homelessness Goals SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.159 | Homelessness Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.16 | Food Insecurity Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.160 | Housing Instability Goals SNOMED CT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.161 | Housing Instability Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.162 | Transportation Insecurity Goals SNOMED CT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.163 | Transportation Insecurity Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.164 | Veteran Status Interventions SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.167 | Inadequate Housing Screening Assessments Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.168 | Material Hardship Screening Assessments Questions | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.169 | Stress Screening Assessments Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.17 | Food Insecurity Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.170 | Transportation Insecurity Screening Assessments Questions | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.171 | Unemployment Screening Assessments Questions | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.172 | Veteran Status Screening Assessments Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.173 | Financial Insecurity Screening Assessments Answers | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.174 | Food Insecurity Screening Assessments Answers | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.175 | Health Literacy Screening Assessments Answers | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.176 | Homelessness Screening Assessments Answers | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.177 | Housing Instability Screening Assessments Answers | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.178 | Inadequate Housing Screening Assessments Answers | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.179 | Less Than High School Education Screening Assessments Answers | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.18 | Homelessness Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.180 | Material Hardship Screening Assessments Answers | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.181 | Stress Screening Assessments Answers | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.182 | Transportation Insecurity Screening Assessments Answers | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.183 | Unemployment Screening Assessments Answers | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.184 | Veteran Status Screening Assessments Answers | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.185 | Health Insurance Coverage Status Screening Assessments Answers | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.186 | Health Insurance Coverage Status Screening Assessments Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.187 | Medical Cost Burden Screening Assessments Answers | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.188 | Medical Cost Burden Screening Assessments Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.189 | Elder Abuse Screening Assessments Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.19 | Homelessness Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.190 | Elder Abuse Screening Assessments Answers | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.191 | Elder Abuse Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.192 | Veteran Status Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.193 | Financial Insecurity Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.194 | Food Insecurity Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.195 | Health Literacy Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.196 | Homelessness Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.197 | Housing Instability Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.198 | Intimate Partner Violence Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.199 | Less Than High School Education Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.20 | Homelessness Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.200 | Material Hardship Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.201 | Medical Cost Burden Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.202 | Social Connection Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.203 | Stress Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.204 | Transportation Insecurity Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.205 | Unemployment Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.206 | Social Determinants of Health Screening Assessments And Questions | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.207 | Social Determinants of Health Screening Assessments Questions | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.208 | Social Determinants of Health Screening Assessments Answers | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.209 | Intimate Partner Violence Screening Assessments Answers | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.21 | Homelessness Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.210 | Social Connection Screening Assessments Answers | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.211 | Intimate Partner Violence Screening Assessments Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.212 | Social Connection Screening Assessments Questions | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.213 | Health Insurance Coverage Status Diagnoses SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.214 | Veteran Status Goals | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.215 | Veteran Status Goals SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.217 | Digital Literacy Diagnoses SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.218 | Digital Literacy Diagnoses ICD10CM | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.219 | Digital Literacy Goals SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.22 | Housing Instability Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.220 | Digital Literacy Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.224 | Digital Literacy Diagnoses | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.225 | Digital Literacy Goals | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.226 | Digital Literacy Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.227 | Digital Literacy Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.229 | Digital Access Diagnoses SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.23 | Housing Instability Diagnoses ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.230 | Digital Access Diagnoses ICD10CM | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.231 | Digital Access Diagnoses | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.232 | Digital Access Goals SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.233 | Digital Access Goals | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.234 | Digital Access Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.235 | Digital Access Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.236 | Digital Access Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.237 | Digital Access Screening Assessments | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.238 | Digital Access Screening Assessments Questions | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.239 | Digital Access Screening Assessments Answers | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.24 | Housing Instability Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.240 | Digital Access Screening Assessments And Questions | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.241 | Utility Insecurity Diagnoses SNOMED CT | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.242 | Utility Insecurity Diagnoses ICD10CM | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.243 | Utility Insecurity Diagnoses | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.244 | Utility Insecurity Goals SNOMED CT | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.245 | Utility Insecurity Goals | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.246 | Utility Insecurity Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.247 | Utility Insecurity Procedures | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.248 | Utility Insecurity Screening Assessments | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.249 | Utility Insecurity Screening Assessments Questions | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.25 | Transportation Insecurity Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.250 | Utility Insecurity Screening Assessments Answers | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.251 | Utility Insecurity Screening Assessments And Questions | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.252 | Utility Insecurity Service Requests | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.253 | Social Determinants of Health General Interventions HCPCS | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.254 | Incarceration Status Diagnoses ICD10CM | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.255 | Incarceration Status Diagnoses SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.256 | Incarceration Status Goals SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.257 | Incarceration Status Goals | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.258 | Incarceration Status Diagnoses | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.259 | Incarceration Status Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.26 | Transportation Insecurity Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.260 | Incarceration Status Procedures | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.261 | Incarceration Status Service Requests | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.262 | Language Access Diagnoses | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.263 | Language Access Diagnoses ICD10CM | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.264 | Language Access Diagnoses SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.265 | Language Access Goals SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.266 | Language Access Goals | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.267 | Language Access Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.268 | Language Access Procedures | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.269 | Language Access Service Requests | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.27 | Transportation Insecurity Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.270 | Language Access Screening Assessments | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.271 | Language Access Screening Assessments Answers | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.272 | Language Access Screening Assessments Questions | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.273 | Language Access Screening Assessments And Questions | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.28 | Transportation Insecurity Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.29 | Financial Insecurity Goals SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.3 | Food Insecurity Diagnoses ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.30 | Financial Insecurity Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.31 | Financial Insecurity Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.32 | Financial Insecurity Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.33 | Material Hardship Diagnoses ICD10CM | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.34 | Material Hardship Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.35 | Material Hardship Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.36 | Material Hardship Goals SNOMED CT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.37 | Material Hardship Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.38 | Material Hardship Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.39 | Material Hardship Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.4 | Food Insecurity Goals SNOMED CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.40 | Unemployment Diagnoses ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.41 | Unemployment Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.42 | Unemployment Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.43 | Housing Instability Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.44 | Housing Instability Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.45 | Housing Instability Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.46 | Inadequate Housing Diagnoses SNOMED CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.47 | Inadequate Housing Diagnoses ICD10CM | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.48 | Inadequate Housing Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.49 | Inadequate Housing Goals SNOMED CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.5 | Social Determinants of Health General Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.50 | Inadequate Housing Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.51 | Inadequate Housing Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.52 | Inadequate Housing Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.53 | Inadequate Housing Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.54 | Less Than High School Education Goals SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.55 | Less Than High School Education Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.56 | Less Than High School Education Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.57 | Less Than High School Education Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.58 | Unemployment Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.59 | Unemployment Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.6 | Food Insecurity Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.60 | Unemployment Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.61 | Elder Abuse Diagnoses ICD10CM | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.62 | Elder Abuse Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.63 | Elder Abuse Diagnoses | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.64 | Elder Abuse Goals SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.65 | Elder Abuse Goals | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.66 | Elder Abuse Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.67 | Elder Abuse Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.68 | Elder Abuse Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.69 | Unemployment Goals SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.7 | Food Insecurity Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.70 | Unemployment Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.71 | Social Determinants of Health Goals | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.72 | Stress Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.73 | Stress Interventions SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.74 | Stress Diagnoses ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.75 | Stress Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.76 | Veteran Status Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.77 | Veteran Status Diagnoses ICD10CM | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.78 | Veteran Status Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.79 | Social Connection Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.8 | Social Determinants of Health General Interventions CPT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.80 | Social Connection Diagnoses ICD10CM | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.81 | Social Connection Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.82 | Intimate Partner Violence Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.83 | Intimate Partner Violence Diagnoses ICD10CM | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.84 | Intimate Partner Violence Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.85 | Stress Goals SNOMED CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.86 | Stress Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.87 | Stress Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.88 | Social Connection Goals SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.89 | Social Connection Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.9 | Food Insecurity Interventions HCPCS | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.90 | Veteran Status Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.91 | Veteran Status Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.92 | Stress Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.93 | Social Connection Interventions SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.94 | Social Connection Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.95 | Social Connection Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.96 | Intimate Partner Violence Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.97 | Intimate Partner Violence Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.98 | Intimate Partner Violence Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.99 | Intimate Partner Violence Goals SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.105 | Mechanical Ventilation Procedures | active | 2022-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.106 | Mechanical Ventilation | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.107 | Mechanical Ventilation | active | 2022-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.109 | aPTT Tests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.119 | Opioid Antagonist | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.12 | High Risk Diagnosis for AKI | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.120 | Opioids | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.124 | Immune Modulators | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.130 | Suicide Attempt | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.134 | Central Nervous System Depressants | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.136 | Leukemia or Lymphoma | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.137 | Liver Disease Moderate to Severe | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.138 | COVID19 | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.139 | COVID 19 | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.14 | Hemolytic Uremic Syndrome (HUS) | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.140 | COVID 19 | active | 2022-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.162 | Obesity | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.163 | Antidepressants | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.164 | Antihypertensives | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.165 | Delirium | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.166 | Dementia | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.167 | Psychosis | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.168 | Delirium or Dementia and Other Psychoses | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.169 | Depression | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.170 | Diuretics | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.171 | Epilepsy | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.172 | Neurologic Movement Disorders | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.173 | Neurologic Disorders, Other | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.174 | Neurologic Movement and Related Disorders | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.175 | Peripheral Neuropathy | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.176 | Stroke | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.177 | Abnormal Weight Loss and Malnutrition | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.178 | Intubation | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.179 | Intubation | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.180 | Tracheostomy Procedures | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.181 | Tracheostomy Procedures | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.182 | Head and Neck Surgeries with High Risk Airway Compromise | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.185 | Spinal Surgery | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.187 | Routes of Administration for Opioid Antagonists | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.19 | High Risk Procedures for AKI | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.197 | Hospital Based Dialysis Services | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.198 | Hospital Based Dialysis Services | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.199 | Hospital Based Dialysis Services | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.200 | Nephrectomy | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.201 | Thrombotic Thrombocytopenic Purpura | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.204 | VTE Prophylaxis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.205 | Moderate Injuries | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.206 | General and Neuraxial Anesthesia | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.207 | General and Neuraxial Anesthesia | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.208 | General and Neuraxial Anesthesia | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.209 | Non Invasive Oxygen Therapy by Nasal Cannula or Mask | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.21 | Creatinine Mass Per Volume | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.210 | Continuous and Bilevel Positive Airway Pressure | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.211 | Continuous and Bilevel Positive Airway Pressure | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.213 | Non Invasive Oxygen Therapy | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.214 | Non Invasive Oxygen Therapy Devices | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.216 | Procedural Hospital Locations | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.217 | ASA physical status class | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.218 | Blood urea nitrogen lab test | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.219 | Hemoglobin lab test | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.22 | Anticoagulants for All Indications | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.220 | Smoking status | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.221 | Albumin lab test | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.222 | Leukocyte count lab test | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.223 | Bilirubin lab test | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.224 | Aspartate transaminase lab test | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.226 | Cardiac Arrest | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.23 | Coagulation Disorders | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.230 | PO Antibacterials | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.231 | Injectable Antifungals | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.238 | Neuromuscular Disorder | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.239 | Neuromuscular Disorder | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.24 | Malignant Bone Disease | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.240 | Degenerative Neurological Disorder | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.241 | Degenerative Neurological Disorder | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.242 | Heart and Lung Transplants | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.243 | Heart and Lung Transplants | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.245 | Lung Resections and Excisions | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.246 | Lung Resections and Excisions | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.247 | Chest Wall Procedures | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.248 | Chest Wall Procedures | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.249 | Maxillary Procedures | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.250 | Maxillary Procedures | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.251 | Head, Neck, and Thoracic Surgeries with High Risk Airway Compromise | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.252 | Anesthesia Requiring Monitored Care | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.253 | Anesthesia Requiring Monitored Care | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.255 | Anesthesia Requiring Monitored Care | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.256 | Osteoporosis | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.260 | Rivaroxaban Anticoagulant | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.262 | Fondaparinux Anticoagulant | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.263 | Dalteparin Anticoagulant | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.264 | Heparin | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.268 | Enoxaparin Anticoagulant | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.271 | Undetectable Lab Result Value | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.272 | Undetectable Lab Result Value | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.274 | Dietary Recommendations | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.275 | Bariatric Procedures | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.276 | Telemedicine Services | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.277 | Prostate Cancer Treatment | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.28 | Traumatic Avulsion of Kidney | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.29 | Rapidly Progressive Nephritic Syndrome | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.301 | LDL Cholesterol | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.33 | Obstetrics and VTE Obstetrics | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.34 | Glucose Lab Test Mass Per Volume | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.349 | Tuberculosis for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.350 | Tuberculosis for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.351 | Tuberculosis for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.352 | Androgen Deprivation Therapy for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.353 | Bacillus Calmette Guerin for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.354 | Bladder Cancer for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.355 | Chemotherapy Agents for Advanced Cancer | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.356 | Cystectomy for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.357 | Cystectomy for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.358 | Cystectomy for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.359 | DEXA Bone Density for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.360 | Hospital Services for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.361 | Immunocompromised Conditions | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.362 | Immunocompromised Conditions | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.363 | Immunocompromised Conditions | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.364 | Immunosuppressive Drugs for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.365 | Mixed Histology Urothelial Cell Carcinoma for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.366 | Morbid Obesity | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.367 | Morbid Obesity | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.368 | Morbid Obesity | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.369 | Unavailability of Bacillus Calmette Guerin for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.370 | Urinary Retention | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.371 | Urinary Retention | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.372 | Urinary Retention | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.374 | Face to Face Interaction | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.375 | Face to Face Interaction | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.376 | HIV Viral Load Tests | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.377 | HIV Viral Load Tests | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.389 | Syphilis Tests | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.4 | Nephrectomy | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.79 | Acute Brain or Spinal Injury or Hemorrhage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.8 | Large Body Surface Area (BSA) Burns | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.80 | Pulmonary Arterial Thrombectomy | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.81 | Extracorporeal Membrane Oxygenation | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.85 | Elective Inpatient Encounter | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.86 | Intubation | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.88 | Acute Respiratory Failure | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.89 | Tracheostomy Diagnoses | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.90 | Tracheostomy Procedures | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.91 | Neuromuscular Disorder | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.92 | Degenerative Neurological Disorder | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.93 | Head and Neck Surgeries with High Risk Airway Compromise | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.94 | Oxygen Partial Pressure in Arterial Blood | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.95 | Carbon Dioxide Partial Pressure in Arterial Blood | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.96 | Arterial Blood pH | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1250.2 | Psychological Neuropsychological or Neurobehavioral Testing | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1250.3 | Psychological or Neuropsychological Testing | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.10 | Tricuspid Valve Regurgitation | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.12 | Hypertension | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.2 | Valvular Heart Disease | active | 2022-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.22 | Acute Kidney Injury | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.23 | Anemia | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.24 | Cardiac Arrhythmias | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.25 | Attention Deficit and Hyperactivity Disorder | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.26 | Cerebrovascular Disease | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.27 | Seizure Disorder | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.28 | Proteinuria | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.29 | Thyroid Hormone Disorder | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.30 | Thromboembolic Disease | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.31 | Parkinson's Disease and Parkinsonism | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.32 | Upper GI Diseases | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.33 | Failure to Thrive | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.34 | Osteoporosis | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.35 | Mood Disorders | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.36 | Dyslipidemia | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.37 | Heart Failure | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.38 | Coronary Artery Disease | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.39 | Chronic Kidney Disease | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.40 | Chronic Obstructive Pulmonary Disease | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.41 | Diabetes Mellitus | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1254.1 | EventTiming-TimingEvent | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1254.2 | EventTiming-EventTiming | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1258.1 | Gonorrhea Screening | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1258.2 | Abnormal Weight Loss | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.2 | Prescribable brand and generic non insulin drugs for hyperglycemia in Type 2 Diabetes | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.3 | Prescribable brand and generic insulins and analogues | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.4 | eGFR Using 2021 Race Free Formulas | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.5 | Fructosamine in Serum or Plasma | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.6 | Glucose tests in venous blood, capillary blood, serum/plasma for Diabetes | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.7 | Creatinine in serum/plasma | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.9 | IgE Agonists, prescribable | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.10 | Estrogen Receptor Testing for Orserdu | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.100 | MMR Proficient | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.101 | Systemic Cancer Directed Therapy | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.102 | Face To Face Interaction | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.104 | Erdafitinib | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.107 | Chemotherapy Encounter | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.108 | Urothelial Cancers ICD9 | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.109 | Urothelial Cancer ICD10 | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.11 | Estrogen Receptor Test for Orserdu | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.110 | Urothelial Cancers | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.111 | Prior Therapies for Erdafitinib | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.112 | Urothelial Cancer Histologies | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.113 | Malignant Tumor Behavior | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.114 | Localized Bladder Cancer Stage SNOMED | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.116 | Localized Bladder Cancer Staging | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.117 | Advanced Bladder Cancer Stage | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.118 | Localized Bladder Cancer T Stage | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.119 | Localized Bladder Cancer T Stage | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.12 | Negative | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.120 | Localized Bladder Cancer N Stage | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.121 | Localized Bladder Cancer M Stage | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.122 | Advanced Bladder Cancer M Stage | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.124 | Locoregional Urothelial Cancer ICD9 | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.125 | Locoregional Urothelial Cancer ICD10 | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.126 | Locoregional Urothelial Cancer SNOMED | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.127 | Locoregional Urothelial Cancer | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.128 | FGFR3 Gene | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.129 | FGFR3 Gene Interpretation Positive SNOMED | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.13 | HER2 Negative | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.130 | FGFR3 Gene Interpretation Positive LOINC | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.131 | FGFR3 Gene Interpretation Positive NCI | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.133 | FGFR3 Gene Interpretation Positive | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.134 | FGFR3 Gene Interpretation Negative SNOMED | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.135 | FGFR3 Gene Interpretation Negative NCI | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.137 | FGFR3 Gene Interpretation Negative | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.138 | FGFR3 Molecular Variants | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.139 | Tumor Behavior | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.14 | Endocrine Therapy | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.140 | Physcological Support for Cancer | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.141 | Referral For Pain From Cancer | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.142 | Cancer Pain Education | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.143 | Telehealth Encounters | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.144 | Pain Assessment Score | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.146 | Telehealth Encounters SNOMEDCT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.147 | Telehealth Encounters CPT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.148 | Telehealth Encounters HCPCS | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.149 | Telehealth Encounters All | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.15 | All Metastatic Sites | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.150 | Chemo Admin SNOMEDCT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.151 | Chemo Admin CPT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.152 | Chemo Admin HCPCS | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.153 | Chemotherapy Administration All | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.154 | Radiation Treatment CPT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.155 | Radiation Treatment HCPCS | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.156 | Radiation Treatment SNOMEDCT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.157 | Radiation Treatment All | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.158 | Bipolar Diagnosis Codes | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.159 | Telephone Visits SNOMED | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.16 | All Metastatic Sites | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.160 | Telephone Visit CPT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.161 | Telephone Visits All | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.162 | Adolescent depression screening assessment | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.163 | Adult depression screening assessment LOINC | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.165 | Referral for Depression Adult | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.166 | Referrals for Adolescent Depression | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.167 | Follow Ups for Adolescent Depression | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.168 | FollowUps for Adult Depression | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.169 | Depression Screen Declined for Medical Reason | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.17 | Metastatic Breast Cancer | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.170 | Physical Therapy Evaluations SNOMEDCT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.171 | Physical Therapy Evaluation CPT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.172 | Physical Therapies Evaluations | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.173 | Non Opioid Analgesics | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.174 | Adjuvant Analgesics | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.176 | Lung Cancer ICD9 | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.177 | Lung Cancer ICD10 | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.178 | Lung Cancer | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.179 | Prior Therapies for Osimertinib | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.18 | Stage IA | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.181 | Plan of Care for Pain | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.182 | All Antineoplastic Agents | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.183 | Locally Advanced NSCLC Stage Group | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.185 | Localized NSCLC Stage Group SNOMED | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.186 | Radiation Treatment Management | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.187 | Plan of Care | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.188 | Documentation of Plan of Care | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.189 | Pain Present | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.19 | Stage IB | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.190 | Localized NSCLC Stage Group NCIM | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.192 | Localized NSCLC Stage Group | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.193 | Advanced NSCLC Stage Group | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.194 | NSCLC M Stage (metastatic) | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.195 | NSCLC T Stage | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.196 | NSCLC N Stage | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.197 | SCLC and rarer lung cancer histology | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.198 | EGFR Gene | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.199 | EGFR Gene Interpretation Positive SNOMED | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.20 | Stage IIA | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.200 | EGFR Gene Interpretation Positive LOINC | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.201 | EGFR Gene Interpretation Positive | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.202 | EGFR Osimertinib Molecular Variants | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.203 | EGFR Generic Molecular Variant NCIM | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.204 | EGFR Generic Molecular Variant SNOMED | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.205 | EGFR Generic Molecular Variant LOINC | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.206 | EGFR Molecular Variants Osimertinib PM | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.207 | Osimertinib | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.208 | Pemetrexed | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.209 | Radiation Treatment Management SNOMEDCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.21 | Stage IIB | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.210 | Radiation Treatment Management Codes | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.211 | Radiation Treatment Delivery CPT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.212 | 77427 Management Code | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.213 | Radiation Treatment Delivery HCPCS | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.214 | Radiation Treatment Delivery NCIM | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.215 | Radiation Treatment Delivery SNOMED | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.216 | Radiation Treatment Delivery | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.217 | MET Gene Test | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.219 | Tepotinib | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.22 | Stage IIIA | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.220 | MET Positive gene interpretation | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.227 | MET Exon 14 skipping molecular variant | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.23 | Stage IIIB | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.230 | All Cancer Directed therapies | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.231 | EGFR Amivantamab Molecular Variants | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.232 | EGFR Molecular Variants Amivantamab PM | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.233 | test43 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.234 | ROS1 Molecular Variants Repotrectinib PM | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.235 | ROS1 Repotrectinib Molecular Variants | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.236 | ROS1 Negative (geneinterpretation) SNOMEDCT | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.237 | ROS1 Negative (geneinterpretation) NCI | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.238 | ROS1 Negative (geneinterpretation) SNOMEDCT,NCI | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.239 | ROS1 Positive (geneinterpretation) | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.24 | Stage IIIC | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.240 | ROS1 results (HGNC) | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.241 | ROS1 Gene Rearrangement | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.242 | RET Test (HGNC) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.243 | RET Positive (Genei interpretation ) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.244 | RET Gene Rearrangement | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.245 | RET Negative (geneinterpretaion) SNOMED | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.246 | RET Negative (geneinterpretaion) NCI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.247 | RET Negative (geneinterpretaion) SNOMEDCT,NCI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.248 | RET Fusion Molecular Variants | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.249 | pralsetinib | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.25 | ESR1 Gene Test | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.250 | Repotrectinib Value set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.251 | Amivantamab | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.252 | Alectinib Drug | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.253 | Gemcitabine Drug Value set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.254 | vinorelbine Drug | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.255 | NSCLC_Tumor_resection SNOMEDCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.256 | NSCLC_Tumor_resection CPT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.257 | NSCLC_Tumor_resection SNOMEDCT CPT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.258 | ALK results (HGNC) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.259 | ALK Positive (geneinterpretation) SNOMED | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.26 | ESR1 Genetic Mutation | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.260 | ALK Positive (geneinterpretation) NCI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.261 | ALK Positive (geneinterpretation) SNOMEDCT NCI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.262 | ALK Negative (geneinterpretation) SNOMEDCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.263 | ALK Negative (geneinterpretation) NCI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.264 | ALK Negative (geneinterpretation) SNOMEDCT NCI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.265 | Locoregional Sites | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.266 | NSCLC N2 Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.267 | NSCLC N1 Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.268 | NSCLC N0 Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.269 | NSCLC T3_T4 Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.27 | Genetic Test Finding | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.270 | NSCLC T2 Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.271 | NSCLC T1 Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.272 | Locally_Advanced_Metastatic_NSCLC Stage Group | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.273 | Localized_Inclusion_NSCLC Stage Group | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.274 | Localized_Exclusion_NSCLC Stage Group | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.275 | tarlatamab dlle | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.276 | Extensive SCLC Stage Group SNOMEDCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.277 | Extensive SCLC Stage Group NCIM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.278 | Extensive SCLC Stage Group | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.279 | Localized SCLC Stage Group | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.28 | Her2 Negative | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.280 | SCLC M Stage (metastatic) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.281 | SCLC T Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.282 | SCLC N Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.283 | SCLC histology (to include those patients) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.284 | Binimetinib | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.285 | Encorafenib | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.286 | Encorafenib PM Molecular variant | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.288 | BRAF Positive (geneinterpretation) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.289 | BRAF test (HGNC) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.29 | HER2 Positive | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.292 | Prior therapy for Amivantamab | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.293 | ENHERTU Drug | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.294 | Metastatic_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.295 | Locally_Advanced_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.296 | Localized_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.297 | Solid cancer M Stage (metastatic) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.298 | Solid Cancer T Stage | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.299 | Solid Cancer N Stage | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.30 | HER2 Positive | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.302 | HER2_IHC_Positive | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.303 | HER2 Negative (geneinterpretation/Labtestvalue) SNOMED | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.304 | HER2 Negative (geneinterpretation/Labtestvalue) LOINC | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.305 | HER2 Negative (geneinterpretation/Labtestvalue) NCI | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.307 | HER2 Negative (geneinterpretation/Labtestvalue) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.308 | Solid Cancer Diagnosis ICD 9 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.309 | Solid Cancer Diagnosis SNOMED CT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.31 | HER2 Positive | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.310 | Solid Cancer Diagnosis | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.311 | Localized_Solid_Cancer_Stage Group NCIM | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.313 | Localized_Solid_Cancer_Stage Group | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.314 | Locally_Advanced_Solid_Cancer_Stage Group NCIM | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.315 | Locally_Advanced_Solid_Cancer_Stage Group | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.316 | Metastatic_Solid_Cancer_Stage Group NCIM | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.317 | Metastatic_Solid_Cancer_Stage Group | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.318 | Solid Cancer T Stage LOINC | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.319 | Solid Cancer T Stage NCI | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.32 | HER2 Positive | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.320 | Solid Cancer T Stage codes | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.321 | Prior_Systemic_therapy_Enhertu | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.322 | RET test_Solid_cancer (HGNC) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.323 | RET Positive_Solid_Cancer (geneinterpretation) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.324 | RET Negative_Solid_Cancer (geneinterpretation) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.325 | RET fusion Molecular Variants_Solid_Cancer | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.326 | Prior_systemic_therapy_Retevmo | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.327 | Selpercatinib (Retevmo) Drug | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.328 | Breast Cancer Diagnosis ICD9 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.329 | Breast Cancer Diagnosis ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.33 | Metastatic Breast Cancer | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.330 | Breast Cancer Diagnosis | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.331 | Metastatic_Breast_Cancer_Stage Group | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.332 | Locally_Advanced_Breast_Cancer_Stage Group | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.333 | Localized_Breast_Cancer_Stage Group | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.334 | Breast cancer M Stage (metastatic) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.335 | Breast Cancer T Stage | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.336 | Breast Cancer N Stage | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.337 | Metastatic Sites All Breast SNOMEDCT | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.338 | Metastatic Sites All Breast ICD9 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.339 | Metastatic Sites All Breast ICD10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.340 | Metastatic Sites All Breast (grouped, SNOMEDCT/ICD9/ICD10) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.341 | Aromatase_Inhibitor therapy | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.342 | Capivasertib_therapy | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.343 | Fulvestrant_therapy | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.344 | PTEN_gene | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.345 | PTEN_geneinterpretation | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.346 | PIK3CA_gene | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.347 | PI3KCA_geneinterpretation | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.348 | AKTI_gene | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.349 | AKTI_geneinterpretation | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.35 | All Metastatic Sites | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.350 | Progesterone_receptor_gene | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.351 | Progesterone_receptor_geneinterpretation | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.352 | Estrogen_receptor_gene | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.353 | Estrogen_receptor_geneinterpretation | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.354 | Progesterone_receptor_labtest | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.355 | Progesterone_receptor_labinterpretation | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.356 | Estrogen_receptor_labtest | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.357 | Estrogen_receptor_labinterpretation | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.358 | NSCLC M0 Stage | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.359 | HER2_IHC_test_Gene | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.36 | All Metastatic Sites | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.360 | HER2_IHC_test_Lab | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.361 | HER2_Fish_test | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.362 | HER2_IHC_Negative | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.363 | Trodelvy | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.364 | Chemotherapy_breast_cancer | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.365 | Cyclin_dependent_kinase | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.366 | Taxane_Trodelvy | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.367 | Endocrine_therapy | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.368 | HER2_Fish_test_Negative | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.369 | HER2_IHC_Equivocal | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.37 | Locoregional Breast Cancer | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.370 | HER2 Positive_PM_results | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.371 | HER2 test_Lab | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.372 | HER2 test_gene | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.374 | Thyroid Cancer Diagnosis | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.375 | Metastatic_Thyroid_Stage Group | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.376 | RET mutation_Molecular Variants | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.377 | RET Gene mutation | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.378 | Locally_Advanced_Localized_Thyroid_Cancer_Stage Group | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.379 | Thyroid cancer M1_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.38 | Locoregional Breast Cancer | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.380 | Thyroid_cancer_M0_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.381 | Thyroid_cancer_T_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.382 | Thyroid_cancer_T1_T2_T3_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.383 | Thyroid_cancer_T4_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.384 | Thyroid_cancer_N1b_Stage&Above | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.385 | Thyroid_cancer_N_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.386 | Medullary_thyroid_histology | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.387 | RET test_Thyroid_cancer (HGNC) | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.388 | RET Positive | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.389 | NSCLC N3 Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.39 | Locoregional Breast Cancer | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.390 | CRC Cancer Diagnosis ICD9 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.391 | CRC Cancer Diagnosis ICD10 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.392 | CRC Cancer Diagnosis ICD9/ICD10 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.393 | Metastatic_CRC_Cancer_Stage Group | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.394 | Locally_Advanced_Localized_CRC_Stage Group | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.395 | CRC cancer M Stage (metastatic) | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.396 | CRC Cancer T Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.397 | CRC Cancer N Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.398 | KRAS_gene | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.399 | KRAS_negative | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.40 | Locoregional Breast Cancer | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.400 | Fluoropyrimidine_CRC | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.401 | Oxaliplatin | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.402 | Irinotecan_based_therapy | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.403 | anti_VEGF_therapy_CRC | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.404 | anti_EGFR_therapy_CRC | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.405 | fruquitinib | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.406 | Locally_Advanced_CRC_Stage Group | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.407 | Localized_CRC_Stage Group | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.408 | CRC cancer M0_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.409 | CRC_Cancer_T1_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.41 | All Metastatic Sites ICD910 | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.410 | CRC_Cancer_T2_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.411 | CRC_Cancer_T3_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.412 | CRC_Cancer_T4_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.413 | CRC Cancer N1 Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.414 | CRC Cancer N2 Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.415 | CRC Cancer N2b Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.416 | KRAS_G12C_MV | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.417 | KRAS_G12C_PM | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.418 | KRAS_positive | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.419 | Adagrasib | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.42 | Breast Cancer | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.420 | cetuximab_therapy | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.421 | Tamoxifen_therapy | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.423 | Endometrial Cancer Diagnosis ICD 10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.425 | Endometrial Cancer Diagnosis ICD9CM | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.426 | Endometrial Cancer Diagnosis | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.428 | Localized_Endometerial_Stage Group SNOMED | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.429 | Localized_Endometerial_Stage Group NCIM | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.43 | Breast Cancer | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.431 | Endometrial_Sarcoma_Tumor_Histology_exc | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.432 | Endometrial cancer M Stage (metastatic) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.433 | Endometrial_M0_Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.436 | Prior_therapy_Endometrial | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.437 | Paclitaxel_therapy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.44 | Breast Cancer | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.441 | Carboplatin_therapy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.442 | Durvalumab_therapy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.444 | MMR_Gene_Lab_LOINC | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.447 | MMR_Gene_HGNC | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.449 | Endometrial_ Cancer N Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.45 | Endometrial Cancer ICD9 | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.451 | Endometrial_N0_Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.453 | Endometrial_N1_N2_Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.455 | Endometrial_T1_T3_Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.456 | Endometrial_T3_Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.458 | Endometrial_T4_Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.459 | Endometrial Cancer T Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.46 | Endometrial Cancer ICD10 | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.460 | Localized_Endometerial_Stage Group_SNOMED/NCIM | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.461 | Metastatic Sites All CRC | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.462 | Metastatic Sites All CRC ICD 10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.463 | Metastatic Sites All CRC ICD 9 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.464 | Metastatic Sites All CRC (grouped, SNOMEDCT/ICD9/ICD10) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.465 | NTRK Repotrectinib Molecular Variants | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.466 | NTRK_Gene_rearrangment | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.467 | Prior_Systemic_therapy_Repotrectinib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.468 | NTRK_Positive | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.469 | NTRK_test_gene | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.47 | Systemic treatment for endometrial cancer | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.470 | Tamoxifen_Trodelvy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.471 | Toremifene_trodelvy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.472 | Fulvestrant_Trodelvy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.473 | Elacestrant | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.474 | Anastrozole_Trodelvy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.475 | Leuprolide_Trodelvy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.476 | Abemaciclib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.477 | Palbociclib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.478 | Ribociclib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.479 | Carboplatin_Trodelvy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.48 | Endometrial Cancers | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.480 | Cisplatin_Trodelvy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.481 | Cyclophosphamide | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.482 | Methotrexate | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.483 | Gemcitabine | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.484 | Capecitabine | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.485 | Eribulin | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.486 | Doxorubicin | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.487 | Vinorelbine | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.488 | Epirubicin | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.489 | Ixabepilone | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.49 | MSI Testing | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.490 | Olaparib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.491 | Talazoparib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.492 | Entrectinib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.493 | larotrectinib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.494 | Alpelisib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.495 | Capivasertib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.496 | Pembrolizumab | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.497 | Dostarlimab | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.498 | Selpercatinib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.499 | Everolimus | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.50 | MSI High | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.500 | Trastuzumab_deruxtecan | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.501 | Test 23 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.502 | All Metastatic sites Endometrial SNOMED | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.503 | All Metastatic sites Endometrial ICD9 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.504 | All Metastatic sites Endometrial ICD10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.505 | All Metastatic sites Endometrial | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.506 | Create CRC_Cancer_T4a_Stage | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.507 | Create CRC_Cancer_T4b_Stage | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.508 | High Emetogenic Risk Chemotherapy | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.510 | InactiveFollowup | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.53 | MMR Gene Testing | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.54 | MSI High | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.55 | MSI High | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.56 | Early and Limited Stage | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.57 | Early Stage IIB or lower | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.58 | MMR Deficient | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.59 | MMR Deficient | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.6 | Orserdu | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.60 | MMR Deficient | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.61 | Stage IIB or lower and limited | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.62 | Stage III or higher | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.63 | Stage III or higher | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.64 | Stage III or higher | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.65 | Staging Unknown | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.66 | Staging Unknown | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.67 | Staging Unknown | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.68 | Jemperli | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.69 | Uterine Sarcoma | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.7 | Her2 Test For Orserdu | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.70 | Tumor Histology | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.71 | Platinum based therapy | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.72 | Prior Therapies for Tucatinib | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.73 | Tucatinib | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.74 | Colorectal Cancer ICD10 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.75 | Colorectal Cancer ICD9 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.76 | Colorectal Cancer ICD9 and ICD10 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.78 | Advanced or Unresectable Colorectal Cancer Staging | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.79 | 0 to IIIB Colorectal Cancer Staging | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.80 | Colorectal Cancer M1 Stage | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.81 | RAS Genes | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.82 | RAS Gene Interpretation Negative LOINC | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.83 | RAS Gene Interpretation Negative SNOMED | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.84 | RAS Gene Interpretation Negative NCM | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.85 | RAS Gene Negative | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.86 | RAS Gene Interpretation Positive SNOMED | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.87 | RAS Gene Interpretation Positive LOINC | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.88 | RAS Gene Positive | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.89 | Her2 Testing | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.9 | ER Test for Orserdu | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.90 | Patient Reason | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.91 | MSI High NCI | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.92 | MSI Low SNOMED | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.93 | MSI Low LOINC | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.94 | MSI Low NCI | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.95 | MSI Low | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.96 | MMR Deficient NCI | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.97 | MMR Proficient SNOMED | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.98 | MMR Proficient LOINC | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.99 | MMR Proficient NCI | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1262.3 | ICD9 Codes for HIV Diagnosis | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.1 | Inpatient Pneumonia Diagnosis | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.11 | Chest Imaging for Pneumonia, HCPCS | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.12 | Chest Imaging for Pneumonia Grouping Definition | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.18 | ICD9 Abnormal Finding on Chest Imaging | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.19 | ICD10 Abnormal Finding on Chest Imaging | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.2 | ICD9 Pneumonia Definition | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.20 | SNOMEDCT Abnormal Finding on Chest Imaging | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.21 | Abnormal Finding on Chest Imaging | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.22 | SNOMEDCT Pneumonia Definition | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.23 | CAP Concurrent Infections | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.24 | CAP Pneumonia Diagnostic | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.25 | Antibiotic Usage for CAP Diagnosis | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.27 | Legionella Presence by Urine Antigen or DNA | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.29 | Broad Spectrum Antibiotics for MDRO | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.3 | ICD10 Pneumonia Definition | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.32 | CPT Transplants, Stem Cell and Solid | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.33 | HCPCS Transplant, Stem Cell and Solid | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.34 | ICD10CM Transplant, Stem Cell and Solid | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.35 | ICD10PCS Transplant, Stem Cell and Solid | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.37 | SNOMEDCT Transplant, Stem Cell and Solid | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.38 | Transplant, Stem Cell and Solid | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.39 | Antibiotic Usage for CAP Duration | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.40 | CAP Sepsis Diagnostic | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.41 | CAP Respiratory Failure Diagnostic | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.42 | MRSA Organism or Substance in Lab Results | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.8 | Systemic Antimicrobials | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.9 | Chest Imaging for Pneumonia, CPT | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.1 | Problem Type | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.10 | Information Source for Medication Adherence HSLOC | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.11 | Information Source for Medication Adherence | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.13 | Screening and Assessment Survey Codes | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.14 | Unknown and Asked but Unknown (DAR) | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.15 | Yes or No SCT | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.16 | Answer Set with Yes No and Unknowns | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.17 | Common LOINC Lab Codes | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.18 | Radiology Procedures (LOINC) | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.19 | Clinical Tests | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.21 | Universal Common LOINC Lab Orders | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.22 | Route of Administration of Therapeutic Agents | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.23 | Encounter Type | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.24 | Specimen Condition SCT | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.25 | Detailed race including absence reasons. | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.26 | Healthcare Facility type (SCT) | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.27 | Social History Type (LOINC) | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.28 | Social History Type | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.29 | Encounter Type CPT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.3 | Smoking status comprehensive | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.31 | Healthcare Service Location Type Combined | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.4 | Smoking Status Type LOINC | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.5 | Smoking Status Pack Years SCT | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.6 | Smoking Status Type | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.7 | Information Source for Medication Adherence HL7 Role Code | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.8 | Information Source for Medication Adherence ParticpationFunction | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.9 | Information Source for Medication Adherence SCT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.1 | Malnutrition | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.10 | Fracture | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.11 | Transplant Diagnoses | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.13 | Transplant Diagnoses ICD10CM | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.14 | Transplant Diagnoses SNOMED CT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.15 | Respiratory Procedures | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.2 | Moderate Injuries (SNOMEDCT) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.3 | Diabetes | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.4 | Diabetes | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.5 | Diabetes | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.6 | Immobility | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.7 | Smoking status | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.8 | Obesity | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.9 | Hormone Therapy | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.1 | Drug Intervention Not Indicated/Contraindicated | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.10 | Endotracheal Intubation | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.2 | Procedure Not Indicated/Contraindicated | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.9 | Mechanical Circulatory Assist Device | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1289.1 | RXNormSBD0305 | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1289.2 | RXNormSCD0305 | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.4 | Sequential Organ Failure Assessment SOFA | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.5 | Septic Shock | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.6 | Septic Shock | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.1 | Administrative Gender (HL7 V3) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10267 | ParticipationFunction | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10416 | Financially Responsible Party Type Value Set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10612 | Unknown Null | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10637 | PostalAddressUse | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10901 | ParticipationType | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.11610 | x_ActRelationshipDocument | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12199 | LanguageAbilityProficiency | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12212 | Marital Status | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12249 | LanguageAbilityMode | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.14914 | Race Value Set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.15913 | EntityNameUse | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.16926 | HL7 BasicConfidentialityKind | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.18877 | Coverage Role Type Value Set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19185 | Religious Affiliation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19563 | Personal Relationship Role Type | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19579 | Family Member Value | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19601 | x_ServiceEventPerformer | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19717 | No Immunization Reason | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.12 | HealthStatus | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.3 | ReferralDocumentType | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.4 | TransferDocumentType | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.5 | Wound Measurements | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.6 | Wound Type | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.7 | Nutritional Status | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.9 | Nutrition Recommendations | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2 | Advance Directive Type Code | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.22 | HPDocumentType | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20275 | HealthcareServiceLocation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20549 | Criticality Observation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.78 | Observation Interpretation (HL7) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.1 | Initial Case Report Trigger Code Result Status | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.12 | Therapeutic Response to Medication | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.300 | Transmission Based Precaution Types | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.304 | Organism | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.305 | Microbiology and Antimicrobial Susceptibility Tests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.306 | Infectious Disease | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.2 | Codes for MDRO and CDI Summary Data LTCF | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.3 | NHSNPrimaryResidentServiceType | active | 2020-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.4 | Codes for Denominators for Long Term Care Locations LTCF | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.5 | Codes for Prevention Process Measures LTCF | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.9.1 | NHSNReportNoEventsMDROLTCF | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.10 | Codes for Healthcare Personnel Influenza Vaccination (HP FLU) Summary Data | active | 2019-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.11 | Codes for Hemovigilance (HV) Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.12 | Codes for Intensive Care Unit (ICU) Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.13 | Codes for Neonatal Intensive Care Unit (NICU) Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.15 | Codes for Prevention Process and Outcome Measures (POM) Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.16 | Codes for Specialty Care Area (SCA) Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.17 | Codes for Vascular Access Type (Dialysis) Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.18 | NHSNReportNoEventsICU | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.19 | NHSNReportNoEventsNICU | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.20 | NHSNReportNoEventsSCA | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.21 | NHSNReportNoEventsMDRO | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.22 | NHSNReportNoEventsDialysis | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.24 | NHSNVascularSpecimenCollectionSite | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.29 | NHSNSSIDetectionMethod | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.3 | NHSNLastLocationEncounterTypeCode | active | 2020-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.30 | NHSNLOS/MENDischargeDisposition | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.31 | NHSNSSIDetectionMethodType | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.32 | Codes for Outpatient Procedure Component Same Day Outcome Measures Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.33 | NHSNReportNoEventsOPCSameDayOutcomeMeasures | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.34 | NHSNOPCProcedureCategoryCode | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.35 | NHSNReportNoEventsAR | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.4 | NHSNDrugSusceptibilityTestMethod | active | 2020-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.40 | NHSN COVID19 Case Classification | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.5 | NHSN Pathogen Reduced Apheresis Platelet Usage | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.50 | NHSNGenotypicTestInterpretation | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.6 | HealthcarePersonnelType | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.7 | NHSNInfluenzaVaccinationSetting | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.8 | Codes for Antimicrobial Resistance Option (ARO) Summary Data | active | 2020-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.9 | Codes for Antimicrobial Usage, Pharmacy (AUP) Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.1.1 | SurgicalOperationNoteDocumentTypeCode | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.12.1 | Personal And Legal Relationship Role Type | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.4.1 | DischargeSummaryDocumentTypeCode | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.6.1 | ProcedureNoteDocumentTypeCodes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.7.1 | SupportedFileFormats | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.8.1 | ProgressNoteDocumentTypeCode | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.18 | MoodCodeEvnInt | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.19 | ProblemAct statusCode | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.20 | Telecom Use (US Realm Header) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.21 | AgePQ_UCUM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.22 | ProcedureAct statusCode | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.23 | Planned moodCode (Act/Encounter/Procedure) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.24 | Planned moodCode (SubstanceAdministration/Supply) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.25 | Planned moodCode (Observation) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.26 | EntityPersonNamePartQualifier | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.29 | DIRQuantityMeasurementTypeCodes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.31 | ConsultDocumentType | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.32 | DIRDocumentTypeCodes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.33 | INDRoleclassCodes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.34 | Patient Education | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.35 | Pressure Ulcer Stage | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.36 | Pressure Point | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.37 | TargetSite Qualifiers | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.38 | Smoking Status | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.39 | Result Status | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.41 | Tobacco Use | active | 2024-06 | hl7 |
XIG built as of 20 Jun 2025. Found 77285 resources in 1238 packages.
FHIR